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I.  In the COQtcxt of  a people's Europe, the Commission attaches great importance to simplifying and clarifying 
Community law so· as to make  it clearer and more accessible  to the ordinary citizen,  th~ giving him new 
opportunities and the chance to make use of  the specific rights it gives him.  · 
This aim cannot be achieved so long as numerous provisiQns that have been amended several times, often quite · 
substantially, remain scattered, so that they must be sought partly in the original instrument and partly in later 
amending ones. Considerable research work, comparing many different instruments, is thus needed to identizy 
the current rules.  · 
For this reason a codification of  rules that have frequently been amended is also essential if  Community law is 
to .be clear and transparent 
2.  On 1 April 1987 the Commission therefore decided to instruct its staff that all legislative measures should be 
~  after  no  more  than  ten  amendments,  stressing  that  this  was  a  minimum  requi.rcment  and  that 
departments should endeavour to condify at even shorter intervals the texts for which they were responsible, to 
ensure that the Community rules were clear and readily understandable. 
3.  The  Conclusions of the  Presidency of the  Edinburgh  European  Council  (December  1992)  confirmed  this, 
stressing the  importance of legislative codification  as  it offers certainty as to  the  law applicable to  a given 
matter at a given time. 
It must be undertaken in full compliance with the nonnal Community legislative procedure. 
Given  that  no  changes  of substance may  be  made  to  the  instruments  affected  by  legislative  codification, 
Parliament,  the  Council  and  the  Commission  have  agreed,  by  an  interinstitutional  agreement 
dated 20 December  1994,  that  an  accelerated  procedure  may  be  used  ·for  the  fast-track  adoption  of 
codification instruments. 
4.  The  purpose  of  this  proposaJ<Il  for  legislative  codification  of  Council  Directives  81/851/EEC  of 
28 September 1981  on  the approximation  of the laws  of the Member States relating to  veterinary medicinal 
products; 81/852/EEC of28 September 1981  on the approximation of  the laws of the Member States relating 
to analytical, pharmaco-toxicological and clinical standards and protocols in respect ofthe testing of veterinary 
medicinal products; 90/677/EEC of 13 December 1990 extending the scope of Directive 81/851/EEC on the 
approximation of the laws of the Member States relating to  veterinary medicinal  products and laying  down 
additional  provisions  for  immunological  veterinary  medicinal  products;  92174/EEC  of 22  September  1992. 
widening the scope of  Directive 811851/EEC on the approximation of provisions laid down by law, regulation 
or administrative action  relating to  veterinary medicinal products and  laying down  additional provisions on 
homeopathic veterinary medicinal products, is to undertake official codification of  this type. The new directive 
will supersede the various directives incorporated in if2l, their content is fully preserved, and they arc brought 
together with onlv such fonnal amendments as are required  b~· the codification exercise itself. 
4a  In order to point out the satisfactory application of the codification of  the Directive mentioned above, in order 
to  take  into  account  the  fact  that  since  the  last  Directive  cited  in  point  4,  the  European  Agency  for  the 
Evaluation of  Medicinal Products has been established by Council Regulation (EEC) 2309/93 of22 July 1993. 
In  the  same  manner,  in  order to  point  out  that  this  codification  proposal  concerning  medicinal  products 
for human  use  was  created  in  parallel  with  the  codification  proposal  for  Directives  relating  to  veterinary 
medicinal products. 
S.  This  legislative  codification  proposal  was  drawn  up  on  the  basis  of a preliminarv  consolidation.  in  all  the 
official  languages.  The  instruments  amending  it,  carried  out  by  the  Office  for  Official  Publications  of the 
European Communities, by means of  the data-processing system referred to in the conclusions of  the European 
Council meeting  at Edinburgh. Although  the articles have  been  given new numbers,  the  old numbering  has 
been retained in the margin for ease of  reference; the correlation between the old and new numbers is shown in 
(I) 
(l) 
a table set out in Annex III of  the consolidated Directive.  · 
Entered in the legislative programme for 1998. 
See Annex n, Pan A of  this Proposal. 
2 Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DIRECTIVE 
of  ••• 
on the CoDUDuility code relating to. 
veterinary medicinal products . 
, THE EUROPEAN PARLI.AMEN'i AND THE CQUNCll.. OF THE EUROPEAN 
UNION, 
Having regard to the Treaty establishing the Emopean Community, and in 
particular Article 95·thereot:  · 
Having regard to the proposal from the·Commission,· 
·Having regard to the opinion of  the Economic and Social Committeen>, 
Acting in accordance with the procedure laid down in Article 251 of  the Treaty<l>, 
(1)  Whereas  Council  Directive  811851/EEC  of 28  September  1981  on  the 
approximation  of the  laws  of the  Member  States  relating  to  veterinary 
medicinal productsC31,  Council Directive  81/852/EEC of 28 September  1981 
on the approximation of  the laws of  the Member States relating· to analytical, 
phannaco-toxicological and clinical standards and protocols in respect of the 
testing of veterinaiy medicinal products<•>,  Council Directive 90/677/EEC of 
13  December  1990  extending  the  scope  of Directive  81/851/EEC  on  the 
approximation  of the  laws ·  of the  Member  States  relating  to  vetefinary 
medicinal products and laying down additional provisions for immunological 
veterinary  medicinal  products<S>,  and  Council  Directive  92n41EEC  of 
22 September  1992  widening  the  scope  of Directive  811851/EEC  on  the 
approximation of provisions  laid down by  law, regulation or administrative 
action relating to veterinary medicinal products and  laying down additional 
provisions  on  homeopathic  veterinary  medicinal  products~'>  have  been 
frequently and substantially amended; whereas, in the interests of clarity and 
rationality,  the  said  Directives  should  therefore  be  codified  by  assembling 
them in a single text; 
U>  OJC 
(1) 
CJl  OJ L317, 6.11.1981, p.  1. Directive as last amended by DirectiVe 93/40/EEC (OJ L 214, 24 .. 8.1993, p. 31). 
14>  OJ L 317, 6.11.19&1, p. 16.  Directive as last amended by Directive 93/40/EEC. 
<S>  OJ L 373, 31.12. 990, p. 26. 
<•>  OJ L 297, 13.10.1992, p.  12. 
3 {2)  Whereas the primary pUrpose of  any rules for the production and dislnbUnon  1.  811851/EEC 
· ofveterin_ary medicinal products must be the ~guarding  of  public: health; 
{3)  Whereas, however, this objective must be achieved bY means which will not  2.  81/851/EEC 
hinder the development of  industly and trade in medicinal products within the 
Community; 
{  4) Whereas, in so far as the Member States already have certain provisions laid  3.  811851/EEC 
down  by  law,  regulation  or  adininistrative  action  governing  veterinary 
medicinal products, such provisions diff~ in essential principles; whereas this 
(adapted) 
results in the hindering of  trade in medic:inal.products within the Community, 
thereby directly affecting the functioning of  the internal market;· 
(S)  Whereas such hindrances must, accordingly, be removed; whereas this entails 
approximation of  the ~levant  provisions;  4.  81/851/EEC 
{6)  Whereas it is necessary from the  ~int of  view of public health and the free 
movement of veterinary medicinal products for the competent authorities to  3.  90/676/EEC 
have  at  their  disposal  all  useful  information  on  authorized  veterinary 
medicinal products in the form of approved summaries of  the characteristics 
of  products; 
{7)  Whereas, with the exception of  those medicinal products which are subject to 
'  the  ~entralized Community  authorization procedure  established by  Council  3.  93/40/EEC 
Regulation  (EEC)  No  2309/93  of 22  July  1993  laying  down  Community  (adapted) 
procedures  for  the authorization and  supervision of medicinal  products for 
· human  and  veterinary  use  and  establishing  a  European  Agency  for  the 
Evaluation of  Medicinal Products''l, a marketiilg authorization in one Member 
State ought to be recognized by the competent authority of  the other Member 
States unless there are serious grounds for supposing that the authorization of 
the  veterinary medicinal product concerned may present a risk to human or 
animal health, or to the environment; whereas, in the event of  a disagreement 
between  Member  States  about the  quality,  the  safety  or the  efficacy  of a 
medicinal product, a scientific evaluation of  the matter should be undertaken 
according to a Community standard, lead to a single decision on the area of 
disagreement,  binding  on  the  Member  States  concerned;  whereas  this 
Decision should be adopted by a rapid procedure ensuring close cooperation 
between the Commission and the Member States; 
(8) Whereas,  for  this purpose,  a Col:nmittee for Veterinary  Medicinal Products 
should  be  set  up  in  accordance  with  the  European  Agency  for  the 
Evaluation of  Medicinal Products laid down in the aforementioned Regulation  10.  81/851/EEC 
{EEC) No 2309/93.  (adapted) 
Ill  OJ L214, 24.8.1993, p. 1; R.cguJalioo as amended by Commission Regulation (EC) No 649198 (OJ L 88, 24.3.1998, p. 7). 
4 · (9): Whefc:as tbis Directive is only one  stage  in the achievement. of the  aim of  11. 
freedom of movement of vete.rinaiy mediciDal  produets; whereas, however, 
for thiS purj,ose, new .measures will prove necessary, in. the light of  experience 
· gained • especially within the CoJDIQittee for ·veterinary Medicinal Products -
·  for the· removal of  the remaining bmiers ~  freedom of  movement; 
(10)Whereas  medicaled  feedingstuffs  do  not  come  within  the  scope  of this  6. 
Directive;  whereas,  however,  it  is  necessary~ for  Q<lth  public  health·  and 
. economic reasons. to prohibit the use of  UDIUJtborized medicinal products in 
the manu&cture of  medicated feedingstuffs; 
(ll)Whereas  the  concepts  of harmfulness  and  therapeutic  efficacy  can  be  7. 
·  examined only in relation to one another and have only a relative significance, 
depending on the progress of  scientific knowledge and the use for which the 
medicinal product is intended; whereas the particulars and documents which 
must accompany an application for marketing authorization must demonstrate 
that potential hazards are outweighed by the benefits due to efficacy; 
' 
(12)Whereas  marketing  authorization  should  be  refused  where  a  medicinal  7. 
product lacks therapeutic effect or where there  is insufficient proof of such 
effect; whereas the concept.oftherapeutic effect must be understood as being 
the effect promised by the manufacturers; 
(13)Whereas  such  marketing  authorization  should  li1so  be  refused  where  the  8. 
withdrawal period indicated is not long enough to eUminate health hazards 
arising from residues; 
(14)Whereas,  before  an  authorization  to  market  an .immunological  veterinary  5  . . 
medicinal  product can be  granted,  the  manufacturer must  demonstrate  his 
ability to attain batch-to-batch consistency; 
(15)Whereas the competent authorities should also be empowered to prolnbit the  ,  6. 
use  of  an  immunological  veterinary  medicinal·  product  when  the 
immunological responses of  the treated animal will interfere with a national or 
Community  programme  for the  diagnosis,  eradication or control of animal 
disease; 
(16)Whereas it is desirable in the first instance to provide users of homeopathic  7. 
medicinal products with a very clear indication of  their homeopathic character 
and with sufficient guarantees of  their quality and safety; 
(17)Whereas  the  rules  relating  to the  manufacture,  control  and  inspection  of  8. 
homeopathic veterinary medicinal.products must be harmonized to permit the 
circulation throughout the Community of medicinal products which are safe 
· and of  good quality; 
s 
81/851/EEC 
(adapted) 
.81/851/EEC 
81/852/EEC 
(adapted) 
81/851/EEC 
(adapted) 
81/851/EEC 
(adapted) 
90/677/EEC 
90/677/EEC 
92174/EEC 
92174/EEC (18)Wbem15, having regard to the particuhir cbaracteristics ofthese·h~c 
veterinary medicinal poducts, such as the very low level of  active principles 
they contain-and the difficulty of  applying to them the conventional statistical 
methods ·  relatiDg  to  clinical  trials,  it  is·  desirable  to  provide  a special, 
simplified registratiOn procedure for those trBditional homeopathic medicinal 
products which are placed on the market without therapeutic -indications in a 
pbalmaceutical form and dosage which do not present a risk for the animal; 
(19)Wbereas  the  usual rules  governing  the  authorization  to market_ veterinary 
·  medicinal ·prOducts  must  be  applied  to homeopathic. veterinary  medicinal 
productS · marketed  with  therapeutic  indications  or  in. a  form  which  may 
present risks which must be balanced against the desired therapeutic effect; 
whereas· Member  States  should  be  able  to mly particular  rules  for  the 
evaluation of  the results of  tests and trials intended to establish the safety and 
efficacy  of these  medicinal  products  for  pet animals  and  exotic  species, 
· provided that they notify them to the Commission; 
(20)Whereas in order to better protect human and animal health and avoid any 
unnecessary duplication ofeffort during the examination of  application for a 
marketilig  authorization,  Member  States  should  systematically  prepare 
assessment reports in respect of each veterinary medicinal product which  is 
authorized  by  them,  and  exchange  the  reports  up(m  request;  whereas, 
furthermore, a Member State should be able to suspend the examination of  an 
.application for authorization to place a veterinary medicinal product on the 
market which is CUJ'I'Cntly under active consideration in another Member State 
with a view to recognizing the decision reached by the latter Member State; 
(21 )Whereas, in order to facilitate the movement of  veterinary medicinal products 
and  to  prevent  the  checks  carried  out  in  one  Member· State  from  being 
repeated in another,  harmonised requirements  for  manufacture  and  imports 
from third countries, and the grant of  corresponding authorization, should be 
applied to veterinary medicinal products, 
(22)Whereas the quality ofveterinary medicinal products manufactured within the 
Community should be guaranteed by requiring compliance with the principles 
of good  manufacturing practice  for .  medicinal  products  irrespective  of the 
final destination of  the medicinal products; 
(23) Whereas  measures  should  also  be  taken  to  ensure  that  distributors  of 
veterinary medicinal prpducts are authorized by Me~  States and maintain 
adequate records; 
6 
9.  92f141EEC 
(adapted) 
11.  921741EEC 
(adapted) 
4.  93/40/EEC 
{adapted) 
12  81/851/EEC 
(adapted) 
7.  90/676/EEC 
(adapted) 
10.  90/676/EEC {24)Wheteas standardS and.protocOJs for. the perfonliance of  tests on veterinary  3. 
· ·  mediciDal .products 'Ire an effective means of control of these products and, 
hence, of protecting public health and can facilitate  the movement of these  + 
productS by laying clown UDiform rules applicable to tests and the compilation 
of  dossiers,·allowing the competent authorities to·arrive .at their decisions on  4. 
the basis of uoifom tests and by reference to uniform criteria, and therefore 
helping to obviate diff~ces  in evaluatioD; 
(25)Whereas it is  advisable· to stipulate more  precisely the  cases in which the 
results pf  pharmacological and toxicological tests or clinical1rials do. not have  6. 
to. be  provided  with ·a view  to  obtaining  authorization  for  a· veterinary 
mediciDal product which is essentially similar to an innovative product, while 
ensuring that  innovative  forms  are  not placed  at a disadvantage;  whereas, 
however, there are reasons of  public policy for not repeating tests carried out 
on aDimals without overiding cause; 
(26)Whereas following the establishment of  the illternal market. specific controls  S. 
to guarantee the quality of  veterinary _medicinal products imported from third 
countries can be waived only if  appropriate mangeoients have been made by 
the  COmmunity to ensure that the necessary controls are  carried out in thp 
exporting C01Dltry; 
(27)Whereas  it  is  desirable  to  codify  and  improve  ·the·  cooperation  and  6. 
exchange of  information  between  Member  ·States  relating  to  the 
Surveillance o(  veterinary medicinal· products and in particular the monitoring 
of adverse  reactions  1Dlder practical conditions of use  through the natiorud 
pharmacovigilance systems; 
(2S)Whereas in order to improve the protection ofpublic health._it is necessary to  7. 
specify that foodstuffs for human consumption may not be taken from animals 
which have been used in clinical trials of  veteriDary medicinal products 1Dlless 
a· maximum residue limit has been laid down for residues  of the veterinary 
medicinal prQduct concerned in accordance with the provisions of ColDlcil· . 
. Regulation (EEC) No 2377190 of 26  JlDle  1990 laying down a Community 
prOcedure  for  the  establisbment  of maximum  residue  limits  of veterinary 
medicinal products in foodstuffs of  animal originllt.; 
(29)Whereas  the  Commission  should  be  empowered  to  adopt  the  7. 
necessary changes laid down in Annex I in order to adapt to  scientific and 
technical progress; . 
(30)Whercas,  this  Directive  is  without  prejudice  to  the  obligations  of the 
Member States concerning the deadlines for transposition set out in Annex n, 
~~- . 
HAVE ADOPTED nns DIRECTIVE: 
81/852/EEC 
(adapted) 
90/676/EEC 
93/40/EEC 
93/40/EEC 
93/40/EEC 
90/677/EEC 
{adapted) 
(II  OJ  L 224,  18.8.1990,  p.'  1;  RCgulmoo  u: Wt IIDCDdccl  by C®Jmiuioa  R.cgulatiOD  (EC) No  1951198  (OJ  L 254, 
16.9.1991, p. 7).  .  . 
7 . TI1'UI 
DEFINITIONS 
Article 1 
For the purposes of  this Directive, the following terms shall bear the following meanings:  65/65/EEC 
Art. 1 (1) and (2) 
1.  ·Proprietary medicinal prodUct:  (adapted) 
Any ready-prepared medicinal product placed on the market under a special name 
·and in a special pack.  · 
2.  Veterinllry medicinal product:  81/851/EEC 
Art. 1 (1) 
Any  substance  or combination of substances _presented  for  treating or preventing  (adapted) 
disease in animals. 
Any substance or combination of  substances which may be administered to animals 
with a view to making a medical diagnosis or to restoring, correcting or modifying 
physiological  functions  in animals  is  likewise  considered  a veterinary  medicinal 
product. 
3.  Ready-made veterinary medicinal, product 
shall mean  any veterinary medicinal product prepared· in  advance which does not 
comply with the definition of  proprietary medicinal products and which is marketed 
in a pharmaceutical form which may be used without further processing.  · 
4.  Substance: 
Any matter irrespective of  origin which may be: 
- human, e.g. human blood and human blood products; 
- animal, e.g. micro-organisms, whole animals, parts of organs,  animal secretions; 
toxins, extracts, blOod products; 
8 
81/851/EEC 
Art. 1 (2), 2nd indent 
65/65/EEC 
Art. 1 (3) 
81/851/EEC 
Art. 1 (1) 
(adapted) •  vegetable~ e.g. micro-organisms, plants, -parts of  plants, vegetable secretions, 
~·  .  . 
.  . 
•  chemical, e.g. clements, Daturally occurring chemical materials and chemical. 
products .obtained by chemical change or synthesiis. 
65/65/EEC, 
Art. 1 (3) 
81/851/EEC. 
Art. 1 (1) 
(adapted) 
. 5.  Pr.,bcfor medicmedfeedingstuffi  81/851/EEC 
Art. 1 (2), 3td and 
Ally veterinary medicinal product prepared in adVBJltce with a view to the subsequent  4th indents 
manufacture ~f  medicated fccdingstuffs, 
6.  Medicatedfeedingltuffi 
Any mixture of  a veterinary medicinal product or Jm:xlucts and feed or feeds. which is 
ready  prepared ·for  marketing  and  intended  to be  fed  to animals  without  further 
processing, because of its curative or preventive  properti~ or other properties a5 a 
medicinal product covered by point 2. 
7.  Immunological veterinary medicinal product 
A veterinary medicinal product administered to animals in order to produce active or 
passive immunity or to diagnose the state of  immunilty. 
8.  Homeoptllhic veterinary medicinal product 
Any  veterinary  medicinal  product  prepared  irom  products,  substances  or 
compositions  called  homeopathic  stocks  in  ac1rordance  with  a  homeopathic 
manufacturing  procedure  described  by  the  EuroJICali  Pharmacopoeia  or,  in  the 
absence  thereof,  by  the  pharmacopoeias  currently  used  officially  in  the 
Member Swes. 
A  homeopathic  veterinary · medicinal  product  may  also  contain  a  number  of 
principles. 
90/677/EEC 
Art. 1 (2) 
92174/EEC 
Art. 1 
9.  Withdrawal period  81/851/EEC 
Art. 5, 3rd paragraph, (8) 
Period between the last administration of  the veterinary medicinal product to animals  (as amended by 
under normal conditions of use and the production ,of foodstuffs from such animals,  90/676/EEC Art. 1 (5)) 
in order to ensure that such foodstuffs do not contain residues in quantities in excess  (adapted) 
of  the maximum limits laid down in applying Regula.tion (EEC) No 2377190. 
9 10. A.dversef'eaction  81/851/EEC · 
Art. 42b 
A reaction which is harmfUl and unintelided and Which occurs at doses normally used  (as amended by 
in animals for the prophylaxis, diagnosis or.treatment of  disease or the modification  93/40/EEC Art. l (12)) 
of  physiological timction. 
11.  Serious adverse reaction 
An  adverse  reaction  which  is  fatal,  life-threatening  lesion-producing,  disabling, 
incapacitating, or which results in permanent or prolonged symptoms in the animals 
treated 
12.  Unexpected adverse reaction 
An  adverse  reaction  which  is  not  mentioned  in  the  summary  of the  product 
characteristics. 
13. Serious unexpected adverse reaction 
An adverse reaction which is both serious and unexpected 
14  . .  Wholesale dealing in veterinary medicinal products 
Any activity which includes the purchase, sale, import, expon, or any other 
commercial transaction in veterinary medicinal products, whether or not for profit, 
except for: 
- the supply by a manufacturer of  veterinary medicinal products manufactured by 
himself, 
- retail supplies of  veterinary medicinal products by persons entitled to carry out 
such supplies in accordance with Article 66. 
15. Agency 
European  Agency  for  the  evaluation of medicinal  products  set  up  by Regulation 
(EEC) No 2309/93. 
16.  Risk to human or animal health or the environment 
Any  risk referring  to the  quality,  safety  and  efficacy of the  veterinary  medicinal 
producL 
10 
81/851/EEC 
Art. 50a (1 ), 2nd 
subparagraph 
(as amended by 
90/676/EEC ArL I (27)) 
{adapted) 
81/851/EEC 
Art. 16 (1), 
(as amended by 
93/40/EEC ArL 1 (10)) 
(adapted) 
81/851/EEC 
Art. 18 (1 ), footnote 
(as amended by 
93/40/EEC Art. 1 (1 0)) 
(adapted) TITLEU· 
~pe 
·Article2 · 
The provisious of  this Directive sba11 apply to veterinazy medicinal products 
Article3 
This Directive shall not apply to: . 
L  Medicated feedingstuffs set out in Council Directive 90/167/EECY); 
81/851/EEC 
Art..2.(1) 
(adapted) 
81/851/EEC 
Art. 2 (2), 1st indent 
(adapted) 
· However, ·medicated feedingstuffs may be prepared only from pre-mixes which have  81/851/EEC 
been authorized ·under this Directive;  Art. 2 (3) 
(adapted) 
2.  inactivated  immunological  veterinary medicinal  products  which  are  manufactured  90/677/EEC 
ftom pathogens obtained ftom an animal or aiJ.ima1s 'from a holding and used for the  Art. 1 (3) 
· treatment of  that animal or the animals of  that holding in the same locality;  (adapted) 
3.  Any medicinal product prepared in a pharmacy in accordince with a prescription for 
an individual animal (commonly known as the magistral formula); 
65/65/EEC 
Art. 1, points 4 and s 
(as amended by 
891341/EEC Art. 1 (2)) 
(adapted) 
4.  Any  medicinal  product·  prepared  in  a  pharmacy  in  accordance  with  the  81/851/EC 
prescriptions of a pbannacopoeia  and  is  intended  to be  supplied  directly  to  the .  Art. 1 (  1) 
end-user (commonly known as the official formula);  ·  (adapted) 
1
81/851/EEC 
Art. 2 (2}, 3rd indent 
S.  Veterinary tnedicinal products based on radio-active isotopes; 
6.  Any  additives  covered  by  Council  Directive  70/524/EEOll,  where  they  arc  811851/EEC 
iDcoJP.orated  in  animal  feedingstuffs  and  supplementary  animal  feedingstuffs  in  .Art. 1 (4) 
accordance with tbat Directive.  (adapted) 
(I)  OJ L 92. 7. 4.1990, p.  42.  . 
(2)  OJ L 270, 14.12.1970, p~ I; Dim:tM  a  last IIIICDdccl by Qm!missioo Directive 98119/EC (OJ L 96, 28.3.1998, p. 39). 
11 Article4 
1.  Member  States •Y.  provide  that  t,bis  Directive  sball  not apply  to non-ictivated  90/677/FJ:.C 
immunological.veteJ:jnary medicinal products manufactured from. pathogens obtained·  Art. 1· (4) 
from an animal or animals from a holding and used for·the treatment ofthat animal  (adapted) 
of  that holdiDg in the same lQcality. 
2.  Member States may permit exemptions on their territory  in respect  of.. veterinaly  81/85 1/EEC . 
medicinal products intended solely for aquarium· fish. cage birds, homing pigeons,  Art. 3 
terrarium  animals .  and  small  rodents, from  the  proVisions  in Articles  5,  7 and ·  8, 
provided  that such products do not· contain subStances the  use  of which requires 
veterinary  control  and  that  all  possible  measures  have  been  taken  to  prevent 
unauthorized use or  the products, for 9ther animals. 
TITLEm 
MARKETING 
Chapter I 
Marketing  ·authorization 
ArticleS 
No veterinary medicinal product may be placed on the market of  a Member State unless a 
marketing authorization has  been  issued by the competent authorities of  that Member 
State in  accordail~:e with this Directive or a marketing authorization has been granted in 
accordance with Regulation (EEC) No 2309/93.  · 
Article6 
.  .  .  . 
In order  that  a  veterinary  medicinal  product  may  be  the  subject  of a  marketing 
authorization for the  pU;J"POse  of administering it to food-producing  animals, the active 
substances which it contains must be shown in Annexes I, n  or m  of Regulation (EEC) 
No2377/90. 
Article 7 
Where the health situation so requires, a Member State may authorize the marketing or 
administration to animals of veterinaly medicinal products which have been authorized 
by another Member State in accordance with this Directive. 
12 
81/851/EEC 
Art. 4 (1), 1st 
subparagraph 
(as amended by 
93/40/EEC An. 1 (1)' 
(adapted) 
81/851/EEC 
Art. 4 (2), 1st 
subparagraph 
(as 'amended by 
90/676/EEC An. 1 (  4)) 
(adapted) 
81/85 1/EEC. 
Art. 4 (1), 2nd 
subparagraph 
(as amended by 
90/676/EEC An. 1 (4)) 
(adapted) Article 8  · 
In the·event of  serious disease epidemic, Member States may provisionally allow the use · 81/85 1/EEC  · 
of  immunological veterinary medicinal products without the authorization for placing on  Art. 4 {1), 3rd 
the market,  in ·the  absence  of ·a  suitable  medicinal  product  and  after  informing  the  subparagraph 
Commission of  the detailed conditions of  use.  {as amended. by 
90/676/EEC Art. 1 (  4)) 
{adapted) 
Article 9 
No veterinary medicinal product may be administered to animals  unless- the marketing 
authorization  has been  issued,  except  for  the  tests  of veterinary  medicinal  products 
referred to in Article  12 {3)  G) which have  been  accepted  by the  competent  national 
authorities, following notification or authorization, in accordance with the national rules 
in force. 
Article 10 
1.  Where there is no authorized medicinal product for a condition, Member States may 
exceptionally,  in particular in order to avoid causing unacceptable suffering to the 
animals concerned, permit the administration by a veterinarian or under his/her direct 
personal responsibility to an animal ·or to a small number of  animals on a particular 
holding: 
(a)  of a veterinary medicinal product authorized in the Member State cancerned under 
this  Directive  or under  Regulation  (EEC)-No  2309/93  for  use  in  another  animal 
species, or f~r another condition in the same species; or 
{b)  if  there is no product as referred to in point(a), of  a medicinal product authorized for 
use  in the Member State concerned in human beings  in accordance with Directive 
[65/65/EEC] or wtder Regulation (EEC) No 2309/93; ()r 
(c)  if  there is no product as referred to in point {b) and within the limits of  the law of  the 
Member  State  concern~  of  a  veterinary  . medicinal  -product  prepared 
extemporaneously  by a person  authorized  to do  so  under  national  legislation  in 
accordance with the terms of  a veterinary prescription. 
For the  pwposes of this  paragraph,  the  phrase  'an animal  or a small  number  of 
animals  on  a particular holding'  also  covers  pets,  and  shall be  interpreted  more 
flexibly for minor or exotic animal species which do not produce food. 
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81/851/EEC . 
Art. 4 (3), lst 
subparagraph 
(as amended by 
90/676/EEC Art. 1 (4)) 
_(adapted) 
81/851/EEC 
Art. 4 (4), 1st and 2nd 
subparagraphs 
(as amended by 
90/676/EEC Art. 1 (4)) 
(adapted) 2.  The provisions of  paragraph 1 shall apply provided tbat the medicinal product, where 
.administered to food-producing animals,  contains only substances to be found  in a 
veterinary  medicinal  product· authorized  for  such  animals  in  the  Member  State 
concerned  and  that  in  the  c;ase  of  food·prod~g animals  the  veterinarian 
responsible specifies an appropriate withdrawal period. to ensme tbat food produced 
from the treated animals does not contain residues hann1W. to consumers. 
Unless the  medicinal. product  used  indicates ·a  withdrawal  period  for  the  species 
concerned, the specified withdrawal period shall not be less than: · 
7days 
7days 
28 days 
500 degree· days 
eggs,_ 
mille, 
meat fn;mfpoultry and mammals including fat and offal, 
meat from fish. 
With regard  to homeopathic  veterinary medicinal  products·in which  the  level  of 
· active principles is equal to or less than one part per million, the withdrawal period 
referred to in the first and second subparagraphs is reduced to zero. 
Article 11 
The veterinarian shall keep adequate records of the date of examination of the animals, 
· details of  the owner, the number of  animals treated, the diagnosis, the medicinal products 
prescrib!'d,  the  dosages  administered,  the  duration  of ·treatment  and  the  withdrawal 
periods recommended, and make these records available for inspection by the competent 
authorities for a period of  at least three years. This requirement may be extended by the 
Member States to food-producing animals. 
Article ll 
1.  For the purposes of  obtaining an authorization for placing on the market irrespective 
ofthe procedure established by Regulation (EEC) No 2309/93, an application shall 
be lodged by the competent authority of  the Member State concerned. 
2.  A marketing  authorization may only be  granted to an apPlicant  established  in .the 
Community. 
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811851/EEC 
Art. 4 (4), lst.and 2nd 
subparagraphs 
(as amended by 
90/676JEBC Art. 1 (4)) 
(adapted) 
92174/EEC 
Art. 2 (1}, 2nd 
subparagraph 
(adapted) 
81/851/EEC 
Art. 4 (4}, 3rd 
subparagraph 
(as amended by 
90/676EEC Art. 1 (4)) 
(adapted) 
81/851/EEC 
Art. 5, 1st subparagraph, 
(as amended by 
90/676/EEC Art. 1 (5)) 
(adapted) 
81/851/EEC 
Art. 5, 2nd suPparagraph 
(as amended by · 
93/40/EEC Art. 1 (3)) 
(adapted) ·  · 3.  The  following  partiCuiars  and documents  sbal1  be  appc:Dded  to the. application· in 
aceordance with .AnneX 1: .  '  . 
(a)  name or business DIIDe and permanent lddress or registered place of  business of  the 
~.responsible for placing. tbe product on the market and, if  different,_ of the 
IDIID1Ifilcture or manuficturers ·involved and of  the sites of  manufacture; 
'81/SSJ~C . 
Art. s. 3rd subparagraph, 
points 1  to 9 
(as amended by 
99/676/EEC Art. 1 (S)) 
(adapted) 
· (b) name of  tbe ~  m~cinal  product (brand name, non-proprietary ~e~·  with  + 
or without a trademark, or· name of  tbe manuf8cturer or scientific name or formula, 
with or without a tradCmark, or  the Dlllle oftbe manufacturer); ·  ·  · 
(c)  qualitative  and  quantitative  particulars  of all  tbe  constituents  of tbe  Veterinary 
medicinal product, usiug tbe usual terminology, but not empirical chemical formulae 
· lnd  giving  the  intemational  non-proprietary  name  recommended  by  the  World 
Health OrganizatioD, where such a name exists; 
(d)  description oftbe method of  man~;  _  · 
·(e)  therapeutic indications, contra-indications and adverse reactions; 
(f)  dOsage for the various species of  animal for which the veterinary medicinal product 
. is  intended,  its  pharmaceutical  fOI'Ult  method  and  route  of administration  and 
proposed shelf life;  · 
(g) if  applicable, explanations oftbe precautionary and safety measures to be taken when 
tbe product is stored, when it is administered to animals and when waste therefrom is 
disposed of, together with an indication of  any potential risks tbe medicinal product 
might pose to the environment and the health of  humans, animals or plants; 
(h)  indication of the withdrawal period.  Where necessuy, the  applicant shall propose 
ilnd justify a tolerance level for residues which may be accepted in foodstuffs without 
risk for the consumer, together with routine analysis methods which. could be used by 
the cOmpetent authorities to trace residues; 
(i)  description of  the control testing methods employed by the manufacturer (qualitative 
and quantitative analysis ofthe co~tuents and the finished product, specific tests 
e.&- sterility tests, test for the presence of  pyrpgens, for the presence of  heavy metals, 
stability tests, biological and toxicity tests, tests on intermediate products);  : 
IS 
81/852/EEC 
. Art. 1' 1st paragraph 
(adapted) (2) 
(j)  results of. 
- physico-chemical, biological or microbioiogical tests, 
- toxicological and pharmacological tests, 
cliQical trials. 
(k)  a summary in accordance with Article 14 of  the product characteristics, one or more 
specimens or mock-ups of  the sales presentation of  the veterinary medicinal product 
together with the p~e  insert; 
(l)  a document  showing  tbat the  manufacturer  is  authorized  in  his own  country  to 
produce vctcrinary medicinal products; 
.  (m) copies of  any marketing authorization obtained in another Member State or in a third 
country for the relevant veterinary medicinal product, together with a list of:those 
Member States  in which an application for authorization submitted  in accordance 
with this Directive  is  under examination.  Copies  of the  summary  of the  product 
characteristics proposed by the applicant in. accordance with Article 14 -~r approved 
by the competent authority of the Member State in accordance with Article 25 and 
copies of  the package insert proposed, details of  any decision to refuse authorization, 
whether in the Community or a third country and the reasons for that decision. 
This infonnation shall be updated on a  regular basis; 
(n)  in the  case ·of medicinal products containing new active substances which are not 
mentioned  in  Annex  I,  ll or ill to  Regulation  (EEC)  No  2377/90, a copy  of the 
docwnents  submitted  to  the  Commission  in  accordance  with  Annex  V  to  that 
Regulation. 
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81/BS11EEC 
.Art. s, ~rd  paragraph, 
point 10, 1st . 
.  subparagraph 
(as amended by 
90/676/EEC Art. 1 (S)) 
81/851/EEC 
Art.· S, Jrd paragraph, 
points 11 and 12 
(as amended by 
90/676/EEC Art. 1 (S)) 
(adapted) 
81/851/EEC 
Art. 5, 3rd paragraph, 
point 13 
(as amended-by 
93/40/EEC Art. 1 (4)) 
.(adapted) 
81/851/EEC 
An. 5, 3rd paragraph, 
point 14 
(as amended by 
90/676/EEC Art. 1 (5)) 
(adapted)  . Article 13 
1.  By way of  derogation from point (j) of Article  12 (3), and without prejudice to the 
law relating to the protection of  industrial and commercial property: 
(a)  the  applicant  sball  not· be  requU"ed  to  provide  the  results  of toxicological  and 
pharmaco!ogical ~  and clinical trials if  he can demonstrate: 
(i)  either that the veterinary medicinal product is essentially similar to a medicinal 
product authorized in the Member State concerned by the application and that 
fh:e  mark~ authorization · holder  · has  agreed  that  .  the  toxicological, 
pharmacological  and  clinical references  contained  in the  file  on  the  original 
veterinary medicinal product  may  be  used  for  the  purpose  of examining  the 
'application·in question; 
(ii) or that the constituent or constituents of  the veterinary medicinal product have a 
well-established medicinal use, with recognized efficacy· and also an acceptable 
level of  safety, with detailed references to the scientific literature; 
(iii) or that the  veterinal'y medicinal  product is  essentially similar to a medicinal 
product which has been authorized within the Community,  in accordance with 
Community provisions in force, for not less than six years and is marketed in the 
Member State for which the application is made;  this period shall be extended to 
I  0 years in the case of  high-technology having been authorized in pursuance of 
the  procedw-e established by Article 2 (5) of Council Directive  87122/EEC111  . 
Furthermore, a Member State may also .extend this period to  10 years by a single 
Decision covering all the medicinal products marketed in its territory where it 
considers this necessacy in the interest of public health.  Member States are at 
liberty not to apply the  six-year period beyond the  date  of expiry of a patent 
·  protecting the origihal medicinal product.  -
(b)  in the. case of  new veterinary medicinal products containing known constituents not 
hitherto  used  in  combination for therapeutic purposes,  the results  of toxicological 
and pharmacological tests and of  clinical trials relating to that combination must be 
provided, but it shall not be necessary to provide the relevant documentation for each 
individual constituent. 
81/851/EEC 
Art. s, 3rd paragraph, 
point 10, 2nd 
subparagraph 
(as amended by 
90/676/EEC Art. 1 (5)) 
(adapted)  . 
2.  Annex I shall apply in like manner where, pursuant to point (aXii) ofparagraph.l,  811852/EEC 
references to published data are submitted.  Art.  1, 2nd paragraph 
(adapted) 
(II  OJ LIS, 17.1.1987, p. 38, DiRctiveJq!CIIled by DiRctive 93/41/EEC (OJL214, 24.8.1993, p. 40). 
17 Article 14. 
The SUDIIlUU')' of  the product cbaracteristics shall contain the following iDformation: 
1.  Name of  the veterinary medicinal products; 
.  '  .  . 
2.  Qualita¢ive  and  quantitative  composition  in  terms  of the  active  substances  and 
constituents  of  the  excipient,  knowledge  of  which  is  essential  ·for  proper 
administtation  of the  medicinal  product;  the  intei:DAtional  non-proprietaty  names 
recouun.ended bY the World Health Organi.z!ltion shall be used, where such names 
exist, or failing this, the usual non-proprietary name (,r chemical description; 
3.  Pharmaceutical form; 
4.  Pharmacological  properties  and, .  in  so  &r  as  this  informition .  is  usetul  for the 
therapeutic: purposes, pharmacokinetic particulars; 
·  S.  Clinical particulars; 
S.l  target species, 
S  .2  indications for use, specifying the target species, 
5.3  contra-indications, 
5.4  undesirable effects (frequency and seriousness), 
S  .S  special precautionS for use, 
S.6  use during pregnancy and lactation, 
S. 7  interaction with other medicaments and other forms of  interaction, 
S.8  posology ~d  method of  administration, 
S.9  overdose (symptoms, emergency procedures, antidotes) (if  necessary), 
. S.l 0 special. warnings for each target species, 
s  .11 withdrawal periods, 
5.12  special  precautions  to  be  taken  by  the  pers~n administering  the  medicinal 
product to animals; 
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81/8~1/EEC 
Art. Sa 
· (as amended by-
90/676/EEC Art. 1 (6)) 
(adapted) 6.. . Pbarmaceutical particulars: 
6.1  major incompatibilities, 
6.2 shelf life; when necessaJ')t after reconstitutiOn of the medicinal product or when 
· the container is opened for the first time,  · 
6.3  special precautions for storage, 
6.4 nature and contents of  container, 
6.5  special  precaution's  for  the  disposal  of unused  medicinal  product  or  waste 
materials, if  any;  ·  .  ·  ' 
7.  Name  or  corporate  name  and  address  or  registered  place  of business  of. the . 
.  authoriZation holder.  · 
Article IS 
811851/EEC 
Art. Sa 
(as amended by 
90/676/EEC An. 1 (6)) 
(adapted) 
1.  Member States shall make all necessary arrangements to enswe ~  the documents  81185 1/EEC 
an~  particulars listed in Article  12 {3) (h), {i), G) and Article 13 (1) are drafted by  Art. 6 
experts  with  the  requisite  technical  or  professional  qualifications  before  being 
submitted to the competent authorities. 
These documents and particulars shall be signed by the experts in question. 
2.  According to their particUlar qualifications, the role of  the experts shall be:  81185 1/EEC 
Art. 7 (1), (2) and (3), 1st 
(a)  to  cany  out  such  work  as  falls  within  their  particular  discipline  (analysis,  subparagraph 
pharmacology  and  similar  experimental  sciences,  clinical  trials)  and  to  describe  (adapted) 
objectively the results obtained in both quantitative and qualitative terms; 
{b)  to describe their findings in accordance with Annex I and in particular to state: 
(i)  in the case of  analysts, whether the medicinal product conforms with the stated 
composition,  providing any reasons for the  control testing methods which  the 
manufacturer is to use; 
19 (ii) in the case of  pharmacologists and appropriately qualified specialists: 
•  the  toxicity of the  medicinal  product  and the  pbarmacological  properti~ 
observed,  ·  · 
•  whether,  after  administration  of the  veterinary  medicinal  product  under 
normal conditions of use  and observance of  1:he recommended withdrawal 
. period, foodstuffs obtained from the·treated animals contain residues which 
might constitute a health hazard to the consumer;  · 
. (iii) in the  case of clinicians, whether they have .found in  animals treated with the 
medicinal  product  effectS  corresponding  to  the information  furnished  by  the 
manufacturer pursuant to Articles  12 and .13 (1 ), whether the medicinal product 
is  well tolerated,.  what  dosage  they  recommend  and  what  are  the  contra· 
indications and adverse reactions, if  any; 
(c)  to  give  reasons  for  the  use  of the  references  to  published  data  referred  to  in 
point {a) (ii) of  Article 13(1). 
3.  The  experts'  detailed  reports  shall  form  part  of th~ documentation  which  the 
applicant shall lodge with the competent authorities. A brief curriculum vitae of  the 
expert shall be appended to each report. 
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81/851/EEC 
Art. 7 (1), (2) and (3), 1st 
subparagraph 
{adapted) 
81/851/EEC 
Art. 7 (3), 2nd 
subparagraph 
(as amended by 
90/676/EEC Art. 1 (8)) .·  Chapter2 
· ParticUlar provisions applicable to · 
homeopathic veterinm:r medi~al  products 
Artiele 16 
1.  Member  States· shall  ensure  that  homeopathic  veterinary  ·medicinal  products  92174/EEC 
manufactured· and marketed within the ·Community are registered or authorized  bl  Art. 6 
·Keordance with the provisions of  Articles 17 (1) and {2),  18 ~d  ·19. Each Member  (adapted) 
State shall take due KCOunt ofregistrations and·authorizations previously granted by 
another Member State.  · · 
2.  A' Member State  may  refrain  from  establishing  a special,  simplified  registration 
procedure  for  the  homeopathic  veterinary  medicioal  products  referred  to  in 
Article 17  (1) and  (2).  A Member  State applying  this  provision  shall inform  the 
Commission accordingly.  The Member State concerned shall, by 31 December 1995 
at the latest, allow. use in its territory of homeopathic veterinary medicinal products 
registered .by other Member States in aceordance with Article  17  (1)  and  (2) and 
Article 18. 
Artic:Jel7 
1.  Only homeopathic veterinary medicinal products which satisfy all of the following  92174/EEC 
conditions may be subject to a special, simplified registration procedure:  Art. 7 (1) 
(adapted) 
they are intended for administration to pet animals or exotic species which  are. 
non food-producing, 
they are administered by a route described in the European Pharmacopoeia or, 
in  absence  thereof:  by  the  pharmacopoeias  currently  used  officially  in  the 
Member States, 
no  specific  therapeutic  indication  appears  on  the  labelling  of the ·veterinary 
medicinal product or in any information relating thereto, 
there is a sufficient degree of dilution to guarantee the safety of the medicinal 
product; in  p~cular, the medicinal product may not contain either more than 
one part per 10 000 of  the mother tincture or more than  Ill  OOth of  the smallest 
dose  used  in  allopathy with regard  to  active  principles. whose  presence  in  an 
allopathic  medicinal  product  results  in  the  obligation  to  submit  a  veterinary 
prescription. 
At the time of registration, Member States shall determine the classification for the 
dispensing of  the medicinal product 
2.  The criteria and rules of  procedure provided for in Chapter 3 shall apply by analogy  92174/EEC 
to the special, simplified registration procedure for homeopthaic veterinary medicinal  Art. 7 (3) 
products  laid down in paragraph  1, with the exception of  the proof of therapeutic  (adapted) 
effect. 
21 3.  The  proof of therapeutic effect sball  not  be  required for homeopathic  veterinary 
medicinal  products registered in accordance  with  paragi-aph  1 of this Article  or,. 
where appropriate, admitted in accordance ~  A:r£icle 16 {2). 
Article 18  · 
92174/EEC 
Art. 4, 2nd subparagraph 
{adapted) 
~  special, simplified application for registration may cover a series of  medicinal products  92174/EEC · 
derived from the  same homeopathic stock or stOCks.  The  following  document shall be  Art. 8 
included with the application in ord'er to demonstrate, in particular, the pharmaceutical  (adapted) 
quality and the batch-to-batch homogeneity of  the products concerned:  · 
scientific Jiame or other name given in a pharmac:opoeia of  the homeopathic stock or 
stocks,  tOgether  with  a  statement  of  the  various  routes.  of  administration, 
pharmaceutical forms and degree of  dilution to be registered, 
dossier  describing  how  the  homeopathic  stock  or  stocks  is/are  obtained  and 
controlled, and justifying its/their homeopathic nature, on the basis of an adequate 
bibliography; in the case of homeopathic veterinary mec;iicinal products containing 
biological substances, a description of the measures taken to ensure the absence of 
pathogens; 
manufacturing and control file for each pharmaceutical form and a description of  the 
method of  dilution and pQtentiation, 
manufacturing authorization for the medicinal products concerned, 
copies  of any  registrations  or  authorizations  obtained  for  the  same  medicinal 
products in other Member States, 
one  or  more  spedmens  or  mock-ups  of the  sales  presentation  of the  medicinial 
products to be registered, 
data concerning the stability of  the medicinal product 
22 Article 19 
.  .  . 
1.  ·Homeopathic vetorioary products other than those refc.rred to in  Article 17 (1) shall  92n4/EEC 
be authorized in actordance with the provisions of  Articles 12 and 13 and Chapter 3.  Art. 9 
{adapted) 
2.  A Member  State  may  introduce  or  retain  in  its  territory  specific  rules  for  the 
pbannacological and toxicological tests and clinical trials of  homeopathic veterinary 
medicinal products' intended .for pet animals and exotic species which are non food-
producing other than  those  referred  to  in Article  17  (1),  in accordance  with the 
principles and cbaracteristics of  homeopathy as practised in that Member State. 
In this case, the Member State concerned shall notify the Commission of  the specific 
rules in force.  · · 
Article20 
This Chapter shall not apply to immunological veterinary medtcinal products. 
23 
92n4/EEC 
Art. 2 (3) 
(adapted) Chapter~ 
Procedure for marketing authorization· 
Article 21 
1.  Member States shall take all appropriate measures to ensure that the procedure for 
granting an authorization to place a veteriDary medicinal product on the market· is 
completed within 210 days ofthe submission of  a validapplication.  · 
2.  Where  a Member  State  notes  that  an  application  for  authorization  submitted  is 
already  under  active  examination  in  another· Member  State  in  respect  of that 
·veterinary medicinal product, the Member State concerned may decide to suspend 
.  the detailed examination of the application in order to await the assessment report 
prepared by the other Member State in accordance with Article 25 (4) . 
.  The Member State concerned shall inform the other Member State and the applicant 
.  of. its  decis.ion to suspend detailed examination of the  application in question.  As 
soon as it has completed the examination of  the application and reached a decision, 
· the other Member State shall forward a copy of  its assessment report to the Member 
State concerned. 
Articlell 
Where a Member State is informed in accordance with Article  12 (3) (m), that another 
Member State has authorized a veterinary medicinal product which is the subject of  an 
application for  authorization  in the  Member State concerned, that Member State shall 
forthwith request the authorities of  the Member State which has granted the authorization 
to forward to it the assessment report referred to in Article 25 (4). 
Within 90 days  of receipt of the assessment report, the Member State concerned shall 
either recognize the decision of the first Member State and the summary of the product 
characteristics as approved by it or, if  it considers that there are  groun~ for supposing 
that the authorization of  the veterinary medicinal product concerned may present a risk to 
human  or  animal  health  or the  environment,  it shall  apply  the  procedures  set out  in 
Articles 19 and 33 to 38. 
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81/851/EEC 
Art. 8 
(as amended by  . , 
93f40/EEC Art. 1 (6)) 
(adapted) 
81/851/EEC 
Art. Sa 
(as amended by 
93/40/EEC Art. 1 (7)) 
(adapted) Articlel3 
In order to examine  the application submitted pursuant to  Articles  12 and  13  (l), the  81185.1/EEC 
competent authority ofdlc Member States:  ·  Art. 9 (I) 
1.  shall check that the documentation submitted m  support of  the appliCation' complies 
with Articles 12 and 13 (l) and, on the basiS ;of the reports drawn up by the experts 
puisuant to :Article  15. (2) and (3), ascertain whether the conditions for the issue of 
the marketing authorizati~n have been fultilled; · 
2.  may· submit the medicinal product,  its raw materials and if  necessazy  intermediate 
products  or other  coostituent materials .for testing  by a State  laboratory  or by a· 
laboratory designated for that purpose, in order to ensure that the  testing methodS 
employed  by the  manufacturer  and  described  in the  application  documents,  in 
accordance with Article 12 (3) (i), are satisfactory; ·  · 
3.  may,  where  appropriate,  require  the  applicant  to provide  further  information  as 
regards the items listed in Articles  12 ~  13  (1). Where the competent authorities 
take this course of action, the time-limits specified in .Article 21 shall be suspended 
until the further data required have been provided. Similarly, these time-limits shall 
be suspended for any period which the applicant may be given  to provide oral or 
written explanations; 
4.  may  require  the  applicant  to  submit  substances  in  the  quantities  necessary  to 
verify the analytical detection method proposed by the  ~pplicant in accordance with 
Article  12 (3) (h) and to  put it into. effect as  part of routine  checks  to  reveal the 
presence of  residues of  the veterinary medicinal products concerned. 
2S 
(adapted) 
81/851/EEC 
Art. 9 {2) 
(as amended by 
90/676fEEC Art. 1 (9)) 
(adapted) 
81/851/EEC 
Art. 9 (3) 
(adapted) 
81/851/EEC 
Art. 9 (4) 
(as amended by 
90/676/EEC Art. 1 (10)) 
(adapted) Artidel4 
Member States sball take all appropriate measures to ensure that 
(a)  the competent authorities ascertain that the manufacturers and importers of  veterinary 
medicinal products from third countries are able to manufacture them in compliance. 
with the details. supplied pursuant to Article 12 (3} (d), and/or to carry out control 
tests· in accordance with the methods described in the application documents under 
Article 12 (3) (i); 
(b)  the competent authorities may authorize manufacturers and importers of veterinary 
medicinal  products  from  third  countries,  where  cirtumstances so justify,  to ·have 
certain stages of manuficture and/or certain of the control tests _.refened  to in {a) 
carried out by third parties; in such cases, checks by the competent authorities shall 
also be carried out in the establishments concerned. 
Articlel5 
1.  Wh~  the marketing  authorization  is  issued,  the  holder shall  be  informed  by the 
competent authorities of  the Member State concerned, of  the summary of  the product 
characteristics as approved by it 
2.  The  competent  authorities  shall  take  all  necessary  measures  to  ensure  that  the 
information  given· in the  summary  is in conformity  with  that  accepted  when  the 
marketing authorization is issued or subsequently. 
3.  The competent authorities shall forward to the Agency a copy of the authorization 
together with the summary of  the product characteristics .. 
4.  The competent authorities Shall draw up an assessment report and comments on the 
dossier as regards the results of the analytical and pbarmacotoxicological tests and 
the  clinical  trials of the  veterinary  medicinal  product  concerned.  The  assessment 
report shall be updated whenever new  information becomes available  which  is of 
importance  for  the  evaluation  of the  quality,  safety  or efficacy  of the  veterinary 
medicinal product concerned. 
26 
, 81/SSl/EEC 
Art. 10 
81/851/EEC 
Art. Sb 
{as amended by 
93/40/EEC Art 1 (5)) 
(adapted) Article 26 
1.  The ·marketing authorization  may require  the  holder  to indicate  on  the  container  811851/EEC 
and/or the outer wrapping !IJl(l the package insert, where the latter iS required. other  Art.  12 
particulars essential for safety or health protection, including any special precautions  (adapted) 
relating  to  use  .and  any  other  Warnings  .  resulting  from  the  clinical  and 
pharmacological trials prescribed in Articles 12 (3) G) and 13 {1) or from experience 
gained during the use of  the veterinary medicinal product once it has been marketed. 
2.  The  authorization  may  also  require  the  inclusion  of a  tracer  substance  in  the 
veterinary medicinal product. 
3.  In  exceptional  circumstances,. and  following  cons.ultation  with  the  applicant,  an 
authorization may be  granted subject to certain specific obligations, and subject to 
BDDual review, including: 
the carrying out of  further ~es  following the granting of  authorization, 
the notification of  adverse 'reactions to the veterinary medicinal product. 
These  exceptional  decisions  may  only  be  adopted  for  objective  and  verifiable 
reasons. 
Article 27 
1.  After a marketing ·authorization bas been issued, the holder must, in respect of the 
manufacturing methods and control methods provided for  in Article  12 (3) (d) and 
(i), take account of scientific and technical progress and intrOduce any changes that 
may be required to enable that veterinary medicinal product to be manuf'a.ctw-ed and 
checked by means of  generally accepted scientific methods. 
These  changes  shall  be· subject to the  approval  of the  competent .  authority  of the 
Member State concerned. 
2.  Upon request from the competent authority, the marketing authorization bolder shall 
also review the analytieal detection methods provided for in Article  12  (3) (h) and 
propose  any  changes  w~cb may  be  necessary ·to  take  account  of scientific  and 
technieal progress. 
3.  The marketing authorization holder shall forthwith inform the competent authority of 
any  new .. information  which  might  entail  the  amendment  of the  particulars  and 
documents referred to in Articles  12 and  13 (1) or of  the approved summary of  the 
product  characteristics.  In  particular,  he . shall  forthwith  inform  the  competent 
authority of  any prohibition or restriction imposed by the competent authority of  any 
country in which the veterinary medicinal product is marketed  and  of any .serious 
unexpected adverse effect occurring in the animals concerned or human beings. 
27 
81/851/EEC 
Art. 15 {2) 
(as amended by 
93/40/EEC Art. 1 (9)) 
81/851/EEC 
Art. 14 (1), 1st 
subparagraph 
(as amended by 
93/40/EEC Art.  I {8)) 
(adapted) 
811851/EEC 
Art.  14 (1), 2nd 
subparagraph and (2) 
(as amended by 
90/676/EEC Art. I (11)) 
(adapted) 4.  The  IJ:I8l'ketiDg  authorization  holder  shall .be ~  tO  mainWn records  of all 
adverse re8ctions observed in animals or human beings. The records ·so estabished 
shall  be  bpt at  least  five 'years  and  shall  be  made  available. to the  competent 
authorities upon request.  · 
5.  The  marketing .  authorization  holder  shall  immediately  inform  the  con1petent 
authorities, with a view to aud1orizatio~ of  any alteration he proposes to make to the 
particulars and documents referred to-m Articles 12 and 13 (1).  · 
Article 28 · 
Authorization shall be valid for five years and sb8n be reliewable for five-year periods, 
on  application  by the  holder  at. least ~  months  before  the  expiry date  and  after 
consideration of  a dossier updating ~e  information previously submitted. 
Articlel9 
81/851/EBC. 
Art. 14 (3) and (4) 
(as amended by 
90/676/EEC Art. 1 (11)) 
(adapted) 
81/851/EEC 
Art. 15 (1) 
(as amended by 
93/40/EEC An. 1 (9)) 
The  granting  of authorization  shall  not  diminish  the  general  legal  liability  of the  81/851/EEC 
manufacturer and, where appropriate, of  the authoriz.ation holder.  Art.13 
Article30 
(b)  has no therapeutic effect or the applicant has not provided sufficient proof of such 
effect as regards the species of  animal which is to be tr~d;  or 
(c)  its qualitative or quantitative composition is not as stated; or 
(d)  the withdrawal period recommended by the applicant is not long enough to ensure 
that foodstuffs obtained from the treated animal do not contain residues which might 
constitute a health hazard to the consumer, or is insufficiently substantiated; or 
(e)  the veterinaty medicinal product is offered for sale for a use prohl'bited under other 
community provisions; or  ·  ·  · 
(f)  a veterinaty medicinal product presents a risk  for  the  protection of public health, 
consumer or animal·healtb. 
Authorization  shall  also  be  withheld . if the  application  documents  submitted  to  the 
competent authorities do not comply with Articles 12, 13 (1) and 15. 
28 
(adapted) ~apter4 
·Mutual reeognition of  authorizations  .  .  . 
1.  In order to mcilitate the adoption of common decisions by Member States on the 
authorization .ofveterinary·medicinal products on the basis of  the scientific criteria of 
quality, safety and efficacy, and to achieve thereby the free .movement of veterinary 
medicinal products .within the Community,  a Committee for V  eteriiwy Medicinal 
Products,  hereinafter  referred  to  as  "the  Committee",  is  hereby  set  up.  The 
Committee shall be part of  the Agency. 
2:  In addition to the  other responsibilities conferred upon it by Community law,  the 
Committee shall examine any question relating to the granting, variation, suspension 
or withdrawal of  marketing authorization which is submitted to it in accordance with 
the provisions of  this Directive. It shall also examine any question relating to tests of 
veterinary medicinal products.  · 
3.  The Committee shall adopt its own rules of  procedure. 
Artide3l 
81/851/EEC 
Art.  16 (1) 
(as amended by 
93/40/EEC Art. i (10)) 
(adapted) 
81/851/EEC 
Art. 16 (2) 
(as amended by 
93/40/EEC Art. 1 (1 0)) 
+ 
811852/EEC 
Art.2 
(adapted) 
81/851/EEC 
Art. 16 (3) 
(as amended by 
93/40/EEC Art. 1 (IO)J 
1.  Before submitting an application for mutual recognition of  marketing authorizations,  81185 1/EEC 
the  holder  of the  authorization  shall  inform  the  Member  State  which  granted  Art. 17 (3) 
the authorization  on  which. the  application  is  based  (hereinafter:  the  referential  (as amended by 
Member State) that an application is to be made in accordance with this Directive  93/40/EEC Art. 1 (10)) 
and shall notify it of any additions to the original dossier; that Member State may  (adapted) 
require the applicant to provide it with all the particulars and documents necessary to 
enable it to check that the dossiers filed are identical. 
'  / 
In addition, the holder of  the authorization shall request the referential Member State 
which granted the initial authorization to prepare an assessment report in respect of 
the  veterinary  medicinal  product  concerned,  or,  if necessary,  to  update  it.  That 
Member State shall prepare it within 90 days of  receipt of  the request 
At the same time as the application is submitted in accordance with paragraph 2 the 
referential  Member Sate  which granted the  initial authorization  shall  forward  the 
assessment  report  to  the  Member  State  or  Member  States  concerned  by  the 
application. 
29 2.  In order  to obtain  the  ie<:Ognition  according  to  the  procedure  laid. down  in this  81/851/EEC 
Chapter in one or·more of  the Member States of  a marketing authorization issued by.  Art. 17 (0  and (2) 
· . a Member State, the holder. of_ the authorization shall submit an application to the  (as amended by 
competent authority .of the Member Siate or Member States concerned, together with  93/40/EEC Art. 1 (1 0)) 
the information and  parti.~  referred to in Articles 12,  13  (1) and  14. He shall  (adapted) 
testify that the dossier is identical to that accepted by the referential Member State,. 
or sball  identify any  additions  or amendments  it may ·contain.  In the  latter case, 
he shall certify that the summary of  the product characteristics proposed by him in 
accordance  with  Article · 14  is  identical  to  that  accepted  by  the  referential 
Member State.  Moreover, he  shall certify that all  the  dossiers filed  as part of this 
procedure are identical. 
3.  The  holder  of the  marketing  authorization  shall  transmit  the  application  to  the 
Agency, inform it of  the Member States concerned and of  the dates of  submission of 
the  application and send it a copy of the  authorization  granted by the referential 
Member State. He shall ~  send the Agency copies of  any such authorization which 
may  have  been  granted  by the  other  Member  States  in  respect of the  veterinary 
medicinal  product  concerned,  and  shall  indicate  whether  any  application  for 
authorization is currently under consideration in any Member State. 
4.  Save in the exceptional case provided for in Article 33 (1), each Member State shall 
recognize the marketing authorization granted by ·the referential Member State within 
90 days of receipt of  the application and the assessment report.  It shall inform the 
referential Member State, the other Member States concerned by the application, the 
Agency, and the authorization bolder for placing the product on the market. 
Article33 
811851/EEC 
Art.17(4) 
(as amended by 
93/40/EEC Art. 1 (10)) 
(adapted) 
1.  Where  a  Member  State  considers  that  there  are  grounds  for  supposing  that  the  811&51/EEC 
. marketing authorization of  the veterinary medicinal product concerned may present a  Art. 18 
risk to  human  or animal  health or the  environment,  it sluill  forthwith  inform  the  (as amended by 
applicant, the referential Member State, any other Member States concerned ey the  93/40/EEC Art. 1 (10)) 
application and the Agency.  The Member State shall  state its reason  in detail and  (adapted) 
shall indicate what action may be necessary to correct any defect in the application. 
2.  All the Member States concerned shall use their best endeavours to reach agreement 
on ·the  action  to  be  taken  in  respect  of the  application.  They  shall  provide  the 
applicant with the opportunity to make his point of view known orally or in writing. 
However,  if the Member States  have  not reached  agreement within  the time-limit 
referred  tQ  in Article 32  (4)  they  shall  forthwith  refer the  matter to  the  Agency, 
according to the reference to the Committee, for the application of  the procedure laid 
down in Article 36.  · 
3·.  Wit,bin the time-limit referred to in Article 32 (4), the Member States concerned shall 
provide the Committee with a detailed statement of  the matters on which they have 
been unable to reach agreement and the reasons for their disagreement The applicant 
shall be provided with a copy of  this information. 
4.  As soon as be is informed that the matter has been referred to the Committee, the 
applicant shall forthwith  forward to the  Committee a copy of the  information and 
particulars referred to in Article 32 (2). 
30 Artiele34 
.  . 
If  several applications submitted in accordance with Articles 12, 13 (l)and 14 have been  81/851/EEC 
made  for marketing  autboriza:tion  for  a  particular  veterinary  medicinal  product  and  Art. 19 
Member States have  adopted divergent  ~isions concerning the  authorization of that  (as amended by 
veterinary  medicinal  p~  or  suspension  or withdrawal"' of that  authorization,  a  93/40/EEC Art. 1 (10)) 
Member. State, or the Commissi911, or the marketing  ~orization holder may refer the  {adapted) 
matter to the Committee for application of  the procedure wd down in Article 36. 
.  ·' 
The Member  State  concerned,· the  marketing  authorization holder or the  Commission 
shall clearly identify the question which is referred. to the Committee for .consideration 
and, if  appropriate, shall inform the aforemention~d  holder thereof. 
The  Member  States  and  the  marketing  authorization  holder  shall  forward  to  the 
Committee all available information relating to the matter in question. 
Artiele35 
The  Member  States  or the  Commission  or the  applicant  or holder of the  marketing  81185 1/EEC 
authorization may, in specific cases where the interests of the Community are involved,  Art 20 
refer the  matter to the  Committee  for  the  application  of the  procedure  laid  down  in.  (as amended by 
Article 36 before reaching a·decision on a request for a marketing authorization or on the  93/40/EEC Arll (10)) 
suspension or withdrawal of  an authorization, or on any other variations to the terms of  a·  (adapted) 
marketing  authorization  which  appears  necessary,  in  particular to take  account  of the 
information collected in accordance with Title VII. 
The Member State concerned or the Commission shall clearly identitY the question which 
is  referred  to  the  Committee  for  consideration  and  shall  inform  the  marketing 
authorization holder.  · 
The  Member  States  .and  the  holder  shall  forward  to  the  Committee  all  available 
information relating to the matter in question. 
31 (3) 
Artiele36 
1.  When reference is ~  to the procedure described in this Article, the Committee 
shall consider the matter concerned and issue a reasoned opinion within. 90 days of 
the date on which the matter was referred to it. 
However,  in cases subiniued to the Committee in accordance with Articles 34 and 
35, this period may be ex1ended l>Y 90 days. 
In case of  urgency, on a proposal frOm its Chairman, the Committee may agree tO a 
shorter deadline;  ·  · 
2..  In order to consider the matter,.the Committee may appoint one of  its members to. act 
as rapporteur. The  CommittCe may also appoint individual experts to advise  it on 
specific questions. When appointing experts, the Committee shall define their tasks 
and specify the time-limit for the completion of  these tasks. 
3.  In  the  cases  -referred  to in  Articles  33  and  34,  before  issuing  its  opinion,  the 
Committee shall provide the· marketing authorization holder with an opportunity to 
present written or oral explanations. 
In the case referred to in Article 35, the marketing authorization holder may be asked 
to explain himself orally or in writing. 
If it considers it appropriate, the Committe.e may invite any other person to provide 
information relating to the matter before it. 
The  Committee may suspend the time-limit referred to in paragraph  1 in order to 
allow the marketing authorization holder to prepare explanations. 
32 
811851/EEC 
Art.21 
{as amended by 
93/40/EEC Art. 1  {1 0)) 
{adapted) 4. ·.'Ibe Ageot:y sball forthwith  infonn the  marketiDg  authorization hoider where  the 
· opinion oflhe Committee is tbat: 
•  the ippUcation does not satisfy the criteria for authorization, or. 
the  summary  of the  product  cbaracteristics  proposed  by  the  applicant  in 
&ccordance with Article 14 should be amended. or 
the  authorization  should  be  granted  subject  to  conditions,  with  regard  to 
conditions considered essential for the safe and effective use of the ·veterinary 
medicinal product including pharmBcovigilance, or  · 
a marketing authorization should be suspended, ~ed  or withdrawn. 
Within  IS days of the receipt of the opinion, the holder may notify the Agency in 
writing of  his intention to appeal. In that case, he sball forward the detailed grounds 
for appeal to the Agency within 60 days of  receipt of  the opinion. Within 60 days of 
. receipt of  the grounds for appeal. the Committee shall consider whether its opinion 
should be revised, and the conclusions reached on the appeal shall be annexed to the 
· assessment report refCITCd to in paragraph 5. 
S.  Within 30 days of its adoption, the Agency shall forward the  final opinion of the 
Committee to the Member States, the Commission and the marketing authorization 
· holder together with a report· describing the assessment of the veterinary medicinal 
product and the reasons for its conclusions. 
In the event of an opinion in favolD' of granting or maintaining an authorization to 
place  the  veterinary  m'edicinal  product  concerned  on  the  market,  the  following 
documents shall be annexed to the opinion: 
(a)  a draft summary of  the product characteristics, as referred to in Article 14; where 
necessmy this will reflect differences in the veterinary conditions pertaining in 
the Member States.· 
(b)  any conditions affecting the authorization within the meaning of  paragraph 4. 
33 
81/851/EEC 
Art. 21  . 
(as amended by 
93/40/EEC Art. 1 (10)) 
(adapted). Article37 
Withm 30 days of receipt· of the opinion, tbC  Co~ion  shall. prepare a ~  of the ·  81/851/EEC 
·decision to be 1Blam in respect of  the application, taking into 'account Community law.  Art. 22 (1) 
(as amended by 
·In the event of a draft decision which enVisages the granting of  marketing authorization,.  93/~0/EEC  Art 1 (1 0)) 
the  docmnents  referred to in Article  36  (5),  2nd  sUbparagraph,  (a)  and  (b)  sba1l  be 
annexed. 
Where, exceptionally,  the draft decision  is not in accordance with the  opinion of the 
Agency, the Ccmimission sball ·also ~  a detailed explanation of the reasons for the 
differences.  · 
The draft decision sball be forwarded to. the Member States and the applicant. 
Article38 
1.  A final decision on the application shall be: adopted in accordance with the procedure 
laid down in Article 91. 
2.  The rules of procedure  of the  Standing Committee  set up  by Article  88  sball be 
adjusted  to take  account  of the  tasks  incumbent  upon  it  in  accordance  with  this 
Chapter. 
These adjUS1ments shall involve the following: 
except in cases referred to in the third paragraph of  Article 37, the opinion of  the 
Standing Committee shall be obtained in. writing,  · 
each Member State is allowed at least 28 days to forward written observations on 
the draft decision of  the Commission, 
each  Member  State  is  able  to  require  in writing  that  the  draft  decision  be 
discussed by the Standing Committee, giving its reasons in detail. 
Where,  in  the  opinion  of  the  Commission,  the  written  observations  of  a 
Member State raise important new questions of a scientific or technical nature which 
have not been addressed in the opinion of  the Agency, the Chairman shall suspend 
the procedure and refer the application back to the Agency for further consideration. 
The provisions necessary for the implementation of  this paragraph shall be adopted 
by the Commission in accordance with the procedure laid down in Article 90. 
3.  A decision as referred to in paragraph 1 shall be  addressed  to the Member States 
concerned by the matter and communicated to the marketing authorization holder. 
The Member States shall either grant or withdraw marketing authorization, or vary 
the  tenns of a marketing  authorization  as  necessary to comply  With  the  decision 
within 30 days of  its notification. They shall inform the Commission and the Agency 
thereat:  · 
34 
81/851/EEC 
An. 22 (2), (3) and (4) 
(as amended by 
93/40/EEC Art. 1 (10)) 
(adapted) Artide39 
. 1.  Any  application: by . the. JDaJtetiDg  authorization  holdei  to  -varY  a  maiketmg 
audtorization  which  has  been  granted  in  accordance  with  the  provisions  of this 
· Chapter  sba1l  be  submitted  to  all  tht:  Member  Staies  which  have  previously 
authorized the veterioary medicinal product concemed. 
The· Commission  sball.  in  consultation  with'  the  Agency,  adopt  appropriate 
arrangements  for  the  examination  of :variations  to  the  terms  of a  marketing 
authorization. 
These arrangements sba11 include a notification. system or administration.procedures 
conceming minor variations and define precisely the concept of"a minor variation". 
These  arrangements  shall  be  adopted  by  the  Commission  in  the  form  of an 
implementing regulation in ~ce  with the·procedme laid down in Article 89.  · 
2.  The  procedure  laid  down  in Articles  36,  37  and  38  shall  apply  by  analogy  to 
· variations made to marketing authorizations for products. 
Article 40 
81/851~ 
Art~ 
(as amended by 
93/40/EEC Art. 1 (10)) 
{adapted) 
1.  Where  a Member  State  considers  that  the  variation  of the  terms of a marketing  81/851/EEC 
authorization  which  has  been  granted  in accordance  with  the  provisions  of this  Art. 23a 
Chapter or its suspension or withdrawal is necessary for the protection of  human or  (as amended by 
aD.imal  health  or  the  environment,  the  Member  State  concerned  shall  forthwith  93/40/EEC Art.  1 (10)) 
refer the matter to the  Agency  for  the application of the procedures  laid  down  in  (adapted) 
Articles 36, 37 and 38. 
2.  Without prejudice to the provisions of  Article 3S, in exceptional cases, where W'gent 
action  is  essential  to protect human  or  animal health  or the  environment,  until  a 
definitive decision is adopted, a Member State may suspend the marketing and the 
use of  the veterinaJy medicinal product concerned on its territory. It shall inform the 
Commission and the other Member States no later than the following working day.of 
the reasons for its action.  · 
3S Al'ticle 41 
Articles 39 and 40 shan apply by amalogy tO veterimuy medicinal productS authorized by 
Member States following an opinion of  the Committee given in accordance with Article 4 
ofDirective 87122/EEC before 1 JamJary-1995.  · 
Article 42 
1.  The Agency sball publish an annual repOrt on the operation of  the procedures laid· 
doWn  in  this  Chapter  and  sball  forward  it. to the  European  P~liament  ·  and  the 
Council for information.  · 
2.  By 1 January 2001, the Commission sball publish a detailed review of  the operation 
of tbe  procedures  laid  down  in this  Chapter and  shall  propose  any  amendments 
which may be necessary to improve these procedures. 
.  . 
The Council shall decide, Under the conditions provided for in the Treaty,  on the 
Commission proposal within one year of  its submission. 
·Artide43 
The provisions of  Articles 31 to 38 sball not apply to homeopathic veterinary medicinal 
products referred to in Article 19 (2). 
36 
811851/EEC 
Art. 23b 
(as amended by  . 
93/40/EEC Art. 1 (1 0)) 
811851/EEC 
Art.23c 
(as amended by 
93/40/EEC Art. 1 (10)) 
811851/EEC 
Art 22 (5) 
(as amended by 
93/40/EEC Art. 1 (10)) 
(adapted) TITLE IV 
MANUFACTURE AND IMPORTS 
Article44 
1. ·  Member States shall take all appropriate measures. to ensure that the manufacture of 
v~  mediciDal  products  in  their telritory  is  subject. to  the  holding  of an 
authorization.  This  lll8llUfacturin  authorization  sball  lilcewise  be  required  for 
veterinary medicinal products intended for export. 
2.  The  authorizatiOn referred to  in paragraph  1 sball be  reqtrlred both for total and 
partial  manufacture  and  for  the  various  processes  of dividing  up,  packaging  or· 
· presentation. 
However,  such  authorization  shall not  be ~  for  preparation,  dividing  up, 
changes in packaging or presentation where these processes are carried out solely for 
the  dispensing  of retail  supply  by  pharmacists  in  dispensing  pharmacies  or by 
persons legally authorized in the Member States to cany out such processes. 
3.  The authorization referred to in paragraph 1 shall also be required for imports from 
third countries into a Member State;  this Title and Article 83  shall apply to  such 
'  imports in the same way as to manufacture. 
Member  States  shall  take  all  appropriate  measures  to  ensure  that  veterinary 
medicinal products brought into their territory from a third country and destined for 
another Member State are accompanied by a copY of  the authorization refeired to in 
paragraph 1.  . 
Article 45 
·auas11EEC 
Art. 24 (1) 
(as amended by 
90/676/EEC Art. .1  (14)) 
(adapted). 
811851/EEC 
Art. 24 (2) and (3), 1st 
subparagraph 
(adapted) 
81/851/EEC 
Art. 24 (3 ), 2nd 
subparagraph 
(as amended by 
90/676/EEC Art. 1 (15)) 
In order to obtain the manufacturing authorization, the applicant shall meet at least the  81185 IIEEC 
following requirements:  Art. 25 
(adapted) 
(a)  be shall specify the veterinary medicinal products and pharmaceutical forms  which 
are  to  be  manufactured  or  imported  and  also  the  place  where  they  are  to  be 
manufactured and/or controlled; 
(b)  he shall have at his disposal, for the manufacture or import of  the above, suitable and 
sufficient premises,  technical equipment  and  control. facilities  .complying with the 
legal requirements which the Member State concerned  lays down· as  regards both 
man~  and control and the storage of  products, in accordance with Article 24; 
(c)  he shall have at his disposal the services of at least one qualified person within the 
meaning of  Article 52. 
The applicant shall provide particulars in his application to establish his compliance with 
the above requirements. 
37 Article 46 
1.  The ~  authority  9f the  Member ·State  sball not  issue  the  maDufaCturing  81/851/EEc 
autborilation until it~  established the ac:curaey of  the parti~  supplied pursuant  ·Art. 26 
to Article 45 by means of  an inquiry canied out by its representatives. .  ~adapted) 
2.  In order to ensure that the requin:ments referred tO in Article 45 ·are complied with, 
authorization  may  be  made  conditional  on  the  fulfilment  Qf  cenain  obligations 
imposed either when authorizatio~ is granted or at a later date. 
3.  The authorization shall apply only to the premises specified in the application and to 
the  veterinary  medicinal  products  and  pharmaceutical  forms  Specified  in  that 
application.  · 
Article 47 
The Member States shall take all appropriate me&SW'CS to ensure that the time taken for  81/85 1/EEC 
the procedure for granting the manufacturing authorization does not exceed 90 days from  Art. 28 (1) 
the day on which the competent authority receives the application.  (adapted) 
Article<t& 
If the  holder  of the  manufacturing  authorization  requests  a  change  in  any  of the  811851/EEC 
particulars referred to in Article  45  (1) (a)  and  (b), the  time  taken for  the  procedure  Art. 28 (2) 
relating to this request shall not exceed 30 days. In exceptional cases, this period of  time  (adapted) 
may be extended to 90 days. 
Article49 
The competent authority of the Member States may require from  the applicant further  81/851/EEC 
information  concerning  both  the  particulars  supplied  pursuant· to Article  45  and  the  Art. 28 (3) 
qualified  person  referred  to  in Article  52;  wh~e the  competent  authority  concerned  (adapted) 
exercises this right, application of the time-limits referred to in Articles 47 and 48 shall 
be suspended until the additional data required have been supplied. 
38 ArtideSO · 
·The flo~  of  a manufactUriug aUthorization sball at least be obliged tQ:  81/851/EEC 
Art. 27 (a) to (e) 
. (a) . have  at bis  disposal  d1e  services  of Staff eomplying  wi1h  the  legal  requirellients  (adapted} 
existing in the Member State c:oncemed as iegards both manufacture and controls; 
· (b)  dispOse of  the: authorized veteriDary medicinal products only in accordance with the 
legislation of  the Member States concerne!it 
(c)  give prior notice to the competent authority of  any changes which he may wish to 
make  to any  of the  particulars  supplied  pursuant  to  Article  45;  the  competent · 
authority shall. in any event, be immediately informed if  the qualified person referred 
to in Article 52 is replaced unexpectedly; 
(d) -allow the representatives of  the competent authority of  the Member State concerned 
access to his premises at any time;  ·  · 
(e)  euable ·the  qUalified  person  referred  to  in  Article  52  to  wry out  hiS  duties, 
particularly by placing at.bis disposal all the neceSS8l)' facilities. 
{f)  comply with the  principles and the guidelines of good manufacturing practice for 
medicinal products laid down by Community law; 
(g)  keep detailed records of  all veterinary medicinal products supplied by him. including 
samples, in acc::ordance with the laws of  the countries of  destination. The following 
information at least shall be recorded in respect of each transac:tion, whether or not it 
i$ made for payment 
- date, 
- name of  the veterinary medicinal product, 
- quantity supplied, 
- name and address of the recipient, 
batch number. 
These records shall be available for inspection by the competent authorities for a period 
of  .at least three years. 
Article 51 
The principles and guidelines. of good manufacturing practice for  veterinary mec!icinal 
products refemd to in Article 50 (t) sball be adopted in the form of  a Directive addressed 
to the Member States in accordance with the procedure laid down in Article 90.  · 
Detailed guidelines sball be published by the Coinmission and revised as appropriate to 
take account of  scientific and technical progress. 
39 
811851/EEC 
Art. 27 (t) and (g) 
(as amended by 
90/676/EEC Art. 1 (17)) 
811851/EEC 
Art. 27a 
(as amended by 
90/676/EEC Art. 1 (18)) 
(adapted) Arttde52 
1.  Member States sball take all appropriate measures to ensure that the bolder of  the  81/851/EEC 
manufacturing autboriDtion bas permanently and  CODtiouo,usly  at his disposal the  Art. 29 
services of  ·at least one  qualified person  who  fulfils the  conditioos  laid down in  (adapted) 
Article 53  and is responsible, in particular, for canying out'the duties specified in 
Article 55.  · 
2.  If  be  personally  fulfils the  conditions  laid  down  in· Article  53,  the  bolder of the 
authorization may himself  assume the responsibility referred to in paragraph 1. 
Article 53 
'· 
1.  Member States sba1l ensure that the qualified person referred to in Article 52  f.Wfi1s  811851/EEC 
the minimum conditions of  qualification set oUt in paragraphs 2 and 3.  Art 31 · 
(adapted) 
2.  The  qualified  person  shall  be .  in  possession  of a  diploma,  certificate  or other 
evidence· of formal qualifications awarded on completion of a university comse of 
study,  or  a  comse  recognized  as  equivalent  by  the  Member  State  concerned, 
extending over a period of  at least four years of  theoretical and practical study in one 
of the  following  scientific  disciplines:  pharmacy,  medicine,  veterinary  science, 
chemistry, pbarmaceutical chemistry and technology, biology. 
However, the minimum duration of the university course may be three and a half 
years where the comse is followed by a period oftheoretical and practical1raining of 
at least one year and includes a training period of  at least six months in a pharmacy 
open to the public, corroborated by an examination at university level, 
Where two university or recognized equivalent courses co-exist in •·Member State 
and where one of these extends over four ,years and the other over three years, the 
diplo~  certificate  or.  other  evidence  of  formal  qualifications  awarded  on 
completion of the three-year university comse or its recognized equivalent ·shall be 
-c:onsidered to fulfil the condition of  duration referred to in the first subparagraph. in 
so far as the diplomas, certificates or other evidence of  formal qualifications awarded 
on completion of  both comses are recognized as equivalent by the State in question. 
40 n.c;. couise sbali include theoretiC8J and practical tuition· bearing upon at least the  81/851/EEC 
fou'owing basic subjects:  ·  .  ·  ·  .  Art. 3 I 
(adapted) 
experimeDta1 physics, 
general and. inorganic chemistry, 
organic chemistry, 
- .  analytical chemistry; 
pbarmaceutical chemistry, including analysis of  medicinal products, 
general and applied biochemistry (medical) , 
physiology, 
microbiology, 
pharmacology, 
phannaceutical technology, 
toxicology, 
pharmacognosy (study of  the composition and effects of  the active principles of 
natural substances of  plant and animal origin). 
Tuition in these subjects should be so balanced as to enable the person concerned to 
fulfi.lthe obligations specified in Article 55. 
In so far as certain diplomas, certificates or other evidence· of formal qualifications 
mentioned in this paragraph do not fu1fi.1 the criteria laid down above, the competent 
authority of the  Member  State  shall  ensure  that  the  person  concerned  provides 
evidence  that  he  has,  in  the  subjects  involved,  the  knowledge  required  for  the 
manllfilctu@ and control of  veterinary medicinal products. 
3.  The qualified person shall have acquired practical experience over at. least two years, 
in one or more undertakings which are authorized manufacturers, in the activities of. 
qualitative  analysis  of medicinal  products,  of quantitative  analysis  of active 
substanceS  and  of the  testing  and  checking  necessary  to  ensure  the  quality  of 
veterinary medicinal products. 
The duration of  practical experience may be reduced by one year where a university 
course lasts for at ieast five years and by a year and a half  where the course lasts for 
at least six years. 
41 Article 54 
! 
1.  A person engaging bi the activities of  the person referred to in Article 52 from the.  81/851/EEC 
time  of the  application  of Directive  81/851/EEC,  but  not  complying  with  the.  Art. 32 
provisions of  Article 53 shall be eligible to continue to engage in those activities in  (adapted) 
the State concemec1  .  . 
2.  The · holder  of a  diploma,  certificate  or  other  evidence  of formal  qualifications 
·  awarded on completion of  a university course • or a course recognized as equi:nient 
by the Member State concerned • in a scientific discipline allowing him to engage. in 
~ · the. activities of the person refeJTed tO in Article 52. in accordance with the laws of 
that State may - if  he began his course prior to 9 October _1981  • be conSidered as 
qualified to cany out in that State. the duties of  the person referred to in Article ·52, 
provided that he has previouSly engaged in the following activities for· at least two 
years  before  before  9 October  1991. in ·one  or more  undertakings  authorized ·to 
manufacture:  production supervision .and/or qualitative and quantitative analysis of 
active substances, and the necessary testing and checking under the direct authority 
of  a person as referred to in Article 52 to QlSW'e the quality of veterinary medicinal" 
products. 
If  the person concerned has acquired the practical experience referred to in the first 
subparagraph  before 9 October  1971, a further  one  year's  practical  experience  in 
accordance  with  the  Conditions  referred  to .  in  the  first  subparagraph  shall ·  be 
completed by him immediately before he engages in such activities. 
42 ArUc:le$5 
l.  · Member States sball take alllppropriate measures .to· ensure that the qualified person 
··referred to in Article 52 is, without prejudice to his zelatio~  with the holder of 
tbe  manufactmiDg  authorization, .  ~iblc, in  the  context  of tbe. procedures 
referred to in Anlcle 56, for CDSUring that: 
(a)  in tbe case of veterinary medicinal products manufactured within the Member 
State  concerned,  each  batch  of veterinary  medicinal  .  products  has  been 
manufactured and checked in·complianc:e with the laws in force in that Member 
Slate and in accordance with the requirements of  the marketing authorization; 
(b)  in tbe case of  veterinary medicinal prOducts coming from. third countries, each 
production batch import&:d has undergone in the importing Member State a full 
qualiWive  analys~, a quantitative analysis. of at least all. the active substances 
and all the other tests or checks necessary to ensure the  quality of veterinary 
medicinal  products  in accordance  \\ith  the · requirements  of the  marketing 
autborization. 
Batches of veterinary medicinal products which have undergone such controls in a 
Member  State  shall  be  exempt from the  above  controls if  they  are  marketed  in 
another Member State, accompanied by the control reports signed by the qualified 
person.· 
.81/851/EEC 
Art. 30 (1), 1st and 2nd 
subparagraphs  . 
(adapted)  . 
2.  In the case of veteriDary medicinal products imported from  a third country, where  811851/EEC 
appropriate  arrangements  have  been  made by the  Community  with  the  exporting  Art. 30 (1), 3rd 
country to ensure that tbe manufacturer of the veterinary medicinal product applies  subparagraph 
standards of good manufacturing practice at least .equivalent to those laid down by  (as amended by 
the Community and to ensure that the controls referred to under point (b) of  the first  93/40/EEC Art. 1 (11)) 
subparagraph of paragraph  1 have  been  carried out  in  the  exporting  country,  the 
qualified person may be relieved ofresponsibili~  for carrying out those controls. 
3.  In all cases, and particularly where the veterinary medicinal products are released for  81/851/EEC 
sale, the qualified person shall certify, in a register or equivalent document provided  Art. 30 (2) 
for the purpose, that each production batch satisfies the provisions of  this Article; the 
said register or equivalent document shall be kept up to date as operations are.canied 
out and shall remain at the disposal of  the representatives of  the competent authority 
for the period specified in the provisions of  the Member State concerned and, in any 
event, for It  least five years. 
Article 56 
Member States shall ensure that the obligations of  qualified persons referred to in Article  81/85 1/EEC 
52 are fUlfilled,  either by means of appropriate administrative measures  or by making  Art. 33 
such persons subject to a professional code of  conduct. 
Member States may provide for the temporary suspension of such  a person  upon  the 
commencement of administrative or disciplinary proceedings against him for  failure  to 
fUlfil his obligations.  -
·Article 57 
The provisions of  this Title shall apply to homeopathic veterinary medicinal products. 
43 
92174/EEC 
Art. 3. 
(adapted) TITLEV 
LABELLING AND PACKAGE INSERT 
Article 58 
I.  The  following  information,  which  sball  conform  with  the  particulars  and  documents 
provided  pmsuant  to  Articles  12  and  13  (1)  and  be .approved  by  the  competent 
· authorities,  sball  appear  in legible  cbaracters  on  containers  and  outer  packages  of 
medicinal products:  · 
(a)  Name of the veterinary medicinal produc:t, which may be a brand name or a non-
proprietary name accompanied by a trade mark or the name of  the manufacturer, or a 
scientific  name. or foim.ula,  with  or without .  a trade  mark,  or  the  name  of the 
manuJBcturer. 
Where the special name of  a medicioal product' coiuaining only one active substance 
is  a brand  name,  this  name  must be .  accompanied  in  legible  characters  by  the 
international non-propriety name recommended by the World Health Organization, 
where such name exists or, where no such name exists, by the usual non-proprietary 
name. 
(b)  A statement of the active substances expressed qualitatively and quantitatively per 
dosage unit or according to the form of administration for  a particular volume  or 
weight, using the  international non-proprietary names recommended by the  World 
Health Organization, where  such names  exist or,  where  no  such names  exist,  the 
usual non-proprietary names. 
(c)  Manufacturer's batch number; 
(d)  Marketing authorization number; 
(e)  Name or corporate name and permanent addreSs or registered place of business of 
the marketing authorization holder and of  the manufactw'er, if  different; 
(f)  The species of animal for which the veterinary medicinal  pro<iuct  is intended;  the 
method and route of  administration;  · 
(g)  The  withdrawal  period,  even if  nil, in  the  case  of veterinary  medicinal  products 
administered to food-producing animals; 
(h)  Expiry date, in plain language; 
(i)  Special storage precautions, if  any; 
G)  Special precautions for disposal of  unused medicinal products or waste material from 
medicinal products, if  any; 
·44 
81/851/EEC 
Art. 43 (1) 
81/851/EEC 
Art. 43 (1), points 1 and 
2 (as amended by 
90/676/EEC Art. 1  (23)) 
(adapted) 
81185 1/EEC  · 
Art. 43 (1), points 3 to 6 
(ada'pted) 
81/851/EEC 
Art. 43 (1), points 7 
and8 
(as amended by 
90/676/EEC Art. I (23)) 
(adapted) 
81/851/EEC 
Art. 43 (1), point 9 
811851/EEC 
Art. 43 (1), point 9a 
(as amended by 
90/676/EEC Art. 1 (23)) 
(adapted) (k) Particulars required to be indicated pursuant to Article 26 (1 ), if  spy; 
(1)  The wOrds "For animal treatment only". 
81/8~1/EEC 
Art. 43 (1), points 10 
andll 
2.  The .~cal  'form and the contents by weight,  volume  or num~  of dose- 81/85 1/EEC 
.  units need only be shown on the outer package.  Art. 42 (2) and (3) 
(adapted) 
3.  The provisions of  Part 1, A of  Annex I, in so far as they concern the qualitative and 
quantitative  composition  of veterinary  medicinal  ~ducts in  respeCt  of active 
. substances, shall apply to the particulars provided for in paragraph 1 (b). . 
4 ..  The particulars mentioned in paragraph 1 (f) to (1) shall appear on the outer package 181/851/EEC 
and on the container of,the medicinal products in the language or languages of  the  Art. 4  7 
country in which they. are placed on the market  (adapted) 
Article 59 
1.  As regards ampoules, the particulars listed in the  first paragraph of Article  58  (1)  81/851/EEC 
shall be given on the outer package.· On the containers, .however, only the following  Art. 44 
particulars shall be necessary:  ·  (adapted)  · 
•  name of  veterinary medicinal product, 
- quantity ofthe.active substances, 
route of  administration, 
- manufacturer's batch nwilber, 
•  date of  expiry, 
•  the words 'For aniinal treatment only'. 
2.  As  regards  small  single-dose  containers,  other  than  ampoules,  on  which  it  is  81/851/EEC 
impossible  to give  the  particulars mentioned  in paragraph  1,  the  requirements  of  Art. 45 
Article 58 (1 ), (~) and (3), shall apply only to tbe outer pickage. 
3.  The particulars mentioned in the third and sixth indents of paragraph 1 shall appear  81/85 1/EEC 
on the outer package and on the container of  the medicinal products in tbe language  Art. 47 
or languages of  the country in whi,ch they are placed on tbe market· 
Article 60 
Where  there  is no  outer package,  all ihe  particulars  which  Should  feawre  on  such  a  81/851/EEC 
package pursuant to the Articles 58 and 59 shall be shown on tbe container.  Art. 46 
(adapted) Artide6i.  · 
. 1.  The inclusion of a package insert in. the packaging ofveteriDary medicinal prOducts  811851/EEC 
sbal1  be obligatory  unless  all  the  information  required  by  this  Article  can  be  Art 48 {1) 
conveyed.on the container and the eXternal packaging, M~  Slates sball take all  {as amended by 
appropriate  measures  to  ensure  that  the  insert  relates  solely  to  the  veterinary  90/676/EEC An. 1 (24)) 
medicinal  product with  which  it is  included.  The  insert  shall  be  in the· official 
langUage  or  languages  of the  :tvfember  State  in. which  the  medicinal  product  iS 
marketed. 
2.  The  package  insert  sball  contain  at least the  following  information,  which  shall  81/851/EEC 
conform  to the  particulm and  documents  provided  pursuant  to  Articles .12  and  Art._48 (2).(a) to {d) 
· 13 {1) and be approved by the competent authorities:  ·  ·  ·  {adapted) 
(a)  name or corporate name and permanent address or registered place of business 
of  the marketing authorization holder and ofthe·manufacturer, if  different; 
(b)  name ofthe veterinary. medicinal product and a statement of  its active substances 
expressed qualitatively and quantitatively; 
The  international  non-proprietary  names  recommended  by  the  World  Trade 
Organization shall be used wherever they exist;  · 
(c)  the therapeutic indications; 
(d)  contra-indications  and  advel'Se  reactions  in  so  far  as  these  particulars  are. 
necessary for the use of  the veterinary medicinal product;  · 
(e)  the species of  animal for which the veterinary medicinal product is intended, the 
dosage for each species, the methOd and route of administration and advice on 
correct administration, if  necessary; 
(f)  the withdrawal period,  even  if this  is  nil,  in the case  of veterinary medicinal 
products administered to food-producing animals; 
(g)  special storage precautions, if  any; 
(h)  particulars required to be indicated pursuant to Article 26 (1), if  any. 
(i)  special  precautions  for  the  disposal  of unused  med.icinal  products  or  waste 
materials from medicinal products, if  any; 
811851/EEC 
An. 48 (2) (e) 
(as amended by 
90/676/EEC An. 1 (25) 
(a))  . 
81/851/EEC 
Art. 48 (2) (f) and (g) 
81/851/EEC 
~48(2)(h) 
(as amended by 
90/676/EEC An. 1 (25) 
(b))_ 
3.  The particulars referred to in paragraph 2 shall appear in the language or languages  81/851/EEC 
of the  country in which  the  product  is  marketed.  The  other  information  shall  be  Art. 48 (3) 
clearly separate from such particulars.  (adapted) 
.46 Article62 
Where the provisions of  this T'ltle are ·not observed and a formal notice addressed to the  81/851/EEC 
· person concerned has been ineft"ectua.l, the competent authorities of  the Member States  Art. 49~ 1st parB&raph 
may suspend or withdraw IIJ81'btinl authorization 
Artide63 
The requirements of  Member states· concerning conditions of supply to the public, the  81/851/EEC 
maricing of  prices on medicinal products for veterinaJy use and industtial property rights  Art. SO 
. shall not be affected by the provisions of  this Title. 
Artide.64 
1.  Without  prejudice .  to para&rapb  2,  the  homeopathic  veterinary  products shall  be  92174/EEC 
identified  by the  inclusion  on  their labels,  in  clearly legible  form, of the  words  Art. 2 (2) 
'homeopathic medicinal. product for veterinary use'.  (~ted) 
2.  In addition  to the  clear  mention of the  words  'homeopathic  veterinary medicinal  92174/EEC 
product  without  approved  therapeutic  indications',  the  labelling  and,  where  Art. 7 (2) 
appropriate,  package  insert  for  the  homeopathic  veterinary  medicinal  products  (adapted) 
referred  to in  Article  17  (1)  shall  bear the  following  information  and  no  other 
information: 
- the  scientific name of the  stock or stocks followed  by the  degree  of dilution, 
using  the  symbols  of the  pharmacopoeia used  in  accordance  with· point  8 of 
Article 1,  · 
- name and address of  the marketing authorization holder and, where appropriate, 
of  the manufacturer, 
- method of  administration and, if  necessary, route, 
expiry date, in clear terms (month, year), 
- pharmaceutical form, 
contents of  the sales presentation, 
special storage precautions, if  any, 
- target species, 
a. special warning if  necessary for the medicinal product, 
·- manufacturer's batch number, 
- registration number. 
47 {.4\ 
TITLE VI 
POSSESSION~  WHOLESALE DISTRIBUTION 
AND DISPENSING OF VETERINARY MEDICINAL PRODUCTS 
Article 65 
1.  Member  States  sball  take  all  appropriate  measures  to  ensure  that  wholesale 
distribution  of  ·  Yeterjnary  medicinal  products  is  subject  to  the  holding  of an 
authorization. and to ensure that the time taken for the procedure for  granting tbis 
authorization  does  not  exceed ·  90 days  from  the  date  on  which  the  competent 
authority receives the application.  · 
Member States may also exclude supplies of  small q\Wltities of  veterinary medicinal 
products from one retailer to another. 
2. · In order to obtain· the authorization for· distribution, the applicant shall bave at his 
disposal technically competent staff and suitable and sufficient premises complying 
with  the requirements  laid  down  in  the Member State  concerned  as  regards  the 
storage and handling of  veterinary medicinal products. 
3.  The bolder of the authorization for  distribution shall  be  required to  keep  detailed 
reco.rds.  The following minimum information shall be recorded in respect of each 
incoming or outgoing transaction:  · 
{a)  date; 
{b)  precise identity of  the veterinary medicinal product; 
(c)  manufacturer's batch number,; 
(d)  quantity rec:eived or supplied; 
(e)  name and address of  the supplier or recipient 
At least once a year a detailed audit sball. be canied out to compare incoming and 
outgoing medicinal supplies with supplies currently held in stock, any discrepancies 
being recorded. 
These records shall be available for  inspection by the competent authorities for· a 
period of  at least three years. 
4!  Member States shall take all appropriate measures to ensure that wholesalers supply 
veterlnaiy medicinal products only to persons permitted to carry out retail activities 
in accordance with Article 66, or to other persons who  are  lawfully permitted to 
receive veterinary medicinal products from wholesalers.  · 
48 
81/851/EEC 
Art. SOa (1), 1st 
subparagraph. 
(as amended by 
901616/EEC Art. 1 (27)) 
(adapted) 
811851/EBC 
Art. SOa {1), 3rd 
subparagraph and (2), (3) 
and(4) 
(as amended by 
90/676/EEC Art. 1 (27)) 
·(adapted) Article 66 
1.  Member States sball take all appropriate measures to ensure dJat the retail supply of 
veterinary mediciDal products is conducted only  by persons wbo  are  permitted  to 
c8rry out such operations by the legislation of  the Member State concerned. 
2.  Any· person permitted under paragraph 1 to sell veterinary medicinal products shall 
be required to keep detailed records. The following information shall be recorded in 
respec:t.ofeacb incoming or outgoing 1ransaction: · 
(a)  date;  · 
(b)  precise identity of  the veterinary medicinal product; 
(c)  manufacturer's batch number; 
(d)  quantity received or supplied; 
(e)  name and address of  the supplier or recipient; 
(f)  where relevant, name and address of  the prescribmg veterinarian and a copy of 
the prescription. 
At least once a year a detailed audit shall be carried out, and incoming and outgoing 
veterinary medicinal  products  shall be  reconciled  with  products  currently held  in 
stock, any discrepancies l:leing recorded. 
These records shall be  available for  inspection by the  competent authorities  for  a 
period of  three years. 
3.  Member States may limit the number of  detailed documenting requirements referred 
to in  paragraph 2. However, these requirements shall always  be applied in case of 
veterinary  medicinal  products  which  are  intended  for  administration  to  food-
producing  animals  and  which  are  available  only on  veterinary  prescription  or in 
respect of  which a withdrawal period must be observed. 
4.  Not later that 1 January 1992, Member States shall communicate to the Commission 
a list of  the veterinaiy medicinal products which are available without prescription. 
After  having  taken  note  of the  communication  from  the  Member  States,  the 
Commission  shall  examine  whether  suitable  measures  should  be  proposed  for 
drawing up a Community list of  such medicinal products. 
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81/851/EEC 
Art. SOb 
(as amended by 
90/676/EEC Art. I (27)) 
(adapted) Article67 
Without  prejudice·  to  stricter  Community  or  national  rules  relating  to  dispensing 
veterinaly medicinal products  and to protect human  and animal health,  a prescription 
shall be required' for dispeDsing to the public the following veterinary medicinal products; 
(a)  ~'products  subject to official restrictions on supply or use, such as: 
the restrictions resultin8 from the implementation of  the relevant United Nations 
conventions an narcotic and psychotropic substances,  · 
the  restrictions  on  the  use  of veterinmy  medicinal  products ·resulting  from 
Community law; 
(b)  those· products  in  respect  of which  special  precautions  must  be  taken  by the 
veterinarian in order to avoid any unnecessary risk to: 
the target species, 
the person administering the products to the animal, 
- the consumer offoodstuffs obtained from the treated animal, 
the environment; 
(c)  those  products  intended  for  treatments  or pathological  processes  which  require  a 
precise  prior diagnosis  or the  use  of which  may  cause  effects  which  impede  or 
interfere with subsequent diagnostic or therape~c  measures; 
(d)  magistral formulae intended for animals. 
In  addition,  a  prescription  shall  _be  required  for  new  veterinary  medicinal  products 
containing  an  active  substance  which  has  been  authorized  for  use  in  a  veterinary 
medicinal product for  less than five years unless,  having regard to the· information and 
particulars provided by the applicant, or experience acquired. in the practical use of the 
veterinary  medicinal  product, the  competent authorities  are  satisfied  that  none  of the 
criteria referred to in (a) to (d) of  the first paragraph apply. 
so 
81/851/EEC 
Art. 4 (3), 3rd 
subparagraph 
(as amen~  by 
90/676/EEC Art. 1 (4)) 
(adapted) Article68 
•1. _.Member: States  shaii ·take  ail  measures. neceSsary· to  ensure· that  only  pei-sQns 
empowered  mider  their national legislation ·in  for~· possess  or have under their 
contro.l veterinarf.medicinal products or substances which may be used as veterinary. 
medicinal  products  that  .have  anabolic,  anti-infectious,  anti-parasitic,:  anti-
inflammatoey, hounolial ~r  psychotropic propertie~ 
2. ·  Member States. shan 11la.i$in a register of manufacturers and dealers permitted· to 
be in possession. Of active .substances ·which  may be used  in the  manufacture of 
veterinary ·medicinal  products  having  the ·properties  referred ·to in ·paragraph  1. 
Such persoos must maintain detailed .records of  an dealing> in subStances which may 
be used in the manufacture.ofveterlnaty medicinal products and keep these records 
· '  available  for  inspection  by  the  Competent  authorities  for  a  period  of at  least 
three years.  . 
3.  Any amendments to be made to the list of  substances referred to in paragraph 1 shall 
be adopted in accordance with the procedure referred to in Article 90. 
Article69 
Member States shall eosure that the owners or keepers of food-producing  animals can 
provide  proof of purchase,  possession  and  administration  of veterinary  medicinal 
produets containing the substances set out in Article 68; Member States may extend the 
scope of  this obligation to other veterinary medicinal products. 
In particular, Member States may require the maintenance of  a record giving at least the 
following information: 
(a)  date; 
· (b)  name of  the veterinary medicinal product; 
(c)  quantity; 
(d)  name and address of  the supplier of  the medicinal product; 
(e)  identification of  the animals treated. 
Sl 
81/851/EEC 
Art. 1 (5) 
(as amended by 
90/676/EEC Art. I (I)) 
(adapted): 
811851/EEC 
Art. SOc 
(as amended by 
90/676/EEC Art. 1 (27)) 
(adapted) Article 70 · 
Nothwitbstanding  Articles  9  ind 67,  Member  States  sball  ensure  that  veterinariaDs  811851/EEC 
providing services in another Member State can take witli them and administer to anjmals  Art. 4 (S) 
SJ]l8ll  quantities  of  ready-made·  veterinaiy  medicinal  Proctucts  not  exceeding  daily  (as amended by 
requirements_ other· than  iuununological  veterinary  M.cdicinal  products  which  are  not  90/676/EEC Art. 1 (4)) 
autb.oriz.ed for use in the M~r  State. in which the semces ~provided  (hereinafter:  (adapted) 
host Member State), providing that the ·foll9wing conditions are satisfied:  ·  · 
(a)  the authorization to place the .product on the Jll&Itet provided for in Articles S, 7 and 
8 has been  issued by the competent authorities of  th~ Member State in whj,ch the 
·  veterinarian is established;  · 
(b) the veterinary medicinal products are transported by the veterinarian in the original 
manufacturer's packaging;  · 
(c)  the  veterinary· medicinal  products  intended  for  administration  to  food-producing 
animals have the  same  qualitative and quantitative composition in  terms of active 
substances as the medicinal products authorized in accordance with Articles 5, 7 mid 
8 in the host Member State; 
(d)  the veterinarian providing services in another Member Stite acquaiius himself with 
the  good  veterinaiy practices  applied  in that Member State  and  ensures  that  the 
. withdrawal  periOd  specified on  the  labelling of the  veterinary medicinal  product 
concerned is complied with, unless he could reasonably be expected to know that a 
longer withdrawal periOd should be specified to comply with these good veterinary 
practices;  . 
(e)  the veterinarian shall not furnish any veterinary medicinal product to the owner or 
keeper of  the animals treated in the host Member State unless this is permissible on 
the basis of  the rules of  the host Member State; iD this case he sball, however, supply 
only  in  relation  to  animals under  his  care  and  only the  minimmn  quantities  of  · 
veterinary  medicinal  product  necessary  to  complete  the  treattnent  of animals 
concerned on that occasion; 
(f)  the veterinarian shall be required to keep detailed records of  the anima)s treated, the 
diagnosis, the veterinary medicinal prOducts administered, the dosage administered, 
the duration of  treatment and the withdrawal period applied. These records shall be 
available for inspection by the competent authorities of  the host Member State for a 
periOd of  at least three years; 
(g) . the  overall  range  and  quantity  of veterinary  medicinal  products  carried  by  the 
veterinarian  shall not exceed that generally .  required  for  the  daily needs  of good 
veterinary practice. 
S2 Artiele71 
1.  ·m  ~  absence·  of ·speeific  Comm~ legislation  concerning  the  use  of  90/677/EEC 
immunologicai veterinary mediciDal products for the eradication or cOntrol of  animal  Art. 4· 
.disease, a MemberS~  ·may, in aceordance with its national legislation, prohibit the  (adapted) 
·IDIIl'lifactuR, import, ~ion,  sale, supply and/or use of  immunological veterinary 
~  Prooucts on the whole or part ofits territorY if  it  is established that:  ·· 
(a)  the  administration  of  the  product  to  arii,ma.IS  Will  interfere·  With  the . 
. implementation of  a nationai programme for the maguosis, control or eradiction 
~f. aniiiud ·  ·disease, .. or  will  cause  difficulties  in  certifying  the  ·absence · of. 
contamination in. live animals or in foodstuffs or other prodUcts obtabled from 
treated IIIJjfuals; 
(b)  the disease to ·which the product is intended to confer imm\lnity is largely absent 
from the tenitory in question. 
2.  The competerit authorities of  the Member States shall inform the Commission of all 
instances in which the provisions of  paragraph I are applied. 
S3 TilLEVll 
P~COV1G~CE 
Article 72 
Member  States ·shall  take ali  apprQpriate  measures  to encomage the reporting to the 
CompeteJ1t  authorities  of Suspected·. adverse  reactions  to  the  veterinary  mediciDal 
products..  . 
ArticlC73 
Si/8Sl/EEC 
.Art.42e 
(as amended by 
93/40/EEC Art. 1  {12)) 
(idapted) 
in order  to ensure  the  adoption  of appropriate  regulatory  decisioris  concerning  the  81185 1/BEC 
veterinary  medicinal  products  authorized· within  tbe  CollliDUility,  having  regard  to  Art. 42a  · 
information  obtained  ab9ut  suspected  adverse··r:eactions  to medicinal  products mider  ·(as amended by 
normal conditions of  use, the Mem~  States shall establish a pharmacovigilance system.  93/40/EEC Art.1 (12)) 
This system shall be used to collect information useful in the SW"Veillance of veterinary. 
medicinal  products,  with particular reference  to adverse  reactions  in animals,  and to 
evaluate such information scientifically. 
Such  infonnation shall  be  collated  with data on  coiisumption of veterina.Iy  medicinal 
products. 
This  system shall also  collate information on  frequently  observed  misuse ·and  serious 
abuse of  veterinary medicinal products. 
Article 74 
The  marketing  authorization· bolder  shall  have  permanently  and  continuously  at his 
disposal an approPriately qualified person responsible for pbarmacovigilance. 
That qualified person shall be responsible for the follo~g: 
(a)  the establishment and maintenance of  a system wbicQ ensures that information about 
all suspeeted adverse reactions which are reported to the personnel of the company, 
including its representatives, is collected and collated at a single point; 
(b)  the preparation for the competent authorities of  the reports referred to in Article 75, 
in such  form  as  may  be  laid  down  by  those  authorities,  in  accordance  with the 
relevant national or Community guidelines; 
(c)  ensuring  that  any  request  from  the  competent  authorities  for  the  provision  of 
additional information necessary for the evaluation of  the benefits and risks afforded 
by a veterinary  medicinal  procluct  is  answered  fully and  promptly,  including  the 
provision of  information about the volume .of sales or prescriptions of  the veterinary 
medicinal product concerned. 
'S4 
81/851/EEC 
Art. 42c 
(as amended by 
93/40/EEC Art. 1 (12)) 
(adapted) Artid~  75 
· 1.  The ~  aUthorization  holder shall  be  required to record  and  to  report all 
·suspected  serious ·adverse .reactions  which  are·  brought  to  his  attention ~to ·the 
rompeti;nt authoritieS immediately, and in any case ~  15 days. of  ~eir  receipt at 
the Jat,est.  .  . 
. 2. . lhe marlccting aUtho~on  holder shall be required to maintain detailed records of 
: all o1her suspected adverse reactions which are reported to him.  · 
Unless .other requirements·· wive been  laid  down as a condition of the  granting of 
authOrization.  ~  records .. shall  be  submitted  to  the  competc:Dt  authorities 
immecljateJy upon request or at· least evezy six months  during  the first' two  years 
followiDg authorization, and once a year for the following three years. Thereafter, the 
records ·shall be· submitted at fiVe-yearly intervals together with the application for 
renewal of  the authorization, or  ~ediatelY upon request These records sball be 
accompanied by a scientific evaluation.  · 
Artide76 
Member  States  shall  ensure  that  reports  of suspected  serious  adverse  reactions  are 
immediately brought  to the  attention  of the  Agency  and  the marketing  authorization 
bolder, and in any case within 15 days of  their notification, at the latest. 
Aiticle 77 
In Older to facilitate the exchange of information about pharmacovigilance within the 
Cmmmmity,  the  Commission,  in  consultation  with  the  Agency,  Member  States  and 
intaested parties, shall draw up guidance on the collection, verification and presentation 
of  adverse reaction reports. 
This guidance sbail lake account of intemational harmonization work carried out with 
regard to tenninology and classification in the field of pharmacovigilance when  use of 
such work can be~  in the field of  the veterinary medicinal product concerned. 
5S 
~11851/EEC. 
Art. 42d 
{as amended by 
93/40~  Art. 1 (12)) 
(adapted) 
811851/EEC 
An. 42f 
(as amended by 
93/40/EEC Art. 1 (12)) 
(adapted) 
811851/EEC 
An.42g 
(as amended by 
93/40/EEC Art. 1 (12)) Article78 
_1,  WbC:re. as.a reSUlt of  the ev3luation Qf adverse rcactioD .rePorts a cOmpetent authority 
·~n. a ·Member Siate.  ecmsiders  tbat a  matbtiilg. authorization  should  be  viried, 
.....  ~.....~ or witbdra  ·  ·  it shall  fortbwitb  infOrm tbe  A,.  ami  the  _;,n.~,-......,  ...  -..-.-'  :wn,  .~eDf:Y  .  ----6 
~hOldei. 
2.  In case ·of urgency,  the ccmlpetcm authority ·of a M~  siate  concerned may 
~  the marbting of a. veteiinmy medieiDal product, provided tbe AypJ.cy  is 
informed no later tban on the first  following worlting day.  · 
li/8S1!F.£c 
Arl42h 
(as amended by . 
93140/EEC Art. 1 (12)) 
(adapted)  . 
Any amendments wbich may be necessary to update the provisions of  Articles 72 to 78 to  81/85 IIEEC 
take account of  scieotific and technical progress shall be 'adopted in a=mlance witb.the  An. 42i  · 
procedure laid down in Article 90.  .  {as amended by 
.S6 
93/40/EEC Art. 1 (12)) 
(adapted) TITLEvm 
SUPERVISION AND SANCTIONS 
Article SO 
1..  The _competent authority 9f the Member State concerned shall ensure by means of 
repeated  iDspection  that  the  legal ·requirements  relating  to  veterinary ·medicinal 
products are complied with.  · 
SuCh inspections shalfbe cmied out by authorized representatives of  the competent 
authority who shall be empowered to:  · 
(a)  inspect manufac:turing or trading estabbsbments and any laboratories entrusted 
by the holder of the manufaCturing authorization, with the task of carrying out 
control tests pursuant to Article 24; 
(b) take samples; 
(c)  examine any documents relating to the object of  the inspection, subject to current 
provisions in the Member States from 9 October 1981  which place restrictions 
on these powers with regard to the description of  the manufdcturing method. 
81/851/EEC 
Art-34, 1st subparagraph 
(as amended by 
90/676/EEC Art. 1 {19)) 
81/851/EEC 
Art. 34, 2nd 
subparagraph 
(adapted) 
2.  Member States shall take all appropriate measures to ensure that the manufacturing  90/677/EEC 
processess used in the manufacture of  immunologi~  veterinary medicinal products  Art. 3 (1) 
are completely validated and batch-to-batch consistency is ensUred.  (adapted) 
3.  The  officials  representing  the  competent  authority  shall  report  after  each  of the 
inspections mentioned in the first paragn~ph on whether the manufacturer complies 
with  ~e principles  and  guidelines  of good  manufacturing  practice  referred  to in 
Article  51.  The  inspected manufacturer  shall  be informed  of the  content of such 
reports. 
Article 81 
81/851/EEC 
Art. 34, 3rd 
subparagraph 
(as amended by 
90/676/EEC Art. 1 (19)) 
1.  Member  States  shall  take  all appropriate  measures  to  ensure  that  the  marketing  8  I/SS 1/EEC 
authorization  holder  and,  where  appropriate,  the  holder  of the  manufacturing  Art. 35 
authorization  furnish proof of  the control tests carried out on the veterinary medical  (adapted) 
product and/or on the  constituents and  interm~  products of the  manufacturing 
process,  in accordance with the methods laid down for the purposes cf marketing 
authorization. 
S7 2.  ·For the  pu,tposes  of:implemeritiug paragraph  l;.Membrer States·iaily reqUire  the.  90/67.7tEEC 
iDarketing authorizition hOlder for iimiiunologiCal vetednary medicinal· products to  Art. 3 (2) 
.  SDlmiit to  .. the competei1t authorities copies of all the  co~l  reports signed by the  .(adapted) 
.'qualified person in accOrdance with Article 55.  ·  · 
The ~etiog  ~riziwon  holder for imm1mological veteriDaiy medicinal proaucts 
. sball  ensure  that an ad~  number of representatiVe  samples  of each  batch  of 
veterinary medical  products  is held  in stock at least up to the  expiiy date,  and 
provide samples promptly to the competent authorities on request. 
Article82 
1:  Where  it  considers  it necessary,. a  Mem:ber  State  may  require  the  marketing  90/677/EEC 
authorization holder for imm1D10logical products to submit samples from the batches  Art. 3 (3) 
of the  bulk  and/or  medical  product  for  examination  by a State  laboratory  or .an  (adapted) 
approved laboratory before entry into circulation. 
In the case of a batch manufactured  in  another  Member  State,  examined  by  ·the 
competent authority of  another Member State and declared to be in conformity with 
national  specifications,  such  a control  may  be  carried  out  only  after the  control 
repons of the batch in question have been cxaolined, after the Commission has been 
informed, and where the difference in veterinary conditions between .the two Member 
States concerned justifies it. 
2.  Except where the Commission has been informed that a long period is necessary to 
complete  the  analyses,  Member  States  shall  ensure  that any  such  examination  is 
· completed within  60  days  of receipt of the  samples.  The  marketing  authorization 
holder shall be notified of  the results ofthe examination within the same time-limit. 
3.  Before  1 January  1992,  the  Member  States  shall  notify  the  Commission  of the 
immunological veterinary medicinal products subject tO compulsory· official control 
before being placed on the market. 
S8 '·.  Article 83  ' .  .  '  . 
.  The Competent .rities  of the Member S~  shall suspeDd or withdraw marketing  '81185 1/EEC 
a~ril.atiOn  ~it  is cl~  that: ·  ·  ·  ·  '·  · Art. 36 
(adapted)" 
·(a) the veteriDary mediciDal product proves to .be harmful )DlCier the ·conditions of  use 
stated at 1he time of  application for authorization or ~sequently; 
·.  .  .  .  . 
(b)  the Veterirwy medicinal product does not have. any therapeutic. effect on the specie$ 
of  animal for which the .treabnent ~  intended; 
{c:)  its qualitative and qu.aniitanve composition is not as stated; 
{d)  the recommended withdrawal period is inadequate to ensure that foodstuffS obtained 
from the  treated animal  do  not· contain residues  which might constitute  a health 
hazard to the consumer;  ·  · 
(e)  the veterinary mediciDa:l product is offered for sale for a use which is prohibited by 
other community provisions. 
However, pending Community rules, the competent authorities may refuse to grant 
authorization for a veterinary medicinal product where such action is necessary for 
tbe protection of  public, consumer or animal health; 
(f)  the information given in the application documents pursuant to Article 12, 13 (1) and 
27 is incorrect;  ' 
{g)  the control tests referred to in Article 81 (1} have not been carried out; 
(h) the obligation referred to in Article 26 (2) has not been fulfilled. 
Authorization may also be suspended, or withdrawn where it is established that: 
(a)  the particulars supporting the aPPlication, as provided for in Articles 12 and  13 (1), 
have not been amended in accordance with Article 27 (1), 
. (b)  any  new  information  as  referred  to in  paragraph  3  of Article  27  has  not  been  (adapted) 
communicated to the competent authorities. 
S9 ·Ai'tide~ 
1.  Without prejudice to Article 83,.Member States shall take.allDecessaJy measures to  81/851/EEC. 
ensure  1hat  .sUpply  of a veterinary  medicinal  product is prohibited; mid  tbat the  Art.·37{1) 
ttlcdicmal ~~is  withdrawn form the market; where: 
(a)  it  is ciear that the veterinary medicinal ploduct is harmful under the conditions of 
'use  stated  It the  time  of the  application  for  authorization  or subsequently, 
.  purswuit to Article 27 {S);  ·  ·  ·  · 
{b)  the. veterina.ey  medicinal  product bas  no  therapeutic  effect· on the  species  of 
animal for wbicb the treatment was intended; 
(c) . the qualitative and quantitative composition of  the veterinary medicinal product 
is not as stated;  · 
(d)  the  recommended  withdrawal  period  is  inadequate to  ensure  that 'foodstuffs 
obtained from the 1reated animal do not contain residues which might constitute 
a health bazard to the consumer; 
(e)  the control tests referred to in Article 81  {1) have not been canied out, or any  (adapted) 
other  requirement  or  obligation  relating  to  the  grant of the  manufacturing 
authorization referred to in Article 44 (1) bas not been complic;d with. 
2.  . The competent authority may. confine the prohibition on supply and withdrawal from 
the market solely to the contested production batches. 
Article85 
1.  The  competent  authority  of a  Member  State  shall  suspend  or  withdraw  the  81/851/EEC 
manufacturing authorization for a category of preparations or for all preparations if  An. 38 
any of  the requirements laid down in Article 45 are no longer met  (adapted) 
2.  The  competent  authority  of a  Member  State  may,  in  addition  to  the  measures 
provided  for  in Article  84,  either suspend  manufacture  or  importS  of veterinary 
medicinal products from  third countries or suspend or withdraw tbC manufacturing 
authorization for a categOry of preparations or for all preparations in the event of 
non-compliance  with the  provisions  regarding  manufacture  or imports  from  third 
COUDtries.  . 
Artide86 
The provisions of  this Title shall apply to homeopathic veterinary medicinal products. 
Article 87 
Member States  shall. take  appropriate  measures  to  encourage  veterinarians  and  other 
professionals concerned to report to the competent authorities any adverse reaction of 
veterinary medicinal products.  · 
60 
92174/EEC 
An. 4 (1) 
(adapted) 
81/851/EEC 
An. 38a 
(as amended by. 
901616/EEC Art. 1 (20)) 
.  (adapted) .TITLE IX 
STANDING .COMMriTEE 
Ai'ticle88 
1.  A Standing  Committee  on  Veterinary  Medicinal  Products  for  the  Adaptation  to 
Technical Progress of  the Directives on the Removal of  Technical Barriers to Trade 
in  ·the  Veterinary  Medicinal  Products Sector,  hereinafter  called  "the  Standing 
Committee", is hereby set up; it sball cons~  of  representatives of  the Member States 
·  with a representative of  the Commission as Chairman. 
2.  The Standing Committee shall .adopt its own rules of  procedure. 
Article89 
Any changes which are necessary in order to adapt Annex I to take account of  scientific 
·and technical progress sball be adopted in accordance with the procedure laid down in 
Article 90. 
61 
81/852/EEC 
Art. 2b. 
(as amended by · 
87/20/EEC Art. 1 (1)) 
(as amended by 
93/40/EEC Art. 2) 
(adapted) 
81/852/EEC 
Art. 2a 
(as amended 87/20/EEC 
Art. 1 (1)) 
(adapted) Article90 
'  .  .  . 
Where the prOcedure laid down in thiS Article. is to. be followed the Commission shall be 
. assisted by the Standing C9mmi~.  .  ·  ·  ·  , 
the rePresentative -of the·.CommisSion shall ~t  to the Standing CoiiiiilittCe a draft or' 
the QleasUi'eS to be takeiL The Stand.iDg Committee  shal~ deliver its opinion on the draft 
Within a time-limit which the 'Chairman may lay down according ~·the·  urgency of the 
matter. The opinion shall be delivered by the majority laid down, in Article 205 (2) of  the 
Treaty in the case of decisions which the Council is required to adopt on a proposal from 
the Cotnmissioil.  The  votes  of the  representatives .of the  Member  StatQs .~  the 
Standing  Committee: shall  be ·weighted  in  the  manner  set  out  iD  that  Article.  The 
Chairman sball not vote. 
The Commission shall adopt the measures envisaged if  they are in accordance with the 
opinion of  the Standing Committee: 
If the  measmes  envisaged  are  not  in accordance  with  the . opinion  of the  Standing 
Committee, or if  no opinion is delivered, the Commission shall, without delay, submit to 
the Council a proposal  ~lating to the measures to be taken. The Council shall. act by a 
qualified majority. 
If  on the expiry of  a period of  three months from the date of  referral to the Council, the 
Council has not acted, the proposed measmes shall be adopted by the Commission. 
Article 91 
Where the procedure laid down in this Article is to be followed the Commission shall be 
assisted by the Standing Committee. 
The representative of the Commission shall submit to the Standing Committee a draft of 
the measures to be taken. The Standing Committee shall deliver its opinion on the draft 
within a time-limit which the Chairman may lay down according to  the  mgency of the 
matter. The opinion shall be delivered by the majority laid down in Article 205 (2) of  the 
Treaty in the case of  decisions which the Council is required to adopt on a proposal from 
the  Commission.  The  votes  of the  representatives  of the  Member  States  within  the 
Standing  Committee  shall  be  weighted  in .  the  manner  set  out  in  that  Article.  The 
Chairman shall not vote. 
The Commission shall adopt the measures envisaged if  they are in accordance with the 
opinion of  the Standing Committee.  · 
If the  measmes  envisaged .  are  not  in  accordance  with  the  opinion  of the  Standing 
Committee, or if  no opinion is delivered, the Commission shall, without delay, submit to 
the Council a proposal relating to the measures to be taken. The Council shall act by a 
qualified majority. 
If on the expiry of a period of  three months from the date of referral to the Council, the 
Council has not acted, the proposed measmes shall be adopted by the Commission, save 
where the Council has decided against the said measures by a simple majority. 
62 
8V~SiiEEC 
Art. 42j 
(as· amended by 
93/40/EEC Art. 1 (13)) 
(adapted) 
811851/EEC 
Art. 42k 
(as amended by 
93/40/EEC Art. I (13)) 
(adapted) Tl1'1.EX  .  .  .. 
. G~  PROYJSIONS 
Artidc:92  . 
Member States sbali take all measures Decessary to ensure that the co~  authorities  81/851/EEC 
~communicate  .the appropriate information to each other, in J)anicuJar regarding .  Art. 39 
compliaace·  with  tbe ~  adopted  for  11lllD11facWriD  authorization,· or  for  (as amended by 
.auiborizatiantoplaceProcluctson·tbem3rket.  - ·  90/676/EECArt:l (21)) 
,  (adapted) 
Upon reasoned request, Member States ·sball fOrthwith communjcate the reports referred 
to in the third~  of  Article 80 (3) to the competent authorities of, another Member 
State. It: idler. CODSideriDg .the 1'eiKU'f:S, the Member Slate receiving the repons considers 
that it caDDOt accept the conclusious reached by the competent authority of  the Member 
State  in wbicb  the  report  was  established,  it sba1l  inform  the  competent  authorities 
concemed  of its  reasons ·and  may  request  further  information.  The  Member  States · 
concerned  sball  attempt  to reach  agreement  If necessary,  in  the  event  of serious 
differences  of opinion,  one  of the  M~  States  concerned  shall  inform  the 
Commission. 
Artiele 93 
1.  Each Member State sball take all appropriate measures to ensure that the Agency is  81185 1/EEC 
informed  immediately  of. decisions  granting  marketing  authorization  and  of all  Art 42 
clecisions  refusing  or withdrawing  marketing  authorization,  cancelling  a decision  (as amended by 
refusing or withcJrawing marketing authorization, prohibiting supply or withdrawing  90/676/EEC Art. 1 (22)) 
a product from the~  together with the reasons on which such decisions are  (adapted) 
based. 
2.  The  DWketing authorization holder  shall  be  obliged to notify  the  Member States 
forthwith  of any  action  taken  by him  to suspend  the  marketing  of a  veterinary 
medicinal  prOduct  or to withdraw  a product  from  the  market,  together  with  the 
reasons for such action if  it concerns the effectiveness of the veterinary medicinal 
product  or the  protection of public  health.  Member  States  shall  ensure  that this 
information is brought to the attention of  the Agency. 
3.  Member States shall ensure that appropriate information about actions taken pursuant 
to paragraphs 1 and 2 which may affect the protection of  health in third countries is 
forthwith brought to the attention of  the relevant international· organizations, with- a 
copy to the Agency.  · 
Artide94 
Member  States  sball  communicate  to  each  other  all  the  information  necessary  to  92174/EEC 
guarantee  the  quality  and  safety  of homeopathic  veterinary  medicinal  products  Art S 
manufactured  and  marketed within  the  Community,  and  in particular the  information 
referred to in Articles 92 and 93. 
63 (5) 
Article95 
1.  'At the ~  of ~e  JbaDUfacturer or exporteJ: of veterinary" mediciDBl ~  or 
the authorities of an importing third country, Member. States shall certify that such 
mamdacturer is in possession of  the manUfacturing authOrization. When isstrlng such. 
certificates; ~eD:Wcr  States shall comp~  with the _following conditio~: 
(a)  lhey shall have  regard  to the  prevailing  administrative  arrangements  of the 
World Health Orgaoization;  . 
(b)  for  veterinaly  medicin81  products  intended  for  export  whiCh_  are  already 
authorized  in  their  territory,  they  shall  supply  the  summary  of the. product 
cbaracteristics  as  approved  in  accordance  with  Article  25  or,  iii the  absence 
thereof: an equiwlent document.  ·  · 
2.  Where tbe manufBcturer is not in possession·oran authorization to place the product 
on  the  market,  be  sba1l  provide  the  authorities  responsible  for  establishing  the 
certificate referred to in the first paragraph with a declaration explaining why such 
authorization is not available. 
Article 96 
Marketing authorizations  and revocations of such authorizations shall be published by 
each Member State in its official gazette. 
Article 97 
The Member States shall not permit foodstuffs for hwnan consumption to. be taken fi:om 
test animals unless maximum residue limits· have been established by the Community in 
accordance  with  the  provisions  of Regulation  (EEC) No  2377/90  and  an  appropriate 
withdrawal period has been established to ensure  that this maximum  limit will not be 
exceeded in the foodstuffs. 
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811851/EEC 
Art. 4 {2), 2nd 
subparagraph 
{as amended by 
93/40/EEC Art. 1 {2)) 
(adapted) .TI'ILEXI 
FIN.AI; MEAsURES 
Article 98 
Directives  Sl/851/EEC;. 81/852/EEC,  90/677/EEC  and 92f/4/EEC  referred  to in 
.Annex n, Part A are repealed, without prejudice to the obligations of the Member 
· ·States in respeet.oftlie ~dJine  for transposition laid down. in Annex n, Part B.  . 
The reference made to the said Repealed Directives shall be construed as references 
to this Directive and should be read in  accordant~ with the correlation table set out 
inADnexm. 
Article 99 
This Directive enters into force on 1 January 2000. 
Article 100 
This Directive is addressed to the Member States. · 
Done at Bussels, 
For the EUI'opean Parliament  For the Council 
The President  The President 
6S ANNEx I· 
-~QUiREMENtS  AND ANALYTICAL PR9TOCOL, 
SAFETY TESTS, PRE-CLINICAL.AND CLINICAL_  · 
FOR TESTS OF VETERINARY MEDICINAL PRODUCTS 
INTRODUCTION  81/852/EEC. 
·Annex 
The particulars and documents accompanying an application for marketing authorization  (as amended by  . 
pursuant to Articles 12 and 13 (1) shall be presented in accordance with the requjrements  92/18/EEC Art. 1) 
set out in this Annex  and taking account of the  guidance  contamed in the 'Notice to  (adapted) 
applicants for marketing authorizations for 'veterinary medicinal prodlicts in the Member 
States  of the  European  CoiDIDUDity',  published  by  the  Commission  in  The  rules 
governing  mediciiUll  products  in  the  Eur,opean  Community,  volume  V:  Veteri1UITJI 
MedicinDI Products. 
In assembling the  dossier  for application for  marketing authorization,  applicants  shall 
take into account the Community guidelines relating to the quality, safety and efficacy of 
veterinary  medicinal  Products  published  by  the  Commission  in  The  rules  governing 
medicinal products in the European Community. 
All information which is relevant to the evaluation of  the medicinal product concerned 
shall be included in the application, whether favourable or unfavourable to the product. 
In particular, all relevant details shall be given of any incomplete or abandoned test or 
trial  relating  to  the  veterinary  medicinal  product.  Moreover,  after  marketing 
'authorization, any information not in the original application, pertinent to the benefit/risk 
assessment, shall be submitted forthwith to the competent authority. 
Member States ensure that all experiments on animals are conducted in accordance with 
Council  Directive  86/609/EEC  of 24  November  1986  on  the  approximation  of laws, 
regulations and administrative provisions of  the Member States regarding the protection 
of  animals used for experimental and other scientific purposesu'. 
·  The provisions of  Title I of  this Annex shall apply to veterinary medicinal products other 
than immunological veterinary medicinal products. 
The  provisions  of Title  II  of this  Annex  shall  apply  to  immunological  veterinary 
medicinal products. 
'0  OJL3SI,ll.2.1916,p.l. 
66 TITLE I 
REQUIREMENTS FOR VEI'ERINARY MEDICiN~  PRODUCTS OTHER THAN . 
.  IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS 
PART I-
SUMMARY OF nJE DOSSIER 
A.  ADMINISTRATIVE DATA 
The  veterinary  mediciDal  product  which  is  the  subject  of the  applicatiOn  shaii  be 
identified by name and by name of  the active substance(s), together with the strength and 
pharmaceutical  form, the  method and  route of administration and a description of the 
final saies presemation of  the producL  .  · 
The name and address of  the applicant shall be given, together with the name and address 
of the manufacturers and  the  sites involved in the  different stages  of the  manufaCture 
(including_the manufileturer of  the finished product and the manufacturer(s} of  the active 
substance(s)), and where relevant the name and address of  the importer. 
The applicant shall identify the number and titles of  volumes of  documentation submitted 
in support of  the application and indicate what samples, if  any, are also provided. 
Annexed to the administrative data shall be a document showing that the manufacturer is 
authorized to produce the veterinary medicinal products eoncemed, as defined in Article 
42, together with a list of  countries in which authorization bas been granted, copies of  all 
the summaries of product characteristics in accordance with Article ·14  as approved by 
Member States and a list of  countries in which an application bas been submitted. 
B.  SUMMARY OF PRODUCT CHARACTERISTICS 
The applicant shall propose a sumnwy of  the product characteristics, in accordance with 
Article 14 ofthis Directive.  · 
In addition the applicant shall provide one or more specimens or mock-ups of the sales 
presentation of the veterinary medicinal product, together with a package  insert where 
one is required. 
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92/18/EEC Art.  I) 
(adapted) '  .•' 
C.  .EXPERT REPORTS  81/852i'EEC 
.  '~ 
In accordance  With  Article  IS· {2)  and  (3),  expert reports  must  be  provided  on the  (as amended by 
aoalytical  documentation,  tbe · phannacotoxieblogical  docuinentation.  the  residues  92/18/EEC Arl:.l) 
doculneDtation aDd the clinical ~on.  ·  ·(adapted)  . 
Each expert report shall consist of  a critical evaluation of the various tests and/or trials 
which have been carried out ill accordimce with this Directive, aDd bring out ~  the data 
relevant  for. evaluation.  The  expert  sball  give ·his  opinion  as  to  whether  sufficient 
guarantees have  been provi<kd  as  to  the· quality,  safety  and  efficacy  of the  product 
concemed. A-factual summary is not sufficient  ·  · 
All importailt data shall be summarized in an appendix to the expert report, whenever 
possible in tabular or graphic form.  The expert report and tbe summaries shall contain 
precise cross references to the inf~rmation contained in the main docmnentation. 
Each expert report shall be prepared by a suitably qualified and experienced person. It 
shall  be  signed  and ·dated  by  the  expert,  and  attached  to  the  report  shall  be  brief 
information about the educational background, training and occupational experience of 
the expert The professional relationship of  the expert to the applicant shall be declared. 
68 ·PART~ 
ANAL\'Ti~  ~HYSICO-CBEMI~  BIOLOGICAL OR.  . ·  ·  .  · 
MICRQBIOLOGICAL)  TESTS OF VETERINARY  MEDICINAL  PRODUCfS 
OTHER THAN IMMUNOLOGICAL VETERINARY MEDiCINAL PRODUcrs 
Ali test ~  shall correspond to the state of scientific progress .at the time  and 
.shall be wlidateid procedures; results ·or the validation Sbldies shall be provided.  . 
All the  test procedure(s)  sbail  be  described  in  sufficiently precise. ~  so  as  to be · 
reproducible in control test; canied out at the request of the competent authority; any 
special  apparatuS  and equipment  whicJt  maY  be  used  shall  be  described  in  adequate 
detail, possibly acc:ompanied by a diagram. The formulae of  the laboratory reagents shall 
be  supplemented,  if necessmy,  by the  method  of preparation.  In the  case  of test 
procedures included in the European Phllnnacopoeia or the pharmacopoeia of  a Member 
State, this description may be replaced by a detailed reference to the pharmacopoeia in 
question. 
A.  QUALITATIVE  AND  QUANTITATIVE  PARTICULARS  OF  THE 
CONSTITUENTS 
The  particulars  and  documents  which  must  accompany  applications  for  marketing 
authorization, pursuant to Article  12 (3) (c), shall be  s~bmitted in accordance with the 
following requirements. 
1.  Qualitative particulars 
'Qualitative particulars' of all the constituents of the medicinal product shall mean the 
designation or description of: 
- the active substance(s), 
the  constituent(s)  of the  excipients,  whatever  their· nature  or  the  quantity  used, 
including  colouring  matter,  preservatives,  adjuvants,  stabilizers,  thickeners, 
emulsifiers, flavouring and aromatic substances, etc, 
the constituents, intended to be ingested or otherwise administered to animals, of  the 
outer covering of  the medicinal products-capsules, gelatine capsules, etc. 
These particulars shall  be supplemented by any relevant data concerning the  container 
and, where appropriate, its manner of  closure, together with details of  devices with which 
the medicinal product will be used or administered and which will be deliv~  with the 
medicinal product. 
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(as amended by. 
92/18/EEC Art. 1) 
(adapted). · 2. · The·~  termiliol()gy',  to ·be ·used in describing  the ··constilueirts. of iDedicioai. ·  lt/8$2/EEC 
products.. ·  Sba1l  mCau.  ilOtwithstanding  the  ispplication  of the  other provisimis of  Annex 
Article.12 (3) (c):  ,  .  ··  . ·  ·  ·  ~  ·  ·  (as ameilded by 
.  .  . 
in reSpect  of substances  which  appear  in  the  ·E~operm PhtzmUzcopr)eia  ·Or~" 
· failing this, in the national plwmacopoeia of  oile of  the Member States, the main 
·title  at  the  head  of the  monograph  in  question.  with  reference  to  the 
pharmacopoeia c:Oncerned, 
in  respect  9f .  othei- substaDces,  the  international  non-proprietary  niine 
recommended  by  the  World  Health  Oi'ganization  (WHO),  which  may  be 
acc:ompanied  by  another  non-Proprietary· name,  or,  failing  these,  the  exact 
scientific  designation;  substances  not having  an  international  non-proprietmy 
~or  an·exact scientific designation shall be descn"bed by a statement ofhow 
and  from  wbat they were  prepared,  supplemented,  where  appropriate,  by any 
other relevant details, 
in respect of  coloming matter, designation by the 'E' code assigned to them in 
Council Directive 78125/EEC of 12 December 1977 on the approximation of  the 
rules of  the Member States concerning the colouring matters authorized for use 
in medici;nal productsU'. 
3.  Quantitative particulars 
3.1.ln order to give 'quantitative particulars' of  all the active substances of  the medicinal 
products; it is necessary, depending on the pharmaceutical form concerned, to specify the 
mass, or the number of units of  biological activity, either per dosage~t  or per unit of 
mass or volume, of  each active substance. 
Units  of biological  activity  shall  be  used  for  substances  which  cannot  be  defined 
chemically.  Where an International Unit of biological activity has been defined by the 
World Health Organization, this  shall be  used.  Where  no  International Unit bas been 
defined, the units of biological activity shall be expressed in such a way as to provide 
unambiguous information on the activity of  the substances.  · 
Whenever possible, biological activity per units of  mass or volume shall be indicated. 
1bis information shall be supplemented: 
in  respect of injectable preparations, by the mass or units of biological activity of 
each active substance in the unit container, taking into account the usable volume of 
the product, after reconstitution, where appropriate,  · 
in respect of  medicinal products to be administered by drops, by the mass or units of 
biological  activity  of each  active  substance  contained  in  the  number  of drops 
corresponding to I m1 or 1 g of  the preparation, 
in respect  of syrups,  emulsions,  granular  preparations  and  other  pharmaceutical 
forms to .be administered in measured quantities, by the mass or units of biological 
activity of  each active substance per measured quantity. 
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(adapted) 3.2. Active:~  present-in the form or~tinds  or derivatives sba11 be descrih® ·  suss21EEC ·. 
quimtitatively by their total-., and if  n~  ·or rel~vant, ~y  the mass of  the active  Annex 
entity or entities of  the  mo~ecule. .  .  (as.amended by 
3.3. For tnediciDal ptbducts cooiaining an  aCtive  substaiJ.ce  which  is the  subject of an. 
application  for  IDBI'lcetiog  authorization .in ,any  t-{ember  State· for  the  first  time,  the 
quantitative  statement  of an  active  substance  which  is  a  salt  or hydrate  shall  be 
Systematically  expressed  in  tenns of the  mass  of the  active  entity or entities  in the 
molecule.  All subsequently luthorized medicinal  products in the  Member  States  shall 
have their quantitative composition stated in the same way for the same active substance. 
4.  · bevelopmeat pha11D8eeutics 
An explanation shall be provided with regard to the choice of'composition, constituents 
and comainer and the  intended function of the excipients in .  the finished  product.  This 
explanation shall be  supported  by scientific  data on  development  pharmaceutics.  The 
overage, with justification thereof: shall be stated, 
B.  DESCRIPTION OF TiiE MANUFACTURING METI:IOD 
The  description  of the  manufacturing  method  accompanying  the  application  for 
marketing authorization pursuant to Article 12 (3) (d), shall be drafted in such a way as to 
give. an adequate synopsis oftbe nature of  the operations employed. 
For this pUrpose it shall include at least: 
mention of  the various stages of  manufacture, so that an assessment can be made of 
whether the processes employed in producing the  pharmaceutical form might have 
produced an adverse change in the constituents, 
·in the case of continuous manufacture,  full details concerning precautions taken to 
ensme the homogeneity of  the finished product, 
the  actual  manufiu:ttuing  formula,  with  the  quantitative  particulars  of all  the 
substances used, the quantities. of excipients, however,  being given in approximate 
terms in so far as the· pharmaceutical form  makes this necessary; mention shall be 
made  of any  substances  that  may  disappear  in  the  course  of manufacture;  any 
overage shall be indicated and justified, 
a statement of the  stages of manufacture  at which  sampling  is  canied out  for  in· 
process control tests, where other data in the documents supporting the application 
show such tests to be necessary for the quality control of  the finished product, 
experimental  studies  validating  the  manufacturing  process,  where  a non-standard 
method of  manufacture is used or where it is critical for the product, 
for sterile products, details of the sterilization processes and/or aseptic procedures 
used. 
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(adapted) C.  CONTROLOFSTARTINQMA~ 
1. For the purposes of  this paragraph, 'starting-materials' shall DieiD all the constituents 
of  the medicinal product and, if  necessary, of its container, as refened to in Section A, 
point 1, above. 
1n the case of. 
an  active  substance  Qot  described  in  the  European  Pharmacopoeia  or  in  the 
pharmacopoeia of  a Member State, 
or 
an  active  substance  described  in  the  European  ·Pharmacopoeia  or  in  the 
pharmacopoeia  of a  Member  State  when  prepared  by a  method  liable  to  leave 
. impurities  not  mentioned  in  the  phannacopoeial  monograph· and  for  which  the 
monograph is inappropriate to adequately control its quality, 
which is manufactured by a person different from the applicant, the latter may 8lTBDge for 
the detailed description.ofthe manumcturing method, quality control during IDIIlllfacture 
and  process  validation  to  be  supplied  directly  to  the  competent  authorities  by  the 
manufacturer  of the  active  substance.  In this  case,  the  manuficturer  shall  however 
provide the applicant with  all the  data  which may  be necessary for  the  latter to take 
responsibility for the medicinal product The manuficturer shall confirm· in writing to the 
applicant  that  he  shall  ensure  batch  to  batch  consistencY  and  not  modify  the 
manufacturing process or specifications without informing 'the applicant DoCuments and 
particulars  supporting  the  application  for  such  a  change  shall  be  supplied  to  the 
competent authorities. 
The particulars and documents accompanying the application for marketing authorization 
pursuant to Article  12 (3) (i) and G> and Article  13  (1), shall include the results of the· 
tests,  including  batch  analyses  particularly  for  active  substances,  relating  to  quality 
control of all  the  constituents used.  These  shall  be submitted  in  accordance  with the 
following provisions. 
1.1. Starting materials listed in pharmacopoeias 
The monographs of  the European Pharmacopoeia shall be applicable to all substances 
appearing in iL 
1n respect of other substances, each Member State may require observance of its own 
national pharmacopoeia with regard to products manufactured in its territory. 
Constituents  ful1illing  the  requirements  of the  European  Pharmacopoeia  or  the 
pharmacopoeia of  one of  the Member States shall be deemed to comply sufficiently with 
Article 12 (3) (i). In this case the description of  the analytical methods may be replaced 
by a detailed reference to the pharmacopoeia in question. 
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Art. 1) 
(adapted) Howevez:;  where  a  Scattibg  material· in  the  Eriropean  'pha,nnacopoeia  or  in  the 
pharmacopoeia  of a  Meinbet  State  has  been  prepared  by  a  method  liable  to  leave 
impurities not controlled in the pbannacopoeia monograph, .these  impurities and their 
maximum  tolerance  limits  must be  declared  and  a  suitable  test procedure  must  be  described.  .  .  . 
Colowing  matter  shalt  in  all  cases,  ~fy  the  requirements  of Council  Directive 
1112SIEEC. 
The routine tests  cani~  out on each batch of  starting materials must be as stated in the 
application  for  marketing. authorization.  If tests  other  than  those  mentioned  in  the 
p~poeia  are  used, proof must  be  supplied  that  the  starting  materials ·meet the 
quality requirements of  that pharmacopoeia. 
In  cases  where  a  specifi,cation  contained  in  a  monograph  of  the  "European 
Phmmacopoeia  or  in  the  national  phannacopoeia  of a  Member  State  might  be 
insufficient to ensuic the quality of  the substance, the competent authorities may request 
more appropriate specifications from the marketing authorization holder. 
The competent authorities shall inform the authorities responsible for the pharmacopoeia 
in  question.  The  marketing  authorization  holder  shall  provide  the  authorities  of that 
phannacopoeia  with  the  details  of the  alleged  insufficiency  and  the  additional 
specifications applied. 
In cases where a starting material is described neither in the European Pharmacopoeia 
nor in the pharmacopoeia of  a Member State, compliance with the monograph of  a third 
country pharmacopoeia can be accepted; in such cases, the applicant shall submit a copy 
of  the monograph accompanied where necessary by the validation of  the test procedures · 
contained in the monograph and by a translation where appropriate. 
1.2. Starting materials not in a pharmacopoeia 
Constituents which are not given in any pharmacopoeia shall be described in the form of 
a monograph under the following headings: 
(a)  the name of the substance, meeting the requirements of Section A point 2, shall be 
suppleme~ted by any trade or scientific synonyms;  · 
(b)  the  definition  of the  substance,  set  down ·in  a  form  similar  to  that  used  in  the 
European  Pharmacopoeia,. shall  be  accompanied  by  any  necessary  explanatory 
evidence, especiillly concerning the molecular structure where appropriate; it must be 
accompanied  by  an  appropriate  description  of the  method  of synthesis.  Where 
substances  can  only  be  described by their manufacturing  method,  the  description 
shall be sufficiently detailed to characterize a substance which is constant both on its 
composition and in its effects; 
(c)  methods of identification may be described  in the  form  of complete techniques  as 
used  for  production of the  substance,  and  in the  fonn of tests  which  ought  to  be 
carried out as a routine matter; 
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92/.18/EEC Art. 1) 
(adapted) (~ purity tests shall be described iii relation to the sum total of predictable impurities, 
especially. those which may have a harmful effect,  and,. if  necessary, those ~ 
having regard to the combination of  substances to which the application refers,· might 
adversely affect the stability of  the medicinal product or aistort analytical results;  · 
(e)  with regard to complex substances of plant or. animal origin, a distinction must be 
made  between the case· where  multiple  pharmacological  effects  render  chemical, 
physical or biological control of  the principal components necessary, and the case of 
substances containing one or inore groups  of principles having similar activity,  in 
respect of  which an overall method of  assay may be accepted; 
(f)  when  Dlaterials  of animal  origin  are  used,  measures  to  ensure  freedom  from· 
potentially pathogenic agents shall ~  described; 
(g)  any special precautions that may be necessaey during storage of  the starting material 
and, if  necessaey, the maximum period of  storage before retesting shall be given. 
1.3. Physico-chemical characteristics liable to affect bioavailability 
The following items of infonnation concerning active substarices, whether or not listed in 
the pharmacopoeias, shall be provided as part of the  general description of the active 
substances ifthe·bio-availability of  the medicinal product depends on them: 
crystalline form and solubility coefficients, 
particle size, where appropriate after pulverization, 
state of  solvation, 
oil/water coefficient ofpartitionl11. 
The first three indents are not applicable to substances used solely in solution. 
2.  Where  source materials such as  micro-organisms,  tissues  of either plant or animal 
origin.  cells or fluids  (including blood) of human or animal origin or biotechnological 
cell constructs are used in the manufacture of veterinary medicinal products, the origin 
and history of  starting materials shall be described and documented. 
The  description  of the  starting  material  shall  include  the  manufacturing  strategy, 
purification/inactivation  procedures  with  ·their  validation  and  all  in-process  control 
procedures· designed to ensure the quality, safety and batch to batch consistency of the 
finished producL 
' 
2.1. When cell banks are used, the cell characteristics shall be shown to have remained 
unchanged at the passage level used for the production and beyond. 
Ill  The competent authorities may also request tbc pKlpH values if  they thiDk dW this iofonnation is essential. 
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(adapted) 2.2: Seed ma!erials; cell banks, -pOols  ~f  serum and other materials of biological-origin  81/852/£EC 
- Whe:Dever-possible, the SOURC materials from which they are derived sluill be tested  Amlex 
for adve$itious agems..  ·  {as amended by 
92118/EEC Art.  1) 
If  the preseuce of potentially pathogenic adventitious agents is  inevitable, the material  {adapted) 
sba1l be used Only when fUrther processing ensures their elimination and/or inactivation, 
and this sb8n be validated  . 
D.  CONTROL  TESTS  CARRIED  OUT  AT  INTERMEDIATE  STAGES  OF  1HE 
MANUFACTURING PROCESS 
The particulars and documents aecompanying an application for marlceting authorization, 
pursuant to Article  12 (3) {i) and (j) and  also Article  13  (1), shall include  particulars 
relating to the product control tests tbat may be carried out at an intermediate stage of  the 
manufacturing  process,  with  a  view  to  ensuring  the  consistency  of the  technical 
characteristics and the production process.  · 
These tests are essential for checking the conformity of the medicinal product with the 
formuJa.when, exceptionally, an applicant proposes an analytical method for'testing the 
finished product which does not include the assay of  all the active substances (or of all 
the excipient components subject to the same requirements as the active substances). 
The same applies where the quality control of  the finished product depends on in-process 
control  tests,  particularly if  the  substance  is  essentially  defined  by  its  manufacturing  method.  .  . 
E.  TESTS ON THE FINISHED PRODUCT 
1. For the control of  the finished product, a batch of a finished product comprises all the 
units of  a pharmaceutical form which are made from the same initial quantity of  material 
and have undergone the same series of  manufacturing and/or sterilization operations or, 
in the  case  of a continuous  production process, all the units manufactw'ed  in  a given 
period of  time. 
The application for marlceting authorization shall ~  those tests which are  carried out 
routinely  on each batch of finished product.  The ftcquency of the tests  which  are not 
carried out routinely sball be stated. Release limits shall be indicated. 
The particulars and documents accompanying the application for marlceting authorization 
pursuant to Article  12 (3) (i) and (j) and also Article  13  (1), shall include particulars 
relating to control tests on the finished product at release. They shall be submitted in 
accordance with the following requirements. 
The provisions of  the  general monographs of the Elll'opean Pharmacopoeia,  or failing 
that, of  a Member State, shall be applicable to all products defined therein. 
If  test procedures and limits other than those mentioned in the general monographs of  the 
E'lll'Opean Pharmacopoeia, or failing this, in the national pharmacopoeia of a Member 
State,  are  used,  proof shall  be supplied tbat the  finished  product would, if  tested  in 
accordance with those monographs, meet the quality requirements of  that pharmacopoeia 
for the pharmaceutical form concerned. 
1S l.i.  G~al  ~erlstics  ~/the  finished prodJu:!  81/8521£EC · 
Almex 
Certain tests of  the general. characteristics of  a product shall always be included among  (as amended by 
the tesrs  em the finished  product. These  tests  sball, wherever applicable, relate to the  92/18/EEC An. 1) 
eontrol  of average  masses  and maximum  deviations,  to  mechanical,  physical  or  (adapted)  . 
~biological  ·  tests,  organoleptic  characteristics,  physical  characteristics  such  as 
density,  pH,  refractive  index,  etc.  For  each  of these  characteristics,·  standards  and 
tolerance limits sball be specified by  the applicant in each particular case.  · 
The·conditioos of the tests, where appropriate, the  equipment/apparatus employed and 
the standards  sball be described. in precise details whenever they are not given  in the 
£111'opean Pharmacopoeia or the pharmacopoeia of the Member States; the same sball 
apply in cases where the methods preScribed by such phalmacopoeias are not applicable. 
Furthermore,  solid  pbarlnaceutical  forms  having  to  be  administered  orally  shall  be 
~bjectcd  to in vitro studies on the b'beration and dissolution rate of  the active substance 
or substances; these studies sball also be carried out where administration is by another 
means  if the  competent  authorities  of the  Member  State  concerned  consider  this 
necessary. 
1.2. Identification and  ~ay  of  active substance(s) · 
Identification  and  assay  of the ·active  substance(s)  shall  be  carried  out  either  in  a 
representative sample from the production batch or in a number of dosage-units analysed 
individually. 
Unless there is appropriate justification, the maximum acceptable deviation in the active 
substance  content  of the  finished  product  shall  not  exceed  :1:  S%  at  the  time  of 
manuf'actlue. 
On the basis of the stability tests, the manutilcturer must propose and justify maximum 
acceptable tolerance limits in the active substance content of the finished product up to 
the end of  the proposed ~elf-life. 
In certain  exceptional  cases  of particularly  complex  mixtures,  where  assay  of active 
substances which are very numerous or present in very low amounts would necessitate 
an intricate investigation difficult to carry out in· respect of each production· batch, the 
assay of one or more active substances in the finished product may be omitted, on the 
express  condition that  such  assays  are  made  at intermediate  stages  in the  production 
process.  This relaxation may not be extended to the characteriz.ation of the substances 
concerned. This simplified ~que  s¥J be supplemented by a metb~  of quantitative 
·  evaluation,  enabling the  competent authority to  have  the  conformity  of the  medicinal 
product with its specification verified after it has been placed on the market. 
An  in  vivo  or  in  vitro  biological  assay  shall  ~  obligatory  when  physico-chemical 
methods  cannot ·provide adequate  information  on the  quality  of the  product Such  an 
assay  shall,  whenever  possible,  include  reference  materials  and  statistical  analysis 
allowing calculation of confidence limits. Where these tests cannot be carried out on the 
finished product, they may be performed at an intermediate stage, as late as possible in 
the manufacturing process. 
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the control tests on·the  finish~ produCt sba1l include, where ~riate,  the· chemical  (as amended by 
and, ·if necessary,  the  toxi~pbarmacological investigation  of the  changes  that  this  92/18/EEC Art. 1) 
substance  has  unc:lergone,  and  possibly  the  charactCrization  and/or  assay  of the  (adapted) 
degradation products; 
1.3. Idei.t;ficalion and  QSJik)l of  excipient components 
In  so  far  as  is  necessary,  the  excipient  components  shall  be  subject  at  least  to 
identification tests.  ·  ·  · 
The test procedure proposed for identifying colouring matters must enable a verification 
to be made that such matters appear in the "list annexed to Directive 78/25/EEC; 
An upper and lower limit test shall be obligatory in respect of  preserving agents and an 
upper limit test for any other excipient component liable to affect adversely physiological 
fimctions; an upper and lower limit test shall be obligatory in reSpect of  the excipient if  it 
is  liable  to  affect the  bio-availability of an  active substance,  unless  bio-availability is 
guaranteed by other appropriate tests. 
1.4. Safety tests 
Apart from the toxico-pharmacological tests submitted with the application for marketing 
authorization,  particulars  of  safety  tests,  such  as  sterility,  bacterial  endotoxin, 
pyrogenicity and local tolerance in animals shall be included in the analytical particulars 
wherever  such  tests  must  be  undertaken  as  a matter  of routine  in  order to  verify the 
quality of  the product. 
F.  STABILITYTEST 
The particulars and documents accompanying the application for marketing authorization 
pursuant to Article 12 (3) (f) and (i) shall be submitted in accordance with the following 
requirements. 
A  description  shall  be  given  of the  investigations  by  which  the  shelf  life,  the 
recommended  storage  conditions  and  the  specifications  at  the  end  of the  shelf life 
proposed by the applicant have been determined.  · 
In the case of  pre-mixes for medicated feedingstuffs,  information shall also be given as 
necessary on the shelf life of the medicated feedingstuffs manufactured from these pre-
mixes in accordance with the recommended instructions for use. 
Where  a finished  product requires reconstitution ·prior to administration,  details of the 
proposed  shelf life  for  the  reconstituted  product  are  required,.  supported  by relevant 
stability data. 
In the case of  multi-dose· vials, stability data shall be presented to justify a shelf life for 
the vial after it has been pun~  for the first time. 
77 .  Where ·a finished product is liable to give rise to ·degr8dation' products, the applicant must 
declare these and indicate characterization methods and test procedureS.  · ·· 
.  .  .  . 
·The conclusibus shall comam the results of analyses, justifYing the proposed shelf-life 
1mder the recommended storage conditions and the specifications of  the finished product 
at the  end of the shelf ~  of the finished product under these recommended  storage 
conditions. 
The maximum  acceptabl~ level of degradation products at the end of  shelf life shall be 
indicated. 
A study of  the interaction between prOduct and container shall be submitted wherever the 
risk of  such interaction is regarded as  possible~ especially where injectable preparations 
·or aerosols for intemal use are concerned 
PART3 
SAFETY AND RESIDUES TESTING 
The  particulmi and  documents  which  shall  accompany  the  application  for  marketing 
authorization pursuant to Articles 12 (3) G) and  13 (I) shall be submitted in accordance 
with the requirements below  .. 
Member  States  shall  ensure  that  the  tests  are  canied  out  in  accordance  with  the 
provisions  relating  to  good  laboratory  practice  laid.  down  by  Council  Directives 
87118/EEC(II and 88/3201EEC!21. 
A. Safety testing 
CHAPTER I 
PERFORMANCE OF TESTS 
L  Introduction 
The safety documentation shall show: 
1.  the  potential toxicity of the  medicinal  product  and  any  dangerous  or undesirable 
effects  which  may  occm under the  proposed  conditions  of use  in  animals;  these 
should  be  evaluated  in  relation  to  the  severity  of the  pathological  condition 
concerned; 
2.  the potential harmful effects to man of  residues of  the veterinary medicinal product 
or substance in foodstuffs obtained from treated animals and what difficulties these 
residues may create in the industrial processing of  foodstuffs; 
3.  the  potential  risks  which  may  result  from  the  exposme  of human  beings  to  the 
medicinal product, for example during its administration to the animal; 
4.  the  potential  risks  for  the  environment  resulting  from  the  use ·of the  medicinal 
product. 
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78 All results shall"be reliable 8Dd valid generally.: Whenever appropriate, iDathemmcalBDd 
Sblt.istical ~  sbaJ1  be  used  in designing  the  experimental'  methOds  and. in 
evaluatiDg :tbe ··results.  AdditioDilly,  cliniciaDs  shall  be  giVen  information  about  the 
therapeutic potential of  the product and about the hazards counected with its use.  · 
.  .  .  . 
In some cases it may be neceSsary to test the metabolites of  the parent compound where 
these represent the residues of  concern. 
An excipient used in the pharmacCutical field for the first time shall be treated like  an 
active substance. · 
2.  Pba~~oloay 
Pbannacological studies are of fundmqental importance in· clarifying the mechanisms by 
which  the  medicinal  product  produces  its  therapeutic  eff~  and  therefore 
pbannacological studies conducted ·in experimental and target species· of animal should 
be included in Part 4. 
However, pharmacological studies may also ·assist in the understanding of  toxicological 
phenomena. Moreover, where a medicinal product produces pharmacological effects in 
the absence of a toxic response, or at doses lower than those requ_ired to elicit toxicity, 
these pharmacological effects shall be  taken into account during the evaluation of the 
safety of  the medicinal product. 
Therefore  the  safety  documentation  shall  always  be  preceded  by  details  of 
pharmacological  investigations  undertaken  in  laboratory  animals  and  all  relevant 
information observed during clinical studies in the target animal. · 
3.  Toxicology 
3.1. Single-dose toxicity 
Single-dose toxicity studies can be used to predict: 
- the possible effects of  acute overdosage in the target species,  · 
- the possible effects.ofaccidental adminis1ration to humans, 
- the doses which may usefiilly be employed in the repeat dose studies. 
Single dose toxicity studies should reveal the acute toxic effects of  the substance and the 
time course for their onset and remission. 
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1'heie ·studies shouid normally be carried out in at least two maminalian species.  One  811852/EEC 
mllfhnMIIian species may ·be replaCed;· if  appropriate, by an animal species for which the  Aunex 
medicinal  product is intended.  At least ~o  different  routes  of adlninisttation should  (as amended by 
normally be studied. One of  these may be the same as, or similar tO, that. proposed for the  92/18/EEC Art I) 
target species. If  substantial exposure ofthe user ofthe medicinal product is anticipated,  (adapted) 
for exampie by inhalation or  .dermal contact, these routes should be studied. 
In order to reduce the number and suffering of the animals involved, new protocols for 
single  dose  toxicity  testing  are  contiriually  being  developed.  Studies  carried  out  in 
accordance with these new p~ures  when properly· validated will be accepted, as well 
as  ·studies  ·carried  out  in  accordance . with  established  internationally  recognized 
guidelines. 
3.2. Repeated-dose t0%icity 
Repeated-dose toxicity tests are intended to reveal any physiological and/or pathological 
changes induced by repeated administration of the  active  substance or combination of 
active substances under examination, and to determine how these changes are related to 
dosage. 
In the  case  of substances  or medicinal  products intended  solely for  use  in non food-
prqd'l:lcing animals, i repeated dose toxicity study in one species of  experimental aniinal 
wiU normally be sufficient This study may be replaced by a studY conducted in the target 
animal. The hquency and route of  administration, and the duration of  the study should 
be chosen having regard to the proposed conditions of  clinical use. The investigator shall 
giv~  his reasons for the extent and duration of  the trials and the dosages chosen. 
In the  case ·of substances  or medicinal  products  intended  for  use  in  food  producing 
animals, the study should be conducted in at least two species, one of  which should be a 
. non-rodent.  The  investigator shall  give  his  reasons  for  the  choice  of species,  having 
regard to the available knowledge ofthe metabolism. of  the prodQct in animals and man. 
. The test substance shall be administered orally. The duration of the test shall be at least 
90  days.  The  investigatOr shall  clearly state and  give  his  reasons  for  the  method  and 
hquency of  administration and the length of  the trials. 
The maximum dose should normally be selected so as to bring harmful effects to light. 
The lowest dose level should not produce any evidence of  toxicity. 
Evaluation  of the  toxic  effects  shall be  based  on  observation  of behaviour,  growth, 
hacmatology and  physiological  tests,  especially those relating to  the  excretory  organs, 
and also on autopsy reports and accompanying histological data. The choice and ~ge  of 
each  group of tests  depends  on  the  species  of animal  used  and  the  state of scientific 
knowledge at the time.  · 
80 lh the case:' of Dew combiDations of laiown substances which have been investiglited in 
IICCQI'd8nce  with the  provisiODS  of this Directive,  the  repeated-dose  tests may,  except 
where toxicity tests have  demonstrated pote!;ltiation or novel toxic  effects,  be .  suitablY 
modified by the investigator, ~  shali submit his reasons for such modifications. 
3.3 •. Tolerance in the target species 
Details should be provided of  any signs of  intolerance which have been observed during · 
studies conducted in the target species in _accordance with the  requirements of Part 4, 
Chapter I.  Section  B.  The  studies  concerned,  the  dosages  at which  the  intolerance 
occurred and the  species .  and  breeds  concerned  should  be  identified.  Details ·of any 
unexpected physiological changes should also be provided. 
3.4. Reproductive toxicity including teratogenicity 
3.4.1. Study ofthe effects on reproduction 
The  purpose  of this  study  is  to  identitY  possible  impairment  of male  or  female 
reproductive function or harmful effects on progeny resulting from the administration of 
the medicinal products or substance under investigation. 
In the  case  of substances  or medicinal  products  intended  for  use  in  food-proc;lucing 
animals, the study of  the effects on reproduction shall be carried out in the form of  a two-
generation study on at least one species, usually a rodent The substance or pr~duct under 
investigation shall be administered to males and females at an appropriate time prior to 
mating. Administration should continue until the-weaning of the F2 generation. At least 
three dose  levels shall be  used. The maximum dose  should be selected so  as to bring 
harmful  effects  to  light  The  lowest  dose  level  should  not produce  any  evidence  of 
toxicity. 
Evaluation of the  effects on reproduction shall-be based upon  fertility,  pregnancy and 
maternal behaviour;  the  suckling,  growth and  development  of the  Fl  offspring  from 
conception to maturity; the development of  the F2 offspring to weaning.· 
3.4.2. Study of  embryotoxic/fetotoxic effects including teratogenecity 
In the  case  of substances  or medicinal  products  intended  for  use  in  food  producing 
animals,  studies  of embryotoxic/fetoto:xic  effects,  including  teratogeilicity,  shall  be 
carried out. These studies shall be carried out in at least two mammalian species, usually 
a rodent and the rabbit. The details of  the test (number of  animals, doses, time at which 
administered  .and  criteria for the  evalUation  of results)  shall  depend  on  the  state  of 
scientific  knowledge  at the  time  the  application  is  lodged  and  the  level  of statistical 
significance which the results should attain. The rodent study may be combined with the 
study of  effects on reproductive function: 
In the case of substances or medicinal_ products which are not intended for use in food 
producing  animals, a  study  of embryotoxic/fetotoxic  effects,  including  teratogenicity, 
shall be required in at least one species, which may be the target species, if  the product is 
intended for use in animals which might be used for breeding. 
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Mutagenicity  ·tests  ~  iDtendcd · to  ·assess  the  .potential  of  substances  to, cause 
. ttansmissible changes in the genetic material of  cells. ·  · 
.  . 
Any new substance intended for. usc in veterinary ~cinal  products must be assessed 
for p:~Ulligcnic properties. 
The number and  types of tests  and the  criteria for  the  evaluation of the  results  shall 
depend on the state of  scientific knowledge when the application is submitted. 
3.6. Carcinogenicity 
Long term animal carcinogenicity studies will usually be required for substances to which 
human beings will be exposed 
which have a close chemical analogy with known carcinogens, 
which  during  mutagenicity  testing  produced  results  indicating  a  ~ssibility of 
carcinogenic effects, 
which have given rise to suspect signs during toxicity testing. 
The state of  scientific knowledge at the time the application is submitted shall be taken 
into account when designing carcinogenicity studies and evaluating their results. 
3.7. Exceptions 
Where  a medicinal  product  JS  intended  for  topical  use,  systemic  absorption  shall  be 
investigated in the target species of animal.  If it is proved that systemic absorption is 
negligible,  the  repeated  dose  toxicity tests,  the  tests  for  reproductive  toxicity  and  the 
carcinogenicity tests may be omitted, unless: 
under the conditions of  use laid down, oral ingestion of  the medicinal product by the 
animal is to be expected, or 
the  medicinal  particular  may  enter  foodstUffs  obtained  from  the  treated  animal 
(intramammary preparations).  · 
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4.1./mmunOtoxicily 
Where the  ~ffects observed. during repeated  dose  studi~ in  animals .  include  specific 
chimges  in  lylllphoid organ weights and/or histology and changes in the  cellularity of 
lymphoid tissues, boDe marrow or peripheral leukocytes,· the investigator shall consider · 
the need for additional studies of  the effects of  the product on the imm1me system. 
The state of  scientific knowledge at the time the application is· submitted shall be taken 
into account when designing such studies and evaluating their results. 
4.2. Microbiological properiies of  residues 
4.2.1. Potential effects on the human gut flora 
The  microbiological  risk  presented  by residues  of anti-microbial  compounds  for  the 
human  intestinal  flora  shall  be  investigated in  accordance with the  state of scientific 
knowledge at the time the application is submitted.  · 
4.2.2. Potential effects on the microorganisms used for industrial food processing 
In certain cases,  it may be necessary to  carry  out tests  to determine  whether residues 
cause difficulties affecting technological processes in industrial foodstuff processing. 
4.3. Observations in humans. 
Information  shall  be  provided  showing  whether  the  constituents  of the  veterinary 
medicinal product are used as medicinal products in human therapy; if  this is so, a report 
should be made on all the effects observed (including adverse reactions) in humans and 
on  their  cause,  to  the  extent  that .  they  may  be  important  for  the  assessment  of the 
veterinary  medicinal  product,  where  appropriate  in  the  light  of trial  results  of 
bibliographical docwnents; where constituents of the veterinary me4icinal products are 
themselves not used or are no longer used as medicinal products in human therapy, the 
reasons should be stated. 
5.  Ecotoxicity 
5  .1. The purpose of  the study of the ecotoxicity of a veterinary medicinal product is to 
assess  the  pot.ential  harmful  effects  which  the  use  of the  product  may  cause  to the 
environment  and  to  identifY  any  precautionary measures  which  may  be  necessary  to 
reduce such risks. 
5.2. An assessment of  ecotoxicity shall be 'compulsory for any application for marketing 
authorization  for a  veterinary  medicinal  product  other than  applications  submitted  in 
accordance with Articles 12 {3) G) and 13 {1). 
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5.3. This assessment sballnormally be conducted in two phases.  , 
In the  first  phase,  the  investigator shall assess the potential extent of exposure to the 
environment of the  product, its .  active  substances  or releVant metabolites,  taking into 
account: 
the target species, and the proposed pattern of  use (for example, mass-medication or 
individual animal medication), 
the method of  administration, in particular the likely extent to which the product will 
enter directly into environmental systems, 
the possible excretion of the product,  its active substances or rel~yant metabolites 
into the environment by treated animals; persistence in such excretia, 
the disposal of  unused or waste product. 
5.4.  In a second  phase, having regard  to  the  extent of exposure  of the product to the 
environment, and the available information about the physical/chemical, pharmacological 
and/or toxicological properties of the  compound  which  has ~  obtained  during the 
conduct of  the other tests and trials required by this Directive, the investigator shall then 
consider whether further specific investigation of  the effects of  the product on particular 
eco-systems is necessary. 
5.5. As appropriate, further investigation may be required of 
fate and behaviour in soil, 
fate and behaviour in water and air, 
effects on aquatic organisms, 
effects on other non-target organisms. 
These further investigations shall be carried out in accordance with the test protocols laid 
down  in  Annex  V of Council  Directive  67/548/EE01'  or  where  an  end  point  is  not· 
adequately  covered  by  these  protocols,  in  accordance  with  ·other  internationally 
recognized protocols. The number and types of  tests and the criteria for their evaluation 
shall  depend  upon  the  state  of scientific  knowledge  at the  time  the  application  is 
submitted. 
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84 Cl!APTER·n 
PRESENTATION OF PAR11CtJLARs AND DOCUMENTS 
As in any scic:otific work, the dossier of  safety tests sliall include the following; 
(a}  an. introduction  defining  the·  subject,  accompanied  by  anY..  useful ·bibliographical 
references; 
(b)  the detailed iden~cation  of  the substance under review, including: 
•  international non-proprietary name (INN), 
International Union of  Pure and Applied Chemistry Name (IUPAC), 
•  Chemical Abstract Service (CAS) number, 
- therapeutical and pharmacological classification, 
synonyms and abb~viations, 
- structural formula, 
•  ~olecular  formula, 
•  molecular weight, 
- degree of  impurity, 
qualitative and quantitative composition of  impurities, 
desc:rip~on of  physical properties, 
•  melting point, 
boiling point, 
•  vapour pressure, 
solubility  in  water  and  organic  solvents  expressed  in  WI,  with  indication  of 
temperature,  ·  ·  · 
•  density, 
.  spectra of  refraction, rotation, etc; 
(c)  a detailed experimental protocol giving the reasons for any omission of  certain tests 
listed above, a description of  the methods, apparatus and materials used, details of 
the species, breed or strain of animals, where they were obtained, their number and 
the conditions under which they were housed and fed, stating inter alia whether they 
were free from specific pathogens (SPF);.  · 
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(d)  all tbe results. obtained, whether favourable or unfavourable. lb~  original data should 
·  be  described  ~  sufficient  detail  U>  allow  the  results  to  be  critically  evaluated 
independently of  their interpretation by the author. By way of  explanation, the results 
may be accompanied by illustrations; 
(e)  a statistical aualysis of  the results, where such is called for by the test programme, 
and variance within the data;  · 
(f)  In objective discussion of  the results obtained, leading to conclusions on the safety 
· of  the substance, on its safety margin in the test animal and the target animal and its 
possible side-effects, on  its fields  of application, on its active dose  levels and, any 
possible incompatibilities; 
(g) · a detl.iled description and a thorough  discussion of the results of the study of the 
safety of residues  in  food,  and  its  relevance  for  the  evaluation  of potential  risks 
presented by residues to humans. This discussion shall be followed by proposals to 
ensUre that any danger to man  is eliminated by applying internationally recognized 
assessment criteria, for example: no observed effect level in animals, proposals for a 
choice of  safety factor and for acceptable daily intake (ADI); 
(h)  a thorough discussion of any risks for  persons preparing the  medicinal product or 
administering  it  to  animals,  followed  by ,proposals  for  appropriate  measures  to 
reduce such risks; 
(i)  a thorough  discussion  of the  risks  which  use  of the  veterinary  medicinal  product 
under the practical conditions proposed may represent for the environment followed 
by appropriate proposals to reduce such risks; 
(j)  all information necessary to acquaint the clinician as fully as possible with the utility 
of  the proposed product. The discussion will be supplemented by suggestions as to 
side-effects and possible treatment for acute toxic reactions in animals to which the 
product is to be administered; 
(k)  a  concluding  expert  report  which  provides  a  detailed  critical  analysis  of the 
information referred to above in the  light of  the state of scientific knowledge at the 
time the application is submitted together with a detailed SUIIliDai)' of all the results 
of  the relevant safety tests and pt;"Ccise bibliographical references. 
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CHAPTERI. 
PERFORMANCE OF TESTS 
1.  IDti'oduc:tion 
For the pmposes of  this Directive, 'residues' means all active substances or metabolites 
thereof wbich mbain in meat or other foodstuffs produced from the animal to which the 
medicinal product in question has been administered. 
The  purpose  of studying  residues  is  to  determine  whether,  and  if so  Wlder  what 
conditions  and  to  what  extent,  residues  persist  in  foodstuffs  produced  from  treated 
animals and to ascertain the withdrawal periods to be adhered to in order to obviate any 
hazard to human health and/or difficulties in the industrial processing of  foodstuffs. 
Assessment of  the hazard due to residues entails establishing whether residues arc present 
in the animals treated under recommended conditions of  U$e and investigating the effects 
of  those residues.  ·  · 
In ~e  case of  veterinary medicinal products intended for llse in food-producing animals, 
the residue documentation shall show: 
1.  to what extent; and how long, do residues of the veterinary medicinal product or its 
metabolites  persist  in  the  tissues  of the  treated  animal  .or ·foodstuffs  obtained' 
therefrom; 
2.  that in order to prevent any risk to the health of  the consumer of  foodstuffs of  treated 
animals,  or difficulties  in the  industrial processing  of foodstuffs,  it  is  possible  to 
establish realistic:: withdrawal periods which can be observed under practical farming 
conditions;  · 
3.  that  practical  analytical  methods  suitable  for  routine  use  are  available  to  verify 
compliance with the. withdrawal period. 
2.  Metabolism and residue kinetics 
2.1. Pharmacokinetics (absorption,  distribution, biotransformation, excretion) 
The purpose of pbarmacokinetic studies with respect to  residue~ of veterinary medicinal 
products  is to  eval~  the absorption, distribution,  biotransformation and excretion of 
the product in the target species. 
The final product, or a formulation which is bioequivalent, shall be administered to the 
target species at the maximum recommended dose. 
Having regard .to the method of administration, the extent of  absorption of  the medicinal 
~ct  shall be fully described. If  it is demonstrated that systemic:: absorption of  produc~ 
for topical application is negligible, further residue studies will not be required. 
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(adapted) The distributiao of  She ttlediciDal product in the  target aDiJiaal sball be ·described; the  ·  81/BS21EEc 
possibiUt)r  of plasma  protein  binding,  or  passage ·into·  .. milk  or  eggs  and· of the  Almei. 
·accumUlation of  lipophilic compounds sball be coasidered.  ·  (as amende4 by 
.  92/18/.EEC Art. 1) 
The pathways for the excretion oftbe product from the target animal shall be described.  (adapted) 
The maj~  metabo~  sball be iden~ed  and characterized. 
22. Depletion of  residues 
The purposes of  these· sau:lies, which measure the rate at which residues deplete in the 
target aoimal  after the  last administriltion of the  medicinal  product,  is  to permit  the 
determination of  withdrawal periods.  · 
At vuyiDg  times  after  die  test  animal  bas  received  the  final  dose  of the  medicinal 
product, the quantities of  residues present sball be determined by appropriate physical, 
chemical  or  biological  methods;  the  technical  procedures  and  the  reliability  and 
sensitivity of  the methods employed shall be specified. 
· 3.  Routine analytical method for the  detection of  residues 
Analytical procedures shall  be  proposed which  can  be  carried out in the  course  of a 
roUtine examination and which have a level of sensitivity such as to enable violations of 
legally·permitted maximum residue limits to be detected with certainty. 
The aoalytical method proposed shall be  described  in ·detail.  It shall be  validated and 
shall be sufficiently rugged for  use  under nonnal conditions of routine monitoring for 
residues. 
The following characteristics shall be described: 
•  specificity, 
•·  accuracy, including sensitivity, . 
- precision, 
•  limit of  detection, 
- limitofqwmtimtion, 
•  practicability and applicability under nonnallaboratory conditions, 
•  susceptibility to interference. 
The suitability of the aoalytical method proposed shall be evaluated in the light of the 
state of  scientific and technical knowledge .at the time the application is submitted. 
88 CHAPTERn 
PRESENT  AnON OF PARnCULARS AND DOCUMENTS 
As in any ·scientific work, the dossier of  residue tests shall include the following: 
(a)  an  iiltroduction  defining  the  subject,  accompanied  by  any  usefUl  bibliographical 
references;  · 
(b) a detailed identification of  the medicinal, including: 
·composition. 
purity, 
batch identification, 
- .  relationship to the final product,' 
specific activity and radio-purity oflabelled substances, 
position of  labelled atoms in the molecule;· 
(c)  a detailed experimental protocol giving the reasons for any omission of  certain tests 
listed above, a description of the methods,  apparatus and materials used, details of 
the species, breed or strain of animals, where they were obtained, their nwnber and 
the conditions under which they were housed and fed; 
(d)  all the results obtained, whether favourable or unfavourable. The original data should 
be  described  in  sufficient  detail  to  allow  the  results  to  be  critically  evaluated 
independently of  their interpretation by the author. The results may be accompanied 
by illustrations; 
(e)  a statistical analysis of  the results, where such is called for by the test programme, 
and variance within the data; 
(f)  an objective discussion of  the results obtained, followed by proposals for maximum 
residue  limits  for  the  active  substances  contained  in  the  product,  specifying  the 
marker  residue  and  target  tissues  concerned,  and  proposals  concerning  the 
withdrawal  periods necessary to ensure  that no  residues  which might constitute a 
hazard for consumers are present ·in foodstuffs obtained from treated animals; 
(g)  a  concluding  expert  report  which  provides  a  detailed  critical  analysis  of the 
-information referred to above in the light of  the state of  scientific knowledge at the 
· time the application is submitted together with· a detailed· SUIDID8I)' of the results of 
the residue tests and precise bibliographical references.  · 
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The ·particulars  and  docwnents  which  shall  accompany  applications  for  marketing  (adapted) 
authorizations pW"SWUlt to Articles 12 (3} G) and 13 (1) shall be submitted in accordance 
with.the.provisions of  this Part. 
CHAPTER I 
PRE-CUNICAL REQUIREMENTS 
Pre-clinical  studies  are  required  to  establish  the  pharmacological  activity  and·  the 
tolerance of  the product. 
A.  Pharmacology 
A.l. PHARMACODYNAMICS 
The study of  pharmacodynamics shall follow two distinct lines of  approach: 
First,  the  mechanism  of  action  and  the  pharm&cological  effects  on  which  the 
recommended application in practice is based shall be adequately described. The results 
shall be expressed  in quantitative  terms (using,  for  example,  dose-effect curves,  time-
effect curves, etc.) and, wherever possible, in comparison with a substance the activity of 
which is well known. Where a higher efficacy is being claimed for an active substance, 
the difference shall be demonstrated and shown to be statistically significant. 
Secondly, the investigator shall give an overall pharmacological assessment of  the. active 
substance,  with special reference to the  possibility of side-effects. ln general, the main 
functions shall be investigated. 
The investigator shall identify the effect of the route of administration, formulation, etc, 
on the pharmacological activity of  the active substance. 
The  investigations  shall  be  intensified  where  the  recommended  dose  approaches  that · 
liable to produce adverse reactions.  · 
The experimental techniques, unless they are standard procedures, shall be described in 
such detail as to allow them to be reproduced, and the investigator shall establish their 
validity. The experimental results shall· be· set out clearly and, for certain types of tests, 
their statistical significance quoted.  · 
Unless good reasons are given to the contrary, any quantitative modification of  responses 
resulting from repeated administration of  the substance shall also be investigated. 
' 
Medicinal  combinations  may  be  prompted  either  on  pharmacological  grounds  or by 
clinical  indications.  ln the  first  case,  the  pharmacodynamic  and/or  pharmacokinetic 
studies shall demonstrate those interactions which might make the, combination itself of 
value in clinical use. ln the second case, where scientific justification far the medicinal 
combination is sought through clinical experimentation, the investigation shall determine. 
whether the effects expected from the combination can be demonstrated in animals and, 
at least,  the  importance  of any  adverse  reactions  shall  be checked.  If a combination. 
includes a novel active substance, the latter shall have been previously studied in depth. Basic pharmacoldnetic information concerning a new active substance is-generally use~ 
in the-clinical context. 
Pbarmacokinetic objectives can be divided into two main areas:  · 
(i)  descriptive pharmacokinetics leading to .  the evaluation of basic parameters such as 
body clearance, vo.lume(s) of  distribution, mean residence time, etc; 
(d) use  of these  parameters  to investigate  the  relationships  between  dosage  regimen, 
· . plasma and tissue concentration and phatmacologic, therapeutic or toxic effects. 
In target species,  pharmacokinetic studies are,  as a rule, necessary in order to employ 
drugs with the greateSt possible efficacy and safety. Such studies are especially useful to 
assist the  clinician  in  establishing. dosage  regimens  (route  and  site  of administration, 
dose,  dosing  interval, number of administrations,  etc.) and  to  adopt dosage  regimens 
according to certain population variables (e.g. age, disease).  Such studies can be more 
efficient in number of animals  and generally provide  more ·information than  classical 
dose titration studies.  ·  · 
In the case of new combinations of known substances which have been investigated in 
accordance with the provisiOns of this Directive,  pbarmacoldnetic studies. of the  fixed 
combination are not required if it can be justified that the administration of the active 
substances as a fixed combination does not change their pharmacoldnetic properties. 
A2.1. Bioavailabilitylbioequivalence 
Appropriate bioavailability studies shall be undertaken to establish bioequivalence: 
when comparing a reformulated medicinal product with the existing one,  · 
when comparing a new method or route of  administration with an established one, 
in all cases referred to in Article 13 (1). 
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The purpose of this stUdy, which sbaD be Carried out with all animal ~ies  for~  .1he  (as .amended by . 
.  mediciDal product is iDtended, is to cmy out in all such animal Jl*ies local and general  92/18/EEC Art. 1) 
·tOlerance triaJs· desigaed to ~lish  a tolerated do4a&e wide enough to allow an adequate  ·(adapted) 
safety ~  and the ·clinical symptOms of  intolerance UsiDg the. recommended route u 
routes,  Ui ·so far as this may be ~eved  by increasiDg the therapeutic dose and/or tbe 
dUration oftreazment 'Jbe repon on the trials sball contain as many details. as possible of 
the  expeCted  phanbacological  effects  and  the  adverse  reactions;  the  laUer  shall  be 
assessed with due regard to the fact~  the anjma]s used may be of  -my  high value. 
The  medicinal  product  sball ·be  administered  at  least  via the recommended  route  of 
administration.  · 
C.  Resistance 
Data on the  emergence of resistant organiSms  are necessary  in the else of medicinal . 
products  used  for  the  prevention  or  treatment  of iilfectious  diseases ·or  parasitic 
infestations in animals. 
CHAPTERn 
CLINICAL REQUIREMENTS 
1.  General principles 
lbe purposes  of clinical  trials  are  to  demonstrate  or  substantiate  the  effect  of the 
veterinary medicinal product after administration of  the recommended dosage, to specify 
its  indications  and  contra-indications  according  to  species,  age,  breed  and  sex.  its 
directions .for use, any adverse reactions which it may have and iis safety and tolerance 
under normal conditions of  use. 
Unless  justified. clinical  trials  shall  be  carried  out with  control  animals  (controlled 
clinical trials). lbe effect obtamed should be compared with a placebo or with absence of 
treatment and/or with  the  effect  of an  authorized  medicinal  product known  to  be of 
therapeutic  value.  All  the  results  obtained,  whether  positive  or  negative,  shall  be 
reported. 
lbe methods used to make the diagnosis shall be specified. lbe results shall be set out by 
making use of  quantitative or conventional clinical criteria. Adequate statistical methods 
shall be used and justified. 
92 In  the case of  a Veteriwuy medicinal pfoduct iDteJ1ded primarily for~  as. a performance·  :Sl/852/EEC ., 
euhancer. parti~.  ~C?n  sball be given tO:  ..  ·  ·  ·  Annex. 
(as imlendcd by 
the yield of  animal produce,  '·  92/l 8/EEC Art. 1) 
(adapted) 
the quality. of  animal produce (organoleptic, nutritional. hygienic and technological 
qualities), . 
• · ·nutritional. efficiency and growth of  animal, 
the general stams of  health oftbe animal. 
Experimental data shall be confirmed by data obtained under ~cal  field conditions. 
Where, in resPect of  particular therapeutic indications, the applicant can show that he is 
unable to provide comprehensive data on therapeutic effect because: 
(a)  the  indications  for  which  the  medicinal  ,Product  in  question  is  intended  are 
encountered so rarely that the applicant cannot reasonably be expected to  provide 
comprehensive evidence; 
(b)  in .the present state of scientific knowledge,  comprehensive information cannot be 
provided; 
the marketing authorization may only be granted subject to the following conditions: 
(a)  the medicinal product in question is to be supplied on veteriuary prescription only 
and may, in certain cases, be administered only under strict veterinary supervision; 
(b)  the  package  insert  and  any  other  information  must  draw  the  attention  of the 
veterinary practitioner to the  faCt  that,  in certain specified respects,  the particulars 
. available concerning the medicinal product in question are as yet incomplete. · 
l.  Performance of trials 
· All  veterinary clinical trials  shall be  conducted in accordance  with a fully  considered 
detailed trial protocol which shall be recorded in writing prior to commencement of  the 
trial. The welfare of the trial animals shall be subject to veterinary supervision and shall 
be  taken  fully  into  consideration  during  the  elaboration· of any  trial  protocol  and 
throughout the conduct oftbe trial. 
Pre-established  systematic  written  procedures  for  the  organization,  conduct,  data 
collection, documentation and verification of  clinical trials shall be required. 
93 Before tbe·c:onaD~tof  ~.trial, the ioforlned consent of  the ~er  bf  the ~jwals  : 81/852/EEC 
to be·used m  the triai shall be obtt.ined and ~eiited.  In particular, .the animalo\\rner  Annex  .. 
sball be informed .  in Writing  of the  CODSCQUeDCCS · of participation in the rtrW  for the  (liS amended by · 
subsequeDt  dispOsai of treated .animals  or  fot tl;le  taldn8 of~  frain ·treated  92/18/EEC Art> I) 
ariimaJs, A copy of  this notification, countersigned and dated by the animal owner, sba1l  (Bdapted)  · · 
be included in the «rial ~on..  · 
Unless the trial is Conducted with, a blind deSign, the provisions ofArtictcs 55, 56 and 57 
c:onceming· the labelling of veterinary medicinal products shall apply by analogy to the 
labelling of formulations intended for use in veterinary clinical trials. In· all cases. the 
words 'for veterinary clinical trial use only'  sb&l1 appear prominently and indebbly upon 
the labelling. 
cHAPTER.m 
PARTICULARS AND DOCUMENTS 
As in any scientific work, the dossier on efficacy sba1l  include an introduction defining . 
the subject accompanied by any useful bibliographical documentation. 
All pre-clinical  and  clinical  documeiuation must  be  sufficiently  detailed  to enable  an 
objec:tive  judgement  to be  made.  All studies  and  trials  must  be  reported,  whether 
favourable or unfavourable to the applicant  · 
i.  Records of pre-eliDical observations 
Wherever possible, particulars shall be given of  the results of: 
(a)  tests demonstrating pharmacological actions; 
(b)  tests  demonstrating  the  pharmacological  mechanisms  underlying  the  therapeutic 
·effect; 
(c)  tests demonstrating the main phannacoldnetic processes  .. 
Should unexpected results occur during the course of  the tests, these should be detailed 
94 Additi_onallytbe ·followmg parti~  sball be ·provided in.appre-elitiical stUdies: 
{a)  a sUmmary; 
{b)  a detAiled.~  protoc9l giving a description of  the methods, apparatus and 
'materials mcd, details such as ·spcc:ies, age, weight, sex, number, breed or strain of 
· animals, identification of. animals, dose,. route and schedule of  administrcition; 
{c)  a staDstical analYsis of  the results where rele~t; 
(d)  an objective discUssion oftbe results obtained, leading to conclusions on.the safety 
and efti..acy. of1he product. 
Total or partial omission of  these data must be explainect 
2.1. Records of  clinical observations 
' 
AU  the· particulars shall be supplied by each of the  investigators on individual record· 
sheets  in  the  case ()f individual  treatment and  collective  record-sheets  in  the  case  of 
collective treatment 
The particulars supplied shall take the following form: 
(a)  name, address, function and qualifications of  investigator in charge; 
I 
(b)  place and date oftreatment; name and address of  owner ofthe anUnals; 
(c)  details  of the  trial  protocol  giving  a description  of the  methods  used,  including 
methods of randomization and blinding, details such as the route of administration, 
schedule of  administration, the dose, identification of  trial aninlals, ~pecies, breeds or 
strains, age, weight, sex, physiological status;  · 
(d)  method of  rearing and feeding, stating the composition of  the feed and the nature and 
quantity of  any additives contained in the feed; 
(c)  case histoey (as full as possible), occurrence and co\U'Se ofanyinter..current diseases; 
{f)  diagnosis and means used to make it; 
.  (g)  symptoms and severity of  the disease, if  possible aceording to conventional criteria; 
· (h)  the precise identification of  the clinical trial formulation \J.scd in the trial; 
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(i)  dosage ·of the inedicmaJ product, method, route'. and ih:quency of ~on  and  81/852/EEC·  ... 
p.:ecautions, if  any, taken duriJig administration {duration of  injection,  etc~);.- AnneX. 
·  ·  ·  ·  ·  ·  (as amended ,by 
(j) ~  'oftteanrient and period of  subsequent obsemition;  92/18/EEC Art.. i) 
(k)  all detailS concerning medicinal products (other thaD that·under study) which have 
beeU lldministered .during the period of  examination, either prior to or concurrently 
with the teSt:_product and, in the Jatter·case, details of  the interactions observed; 
(1)  all i'Csults of  the clinical trials (including unfavourable oi negative results) with a full 
statement of  the .clinical observations and the results of  the objective tests. of  activity 
(laboratory analyses,  physiological  tes_ts),· required  to evaluate the  application;  the 
· techniques  used  must  be specified,  and  the  signifi~ce of any  ~otis  in the 
results explained (for example, variance in method, variance between individuals or 
the  effects  of the  medication);  demonstration  of the  pharmacodynamic  effect  in 
animals sball not in itself suffice to justify conclusions concerning any therapeutic 
effect;  · 
·' 
{m)  all particulars of  any unintended effects, whether harmful or not, and of  any measures 
taken  in  consequence;  the  cause-and-effect  relationship  shall  be  investigated  if 
possible; 
(n)  effect  of animals'  performance  (for  example:  egg-laying,  milk  production  and 
reproductive function); 
(  o)  effects on the quality offoodstuffs obtained from treated animals, particularly in the 
case of  medicinal products intended for use as performance enhancers;  · 
(p)  a conclusion on each individual case or, where collective treatment is concerned, on 
each collective case.  · 
Omission of  one or more items (a) to (p) shall be justified. 
The marketing authorization holder shall make all necessary arrangements to ensure that 
the original documents, which formed the basis of the data_ supplied, are kept for at least 
five years after the veterinary·medicinal product is no longer authorized. 
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In ~  of eacJi  ~Iinical trial,  the  clinical  observations  shall  be  summarized  in  a 
S)'Dopsi$ ~f:tbe trials and the results thereof; indicating in p~cular:  · 
(a)· the .  number  of contrOls,  the  number  of animals  treated  either  individually  or 
· collectively, with a breakdoWn according to speeies, breed or strain, age and sex; 
(b)  the number of animals  withdrawn  prematurelY from  the  trials and the  reasons for 
such wi!Jldrawal; 
(c)  in the. case of  comrol animals, whether they have: 
received no treatment; 
received a plaCebo; 
received another authorized medicinal product ofkno'Wn effect; 
received the active substance under investigation in a different formulation or by a 
differel)t route; 
(d)  the frequency of  observed adverse reactions; 
(e)  observations  as  to  the  effect  on  pcrfongance  (for  example,  egg-laying,  milk 
production, reprOductive function and food quality); 
(f)  details concerning test animals which may be at increased risk owing to  their age, 
their mode  of ~  or feeding,  or. the  purpose  for  which  they  are  intended,  or 
animals  the  physiological  or  pathological  condition  of which  requires  special 
consideration;  · 
(&)  a statisticai evaluation of  the results, when this is called for by the test programme. 
Finally, the investigator shall·draw general conclusions from the experimental evidence, 
expressing his opinion. on the harmlessness uf  the medicinal product under the proposed 
conditions of  use, its therapeutic effect and any useful information relating to indications 
and contra-indications, dosage and average duration of  treatment and where appropriate, 
any interactions observed with other medicinal products or feed additives as well as anY, 
special  precautions  to  be  taken  during  treatment  and  the  clinical  symptoms  of 
overdosage.  · 
In the case of  fixed combination products, the investigator shall also draw conclusions 
concerning the safety and the efficacy of the product when compared with the separate 
administration of  the active substances involved. 
3.  ConcludiD" expert report 
The  concluding  expert report  Shall  provide  a ·detailed critical analysis  of all  the  pre-
clinical and clinical documentation in the light of  the state of  scientific knowledge at the 
time the application is subJ;nitted together with a detailed ·summary of the results of the 
tests and trials submitted ~d  precise bibliographic references. 
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REQUIREMENTS FOR JMMUNOIOOICAL VETERINARY 
.  .. ,  MEDlCINAL PRODUCTS . 
WithoUt prejudice to the specific reqUirements· iaid do'Wn bY Community legislation tor 
the ~~  and eradication of  animal desease; the 'follpwing requir¢ent;s shall apply tO 
fmrmmological :veterinary medicinal products. 
PARTS 
SUMMARY OF THE·DOSSIER 
A.  ADMINISTRATIVE DATA 
The immunological veterinary medicinal product which is the subject of  the application 
shall be ·identified by name  and  by name. of the  active  substances,  together with the 
strength  and  pharmaceutical  form,  the  method  and  route  of administration,  and  a· 
description of  the final sales presentation of  the product 
The name and address of  the applicant shall be given, together with the name and address 
of the  manutacturer  and  the  sites  involved  in  the  different  ·stages  of manufacture 
(including the manufilctuter of  the finished product alid the manufacturer(s) of  the active 
substance(s)) and where relevant the name and address oftbe importer. 
The applicant shall identify the number and titles of  volumes of  documentation submitted 
in support of  the application and indicate what samples, if  any, are also provided. 
Annexed  to  the  administrative  data  shall  be copies  of a document  showing  that  the 
manufacturer is authorized to produce immunological veterinary mFCficinal products, as 
defined in Article 44 (with a .brief description of  the production site). Moreover, the list 
of  organisms handled at the production site shall be given. 
The applicant shall submit a list of countries in which authorization has been granted, . 
copies of  all the summaries of product characteristics in accordance with Article  14 as 
approved  by Member States and  a list of countries  in  which  an  application  bas  been 
submitted.  ·  · 
B.  SUMMARY OF PRODUCT CHARACTERISTICS 
The applicant shall propose a summary of  the product characteristics, in accordance with 
Article 14. 
1n addition the applicant shall provide one or more specimens or mock-ups of  the sales 
presentation of  tbe immunological veterinaly medicinal product,. together with a package 
insert, where one is required. 
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In accordance with Article 15 (2) and(3) expert repoftS must-be provided on ali. aspects  ·cas amended by 
of  1he doc:um.tntation  .  .  ·  . .  92/18/EEC Art. I) 
(adapted) 
Each expert report shall ccmsist of  a critical evaluation· of  the various tests and/or trials, · 
which have been canied out in accordance with this Dh'ective, and bring out all the data 
relevant  for  evaluation.· The  expert  Shall  give  his  opinion ·as  to  whether  sufficient 
guarantees  have  been  provided as  to  the  quality,  safety. and  efficacy  of the  product 
. concemed. A factual SUJDID8l)' is not sufficient. 
. All important data shall be SUJDJDarised in an appendix to the  expert report, whenever 
possible in tabular or graphic form.  The expert report and the summaries shall contain 
precise cross references to the information contained in  the main doc:umentatiol1. 
Each expert report sball be prepared by ·a suitably qualified and experienced -person.  It 
sball  be  signed  and  dated  by the  expert, ,and  attached  to  the  report  shall  be .brief 
information about the  edw;ational baclcground,  training and occupational experience of 
the expert. The professional relationship of  the expert to the applicant shall be declared. 
PART6 
ANALYTICAL  (PHYSico-cHEMICAL, BIOLOGICAL OR. 
MICROBIOLOGICAL)  TESTS  OF  IMMUNOLOGICAL  .VETERINARY 
MEDICINAL PRODUCTS 
AU test procedures used shall correspond to the state of  scientific progress at the time and 
shall be validated procedures; results of  the validation studies shall be proYided. 
All the  test  procedure(s) shall be  described  in sufficiently  precise  detail  so  as .  to  be 
reproducible in control tests, canied out at the request of the  competent authority;  any 
special apparatus  and  equipment  which  may  be  used  shall  be  described  in  adequate 
detail, possibly accompanied by a diagram. The formulae of  the laboratory reagents shall 
be  supplemented,  if necessary,  by  the  manufacturing  method  In  the  case  of test 
procedures included in the European Pharmacopoeia or the pharmacopoeia of  a Member 
State, this description may be replaced by a detailed reference to the pharmacopoeia in 
question. 
99 A.  QUALITATIVE·  AND  ·QUANTITATIVE  PARTICULARS  . OF  THE 
CONSTITUENTS 
The  Particulars  and. documents  which .  must  accOmpany  applicati~ns for  marketing 
authorization, pursuant to_Article  12 (3) (c), shall be submitted in aa:ordance·with the 
following 'requirements.  · 
1.  QuaUtative particulars 
~Qualitative particulars' of  all the constituents of  the immunological veterinary medicinal · 
prQduct shall mean the designation or description of: 
the active substance(s), 
the constituents of  the adjuvants, 
the  constituent(s} of the  excipients,  whatever  their  nature  or  the  quantity  used. 
including  preservatives,  stabilizers,  emulsifiers,  colouring  matter,  flavouring, 
aromatic substances, markers, etc., 
the constituents of  the pharmaceutical form administered to animals. 
These particulars shall be supplemented by any relevant data concerning  ~e  container 
· and.  where  appropriate,  its  manner  of closure,  together  with .details  of devices  with 
which the immunological veterinary medicinal product will be used or administered and 
which will be delivered with the medicinal product. 
2. The  'usual terminology', to be used in describing the. constituents of immunological 
veterinary medicinal products, shall mean, notwithstanding the application of the other 
provisions of  Article 12 (3) (c): 
in respect of substances which appear in the  European Pharmacopoeia or,  failing 
this, in the national pharmacopoeia of  one of  the Member States, the main title of  the 
monograph  in  question,  which  will be  obligatory  for  all  such  substances,  with 
reference to the pharmacopoeia concerned. 
in respect of other substances, the international non-proprietary name recommended 
by  the  World Health  Organization,  which  may  be  accompanied  by another  non-
proprietary name or,  failing these,  the  exact scientific designation;  substances not 
having an international non-proppetary name or an exact scientific designation shall 
be  described.  by  a  statement  of  how  and  from  'what  they  were  prepared, 
supplemented. where aPpropriate, by any other relevant details, 
in  respect of colouring  matter, designation by  the  'E' code  assigned  to  them  in 
Directive 78125/EEC. 
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·~  aider .. to  give.  fbe  'quantitative  particUiars'  of the  acti~  subStances  of an  (as amended by 
immunological veterinary mediciDal product, it is necessary to specify whenever possible  92/l81EEC Art. 1) 
the  number  of  organisms,  the  specific  protem  content,  the  mass,  the  number  of  (adapted) 
lntemational Units ·(RJ) or units of  biological activity,· either per dosage-unit or volume, 
and with regard to the adjuvant and to the constituents of  the eXcipients, .the mass or the 
volume of  each of  them, with due allowance for the! details provided in section B. 
Where an International Unit of  biological activity haS been defined, this shall be used. 
The units of  biological activity for which no pUblished data exist shaD be expressed in 
such a way as to provide unambiguous information on the activity of  the ingredients, e.g. 
by :StatiJig the  immunological  effect on  which  the  method of determining  the  dose  is  based...  .  .  . 
4.  Development pharmaceutics 
An  explanation ·shall  be  provided  with  regard  to  ~e composition,  components  and 
containers,  supported by scientific  data  on  development  pharmaceutics. ~  overage, 
withjustification thereof; shall be stated. The ~cacy  of  any preservative system shall be 
dem~nstrated.  . 
B.  DESCRIPTION  OF  MANUFACI'URING  MEmOD  OF  THE  FINISHED 
PRODUCJ' 
The  description  of the  manufacturing  method  accompanying  the  application  for 
marketiiig authorization pursuant to Article 12 (3) (d), shall be drafted in such a way as to 
give an adequate description of  the nature of  the operations employed. 
For this purpose the description shall include at least: 
the  various  stages  of manufacture  (including  purification  procedures)  so  that  an 
assessment can be made of  the reproducibility of  the manufacturing procedw-e and of 
the  risks  of adverse  effects  on  the  finished  products,  such  as  microbiological 
contamination,  · 
in the case of continuous manufactw-e,  full details concerning precautions taken  to 
ensure the homogeneity and consistency of  each batch !'f  the finished product, 
mention of  substances which cannot be recovered in the comse ofmanufacture, 
the details of  the blending, with the quantitative particulars of  all ~e  substances used, 
a statement of the  stage  of manufactw"e  at which  sampling  is  carried  out  for  in-
process control tests. 
101 C.  .PRODUCTION AND CONTROL OF STAR'fnliG.M\TERIALS · 
For ·the purposes of  this paragraph 'starting materials' means all components ·used. in tJie 
production of  the immunological veterinary medicinal prodUCt.  Culture media-used for 
the production of  the active substance.arc considered as _one single startipg material. 
ln  1.\le we  of 
im  active.· substance  not ·  dcscn~d in  the  European  Pharmacopoeia  or  in the 
pharmacopoeia of  a Member State, 
or 
.- an  active  substance  described  in  the  European  Pharmacopoeia  or  iii  the 
pharmacopoeia -of a  Member  State  when  prepared. by a method  liable  to  leave 
impurities  not  mentioned  in the  pharmacopoeial  monograph. and  for  which  the 
monograph is inappropriate to adequately control its quality, 
which is manufiu:tured by a person different from the applicant, the latter may arrange for 
the detailed description of  the manufacturing method, quality control during manufacture 
and  process  validation  to be supplied  directly  to  the  ~mpetent authorities  by  the 
manufacturer  of ~e active  substance.  In  this  case,  the  manufacturer ·shall  however 
provide the applicant with all the  data which may be necessary for the  latter to take 
responsibility for the medicinal product. The manufacturer shall confirm in writing to the 
applicimt  .  that  he  shall  ensure  batch-to-batch . consistency  and  not  modify  the 
manu13cturing process or specifications without bifonning the applicant. Documents and 
particulars  supporting .  the  application  for  such  a  change  shall  be  supplied  to  the 
competent authorities.  · 
The particulars and documents accompanying the application for marketing authorization 
pursuant to· Article  12 (3) (i) and G) and Article  13  (I) shall include the results of the 
tests relating to quality COD1rol  of all the  components used and shall be submitted in 
accordance with the following provisions. 
1.  Starting materials listed in pharmacopoeias 
The monographs of the European Pharmacopoeia shall be applicable to all substances 
appearing in it. 
In respect of other s)lbstanccs, each Member State may require observance of its own 
national pharmacopoeia with regard to products manufactured in .its tenitory. 
Components  fulfilling  the  req~ents of the  European  Pharmacopoeia  or  the 
pharmacopoeia of  one of  the Member States shall be deemed to comply sufficiently with 
Article 12 (3) (i). In this case the description of  the analytical methods may be replaced 
by a detailed reference to the pharmacopoeia in question.  · 
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(adapted)  . Reference ·to phalmaCopoeias. of tbird 6X)untries  may  be permitted in cases. irhere the 
substance  is  described neither in the ·European Pharmacopoeia  nor  in  the  national 
~ia  concerned; in .that ~  the monograph ,ruill be sUbmitted, accon:ipanied 
where·necessary by a tranilationforwbich the applicant will be  responsibl~.  .  · 
Colouring  matter  sball,  in  all cases,  satisfy  the  reqUirements. of Council  Directive 
78f2S/EEC. 
The routine tests carriCd out on each batch of starting materials must be as stared in the 
·application  for  nlirketing  authorization.  If  tests  other  than. those  mentioned  in the 
pharmacopoeia are used,  proof must  be  supplied that  the  starting materials  meet. the 
quality requirements of  that pharmacopoeia.  ·  · 
In  cases wtiere  a  speCification  or other· provisions  contained  in a monograph  of the 
European Pharmacopoeia or in the national pharmacopoeia of  a Member State might be 
insufficient to eDSW"e the quality of  the substance, th~ competent authorities may request 
more appropriate specifications from the marketing authorization holder. 
The competent authorities shall inform the authoriti~s reSponsible for the pharmacopoeia 
in  question.  The marekting auth9rization  holder  shall  provide  the  authorities  of that 
pharmacopoeia  with  the  details  of  the  alleged  insufficiency  and  the  additional 
specifications applied. 
In cases where a starting material is described neither in the .European Pharmacopoeia 
nor in the pharmacopoeia of a Member State, compliance with the monograph of a third 
country pharmacopoeia can be accepted; in such cases, the applicant shall submit a copy 
of  the monograph accompanied where necessary by the validation of  the test procedures 
contained  in  the  monograph  and  by  a  translation  where  appropriate.·  For  active 
ingredients, demonstration of the  ability of the monograph  adequately to control their 
quality shall be presented. 
l.  Starting materials not listed iD a pharmacopoeia 
2.1. Starting materials of  biological origin 
The description shall be given in the form of  a monograph. · 
Whenever  possible,  Vaccine  production .  shall  be based  on  a seed  lot  system and  on 
established  cell  banks.  For  the  production  of immunological  veterinary  medicinal 
products consisting of  serums, the origin, general health and immunological status of  the 
producing animals shall be indicated; defined pools of  so\U'Ce materials shall be used. 
The  origin  and  history of starting  materials shall  be described .and  documented.  For 
genetically engineered starting materials this information shall include details such as the 
description  of the  starting  cells  or strains,  the  construction ·of the  expression  vector 
(name, origin, function ofthe replicon, promoter enhancer and other regulator elements), 
control of  the sequence of  DNA or RNA effectively inserted, oligonucleotidic sequences 
of plasmid  vector in  cells,  plasmid  used .for cotransfection.  added  or deleted  genes, 
biological properties of the final construct and the genes expressed,  C9PY number and 
genetic stability. 
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(adapted)  . Seed .maienals, mcludmg,eell binks and raw serum for  anti~erum production shall be 
tested fC)J' identity ~d  adventitious agents.  · 
Information sball be provided on all substances of  biologic:il origin used at any stage in 
the man~  procedure. The infonnation shall include: 
'  -
details.ofthe soun:e of  the materiaJs, 
details  of any  processing, ~on  and  inactivation  applied,  with .  data on the 
validation of  these process and in-process controls, 
details of  any tests for contamination carried out,on each batch of  the sUbstance. 
If  the presence of  adventitious agents is dete<:ted or suspected, tb,e corresponding material 
shall  be . discarded  ·or  used  in  very  exceptional  circumstances  only  when  fUrther 
processing of  the procluCt ensUres their elimination and/or inactivation; elimination and/or 
inactivation of  such adventitious agents shall be demonstrated. 
When  cell  banks  are  used,  the  cell  characteristics  shall  be  shown  to have  remained 
unchanged up to the highest passage level used for the production. 
For live attenuated vaccines, proof of  the stability of  the attenuation characteristics of  the 
seed has to be given. 
When required, samples of  the biological starting material or reagents used in the testing 
procedures shall be provided to enable the competent authority to arrange for check tests 
to be carried out. 
2.2. Starting materials of  non-biological or.igin 
The description shall be given in th_e form of a monograph under the following headings: 
the name of  the starting ~terial meeting the requirements of point 2 of Section A 
· shall be supplemented by any trade or scientific synonyms, 
the description of the starting material, set down in a form similar to that used in a 
descriptive item iD the European Pharmacopoeia, 
the function of  the starting material, 
methods of  identification, 
purity  shall  be  descnbed  in relation  to  the  sum  total  of predictable  impurities, 
especially tb,ose  which may have  a harmful effect  and,  if nec:essary,  those which, 
having regard to the. combination of  substances to which the application refers, may 
adversely effect the stability of  the medicinal product or distort analytical results. A 
brief description shall be provided of the tests undertaken to establish the purity of 
each batch of  the starting material, 
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{adapted) •  any. special  Pm:aunons .  which  may  ~  necessary .  during  storage  of the  starting 
~  and,.ifnecessary, its ~e  life~  be given.  · 
D.  CONTROL TESTS DURING PRODUCI'ION  . .  . 
1.  The  particulars- and  documents  accompanying ·  · an · application  for  marketing 
autb.oril.ation,-pursuant to Article 12 (3) (i) and (j) lind Article  13. (1), shall include 
particulars relating to· the contro..l tests which are. carried out on intermediate products 
with  a view to verifying the· consistency of the production process  and  the  final 
-~  ' 
2.  For inactivated or detoxified vaccines, inactivation or detoxification shall be tested 
during  each  production  run .  immediately. after  the  inactivation  or detoxification 
process. 
E.  CONTROL TESTS ON THE FINISHED PRODUCI' 
The particulars and documents acCompanying the application for marketing authorization 
pursuant to Article 12 (3) (i) and (j) and Article 13 (1), shall include particulars relating 
to  control  tests  on  the  finished  product.  Where  appropriate  monographs  .exist,  if 
test procedures  and  limits  other  than  those  mentioned  in  the  monographs  of the 
European Plwmacopoeia, or fAiling this,  in  the national plwmacopoeia of a Member 
State,  are  used,  proof must be supplied that the  finished  product would,  if  tested  in 
accordance with those monographs, meet the quality requirements of  that pharmacopoeia 
for the pharmaceutical form concerned. The application for marketing authorization shall 
list those tests which are .carried out on representative samples of  each batch of finished 
produ~ The frequency of the teSts  which are not carried out on  each batch  shall be 
stated. Release limits shall be indicated. 
1.  General characteristics of  the fmished product 
Certain tests of  the gen~  characteristics of  a product shall be included among the tests 
on  the  finished  product,  even  if they  have  been  carried  out  in  the  course  of the 
manufacturing process. 
These  tests  shall,  wherever  applicable,  relate  to  the  control  of average  masses  and 
maximum deviations, to mechanical. physical, chemical or microbiological tests, physical 
characteristics such· as density, pH, refractive index, etc. For each of  these characteristics, 
specifications, with appropriate confidence limits, shall be established by the applicant in 
each particular case. 
2.  Identification and assay of  active substance(s) 
For all tests, the description of  the techniques for analyzing the finished product ~  be 
set out in sufficiently precise detail, so that they can be reproduced readily. 
The assay of  biological activity of  the active substance(s) shall be carried out either in a 
representative sample from the production batch or in a number of  dosage-units analysed 
individually. 
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~  certain cxcepti,onal cases where assay of  active substarices which are very numerous or  (as amended by. 
present in very low.IIIDPunts would necessitate an. ~cate  investigation difficult to cany_  92/18/EEC Art. 1) 
.out in respect of  each production batch, the assay of  one or more active substances· in.the  (adapted) 
finished product may be omitted, oq the express condition th8t sueh assays are made at 
intenlledWe stages as late as possible in the production process. This relaxation may not 
be  extended  to  the  ~on  of the  .substatlces  concerned.  This  simplifiec:i 
technique shall be supplemented by a method of quantitative ·evaluation,· enabling the 
~  authority to verify tbat the immunological veterinary medicinal product is in 
accordance with ~  formula after it  has been placed on the market. 
I 
3.  ldentifieation and assay of  adjuvants  .  ~ 
In so far as testing procedures are available, the quantity and nature of  the adjuvant and 
its components shall be verified on the finished product. 
4:.  Identification and assay of excipient components 
In so far as is necessary, the excipient(s) shall be subject at least to identification tests. 
The test procedure proposed for identifying colouring matters must enable a verification 
to be made that such matters are permitted under Directive 78/2SIEEC. 
An upper and lower limit test shall be obligatory in respect of  preserving agents; an upper 
limit test for any other excipient components liable to give rise to an adverse reaction 
shall be obligatory. 
5.  Safety tests 
Apart  from  the  results  of tests  submitted  in  accordance  with  Part  7  of this  Annex, 
·particulars of safety tests shall be submitted. These tests shall preferably be overdosage 
studies carried out in at least one of the most  sensitiv~ target species and by at least the 
recommended route of  administration posing the greatest risk. 
6.  Sterility and purity test 
Appropriate tests to demonstrate the absence of contamination by adventitious agents or 
other  substances  shall  be  carried  out  according  to  the  nature-of the  immunological 
veterinary medicinal product, the method and the conditions of manufacture. 
106 7.  JuctivatiOD 
Where  aPPlicable~ a test to verify iliactivation sball ~  carried out on the product in the 
final CCQltainer.  .  . 
~ Residual hWDidlty 
Each batch of  lyophilized product shall·~  tested for residual hUmi~.  · 
9.  Batda-to-batcll.coaslsteDey 
In order to ensure that efficacy of  the product is reproduCible ftom batch to batch and to 
demonstrate conformity with specifications, potency tests based upon in vitro or in vivo 
D;led:lods, includiDg appropriate .reference materials whenever available, shall be carried 
out on eadl fiDa1  bulk or each batCh of finished  product, with apprOpriate  confidence 
limbs;  in . exCeptional  circumstances, · potency  .  testing  may  be  carried  out  at  an 
intermediate stage, as late as possible in the production process. 
· F.  .  STABILITY TESTS 
The particulars and documents accompanying the application for marketing authorization 
pursuant to Article 12 (3) (t) and (i) shall be submitted in accordance with the following 
requirements. 
A description shall be given of  the tests undertaken to support the shelf life proposed by 
the applicant. These tests shall always be real-time studies; they shall be carried out on a 
sufficient number of  batches pr~uced  according to the descn"bed production process and 
on produets stored in the final container(s); these. tests include biological and physico-
chemical stability tests. 
The conclusions shall contain the results of aualyses, justifying the proposed shelf-life 
under all proposed storage conditions.  ' 
In the  case  of products administered  in  the  feed,  information  shall  also be given  as 
necessary on the shelf-life of  the product, at the different Stages of  mixing, when mixed in 
accordance with the recommended instructions.  · 
Where a finished product requires reconstitution prior to administration.  details of the 
proposed shelf-life are required for the prodUct reconstituted as recommended.  Data in 
support ofthe proposed shelf-life for the reconstituted product shall be submitted.  .  . 
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(adapted) PAR.T7 
SAFETY TESTING  · 
A.  INTRODUCI'lON 
1.  The safety ~  shall show the po~  risks  from  the  immlDlological  veterinary 
.  mediciDal prOduct wbich,may occur under the proposed conditions of  use in animals~ 
these shall be  ·evaluated in relation to-the potential benc:fits of  the product. 
Where  imm1Dlologic8l  veterfuary·  mediciDal  products  consist  of live  organisms, 
especially those  which could be shed by_ vaccinated animals;  the potential risk to 
lDlvaccinated animals of  the same or of  any other potentially exposed species shall be  · 
evaluated. 
2.  nie partiCulm mid documents which shall accompany the application for marketing 
authorization  purSuant  to  Article  12  (3j  (j) and  13  (1)  shall  be  submitted  in 
accordance with the requirements of  section B. 
3.  Member Swes shall ensure that the  laboratory tests  are  carried out in conformity 
with  the ·principles  of good  laboratory  practice  laid  down  in  Council  Directives 
87/18/EEC and 88/320/EEC. 
B.  GENERAL REQ~MENTS 
1.  The safety tests shall be caqied out in the target species. 
2.  The dose to be used shall be tbat quantity of  the product to be recommended for use 
and containing the maximum titre or potency for which the application is submitted. 
3.  The sample used for safety testing shall be taken from a batch or batches produced 
according to the manufacturing process descnbed  in the application for  marketing 
authorization.  · 
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1. ·Safety of  the administration of  one dose  (as.imended by 
92/I 8/EEC Art 1) · 
The  immunologi~·. veterinary'  medicinal  product  ~  be  administered  at  tbe  (adapted) 
recommended dose and by each recommended route of8dn;linistration to animals of  each· 
spec:ies and categOry ·in which it is intended for use, including animals of  the minimum 
age of  administration. The animals shall be obserVed and examined for signs of  systemic 
Q.d local reactions. Where appropriatt, these studies shall· include detailed post-mortem 
macroscopic and microscopic examinations of  the .injection site. Other objective criteria 
shall be recorded, such as·~  temperature and performance measurements. 
The animals sba1l be ollserved and examined until reactions may no 'longer be expected, 
but in all cases, the observation and examination period shall be at least  14  days after 
administration. 
l.  Safety of  o~e  administration of  an overdGSe 
An overdose of  the immunoloiicai veterinary medicinal product shall be administered by 
each recommended route of  administration to animals of  the most sensitive categories of 
the target species. The animals shall be observed and examined for signs of  systemic and 
local reactions. Other objective criteria shall be recorded, such as rectal temperature and 
performance measurements. 
The animals shall be observed and examined for at least 14 days after administration. 
3.  Safety of  the repeated administration of  one dose 
Repeated  administration  of one  dose  may  be  required  to  reveal  any  adverse  effects 
induced by such administration. These tests shall be  carried out on the most sensitive 
categories of  the target species, using the recommended route of  administration. 
The  animals  shall  be  observed  and  examined  for  at  least  14  days  after  the  last 
administration for signs of  systemic and local reactions. Other objective criteria shall be 
recorded, such as rectal temperature and performance measurements. 
4.  Examination of reproductive performance 
Examination of  reproductive performance shall be considered when data suggest that the 
starting material  from  which  the  product  is  derived  may  be  a  potential  risk  factor. 
Reproductive performance of males  and  non-pregnant. and  pregnant  females  shall  be 
investigated with  the  recommended dose  and by  each  of the  recommended  routes of 
administration. In addition, hannfu1 effects on the progeny, as  well  as  teratogenic and 
abortifacient effects, shall be investigated. 
These studies may form part ofthe safety studies described in paragraph 1. 
109 5.  · Eumiaation of  lmmunologleal functions 
Where  the  bmriunologicill  veterinary  medicinal. produCt· might  adverselY  affect  the 
immune  response .of the  vaccinated  animal  or  of.  its  oro2tmv,  suitable  tests  on  the 
immunological 1_\mcti'?DS sh&ll be carried out; 
6.  Special requirements for Uve vaeeines: 
6.1. Spread of  the vaccine strain 
Spread of the  vaccine  strain  from  vaecipated to unvaccinated  target animals  sball be 
investigated, using the recommended route of  administration most likely to result in the 
spread. Moreover, it may be necessary to investigate the  spread to non  target species 
which could be highly susceptible to a live vaccine strain.  · 
6.2. Dissemination in the vaccinated animal 
Faeces, wine, milk, eggs, oral, nasal and other secretions shall be tested for the presence 
of  the organism. Moreover, studies may be required of  the dissemination of  the vaccine 
strain  in  the  body, with  particular  attention  being  paid  to the  predilection  sites  for 
replication of the  organism.  In the case of live vaccines for well established zoonotic 
diseases for food producing animals, these studies must be undertaken. 
·  6.3. Reversion to virulence of  attem«lled vaccines 
Reversion to virulence shall be investigated with material from the passage level which is 
least attenuated between the  master seed and the  final product.  Th~ initial vaccination 
shall be carried out using the recommended route of  administration most .likely to lead to. 
reversion to virulence. At least five serial passages through animals of  the target species 
shall be undertaken. Where tl$ is not technically possible due to failme of  the organism 
to replicate adequately,  as many passages as possible shall be carried out in the target 
species. If necessary,  in vitro propagation of the organism may be carried out between 
passages in vivo. The passages shall be undertaken by the route of administration most 
likely to lead to reversion to virulence. 
6.4. Biological properties of  the vaccine strain 
Other tests may be necessary to determine as precisely as possible the intrinsic biological 
properties ofthe vaccine strain (e.g. neW'otropism). 
6.5. Recombination or genomic reassortment of  strains 
The probability of  recombination or genomic reassortment with field or other strains shall 
be discussed. 
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For iDmlunoiogiCat veteriDary medicinal products, it will normally not be ·necessary to  .  (as amended by 
undertake a study ofresidues. However, where adjuvants and/or preservitives are used in  92/18/EEC Art. 1) 
the mailuDcture of  immunological veterinary medicinal product,s,  ~onsideration shall be  (adapted) 
given· to the possibility of any .residue  remaining .in .  the  foodstuffs~ If necessary,  the 
effects of  such residues sball be investigated. Moreover, in the case of"li\te. vaccines for 
zoonotic diselses. the ~on.of  residues at the injection site may be required in 
~n  to the-~  described ~·paragraph  6.2. 
A proposal for, -a withdrawal period sball be made and its adequacy shall be. discussed in 
relation to any·resid_ue studies which have·been undertiken. 
8.  IDteractioas 
Any known interactions with other pJOducts shall be indicated. 
D.  FIELD STUDIES 
Unless justified, results from  laboratory studies shall be supplemented with supportive 
data from field studies. 
E.  ECOTOXICITY 
The purpose of the study of the ecotoxicity of an  immunological  veterinary medicinal 
.product is to assess the potential harmful effects which the use of  the product may cause 
to the environment and to identify any precautionary measures which may be necessary 
to reduce such risks. 
An assessment  of ecotoxicity  shall  be  compUlsory for any  application  for  marketing 
authorization for an immtinological veterinary  medi~inal product other than applications 
submitted in accordance with Article 12 (3)(j) and 13 (1). 
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The first phase of  the assessment shall always be cmied out: the investigator shall assess · (as amended by 
the.potential extent of  exposure of  the environment to the prOduct, its ~ve  substances,  .92118/EEC Art. 1) 
or relevaDt metabolites, taking into acco~  (adapted)  · 
the target species and the proposed pattern of  use (for example, mass medication or 
individual animal medi~on), .  ·  · · 
· the method of  adinbustration, in particular th~ ukely extent to which the ~duCt  will 
enter directly into environmental system,  · 
the possible excretion of the product, its active sub~  or relevant metabolites 
into the environment by treated animals, persistence in such excretia, 
the disposal of  unused or waste product 
Where the conclusions of the first phase indicate potential exposure of the environment 
to the. product, the applicant shall proceed to the second phase and evaluate the potential 
ecotoxicity of  the product. For this purpose, he shall consider the extent and duration of 
exposure  of  the  environment  to  the  product,  and  the  information  about  the 
physical/chemical,  pharmacological  and/or  toxicological  properties  of the  compound 
obtained during the conduct of  the other tests and trials required by this Directive. Where 
necessary,  further  investigations on the  impact of the  product (soil,  w~r. air, aquatic 
systems, non-target organisms) shall be carried out 
These further investigations shall be carried out in accordance with the test protocols laid 
down  in  Annex  V to  Council  Directive  67/548/EEC  or  wheri:  an  end  point  is  not 
, adequately  .covered  by  these  protocols,  in  accordance  with  other  internationally 
recognised  protocols  on  the  immunological  veterinary  medicinal  product  and/or  the 
active substances and/or the excreted metabolites as appropriate. The number and types 
of tests and  the  criteria for  their evaluation  shall  depend  upon  the  state  of scientific 
knowledge at the time the application is submitted. 
112 PAR.TI  ·· 
EJI'FICACY TRIALS  I 
A.  INTRODUCTION. 
1.  1'he purpose of  1he trials described in this Pmt is to demonstrate or to confirm the 
etlicacy of  thO immunological veterinary .medicinal product. All claims made ·by the 
. appliCant with regard to the properties. etreC:ts and use of  the produ~  shall be fully 
supported by· results of specific  trials  contained  in the  application  for· marketing 
authorization.  ·  · 
2.  The particulars and· docUments which  sb8n  accompany -applications  for marketing 
authorizations  pursuant  to Article  12 J3)  0)  and  13  (1)  shall  be  submitted·  in 
accordance with the provisions below.  · 
3.  All veterinary clinical tri8Ls shall be condu~.ed  in accordance with a fully considered 
detailed trial protocol which shall be recorded in writing prior to commencement of 
the trial. The welfilre of the trial animals shall be subject to veterinary supervision 
and shall be taken tUlly into consideration during the elaboration of  any trial protocol 
and throughout the conduct of  the trial. . 
PJ'e.established  systematic  written  procedures  for  the  organization,  conduct,  data 
c~llection, documentation and verification of  clinical trials shall be required. 
4.  Before the  commencement of any trial, the informed ·consent of the  owner of the 
animals to be used in the trial shall be obtained and documented. In particular, the 
animal owner shall be informed in writing of  the copsequences of  participation in the 
trial for the subsequent disposal of treated animals  or for the taking of foodstuffs 
from  treated animals  .. A copy of this notification,  countersigned  and  dated by the 
animal owner, shall be included in the trial documentation. 
5.  Unless the trial is conducted with a blind design,  the provisions of Articles 55,  56 
and 57 shall apply by analogy to the labelling of formulations  intended for use  in 
veterinary clinical trials. In all cases, the words 'for veterinary clinical trial use only' 
shall appear prominently and indelibly upon the labelling. 
B.  GENERAL REQUIREMENTS 
1.  The choice ofvaccine strains shall be justified on the ~is  ofepizoological data. 
2.  Efficacy  trials  carried  out  in the  laboratory  shall  be  controlled  trials,  including 
untreated control animals. 
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(as amended by 
92/18/EEC Art. 1) 
(adapted) 1n generai. these 1rails sbaD  ~  supported by trials carried out iii .  field. conditioils, 
iDchJdjng 1l1l1reated control animals  •. 
.  . 
All trials ihal1 be described in sufficiently precise details so as to be reproducible in 
control trials, carried out at the request of  the competent authorities. The investigator 
·shall demonstrate  the  validity .of all the  techniques  involved.  All  results  shall be 
picsented as ptee!:isely as possible. · 
All reswts obtained,. whether favoUrable or unfavourable, shall be reported. 
3.  The  efficacy  of  an  immunological  veterinBry 'memcinal  product  shall  be 
deDaonstrated for each categoey  of each species recommended. for  vaccinatio~ by 
each  recommended  route  of administration  and  using  the  proposed  schedule  of 
administration.  The  influence  of  passively  acquired  and  maternally  derived 
. antibodies on the efficacy of a vaccine shall be adequately evaluated. Any claims 
regarding the onset and duration of  protection shall be supported. by data from trials. 
4.  The efficacy of  eich of  the components of  multivalent and combined immunological 
veterinaly medicinal products shall be demonstrated. If  the product is recommended 
for administration in  combination with or at the  5ame  ~e  as  another veterinary 
medicinal product, they shall be shown to be eompatible. 
S.  Whenever  a product  forms  part  of a  vaccination  scheme  recommended  by the 
applicant, the priming  or booster effect or the  contribution of the  p,roduct  to the 
efficacy of  the scheme as a whole shall be demo~. 
6.  The dose to be used shall be that quantity of  the product to be recommended for use 
and containing the minimum titre or potency for which the application is submitted. 
7.  The samples used for efficacy trials shall be taken from a batch or batches produced 
according to the  manufacturing process described in the application for marketing 
authorization.  · 
8.  For  diagnostic  immunological  veterinary  medicinal  products  administered  to 
animals,  the  applicant  shall  indicate  how  reactions  to  the  product  are  to  be 
interpreted. 
C.  LABORATORY TRIALS 
1.  In principle,  demonstration of efficacy shall be undertaken  upder well  controlled 
laboratoey  conditions  by  challenge  after  administration  of the  immunological 
veterinary  medicinal  product  to  the  species  animal  under  the  recommended 
conditions of  use. In so far as possible, the conditions mider which the challenge is 
carried out shall mimic the natural conditions for infection, for example with regard. 
to the_ amount of  challenge. organism and the route of  administration of  the challenge. 
2.  If  PoSSible, the immune mechanism (cell-mediatedlb.umoral, local/general classes of 
immunoglobulin) which  is  initiated  after the  administration  of the  immunol~gical 
veterinary  medicinal  product  to  target  imimals  by  the  recou;unended  route  of 
administration shall be specified and documented.  · 
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(~) D.  FIELD TRIALs 
1.,  Unless juStified, resuits froJn laboratory trials shall be suppleiliented with data from 
field trials:~  ·  ·  · 
2.  · w=e laboratory trials cannot be supportive  cie efficacy, the peiforinance of field 
- ~-alone  may be acCeptable. 
PART9' 
PARTICULARS· AND  DOCUMENTS CONcERNING SAFETY TESTING AND 
EmCACY. TRIALS  OF  IMMUNOLOGIC~ VETERINARY  MEDICINAL 
PRODUcrs 
A.  INTRODUcriON 
As in  any  scientific work,  the dossier of safety and efficacy studies  shall include  an 
· introduction defining the subject and indicating the tests yvhich have been carried out in 
eompliance with Parts 7 and 8, as well as a summary, with references to the published 
literature. Omission of any tests or trials listed in Parts 7 and 8 shall be indicated and 
discussed. 
B.  LABORATORYSTUD~ 
The following shall be_ provided for all studies: 
2.  the name of  the body having canied out the studies; 
3.  a detailed experimental protocol giving a description of  the methods, apparatus and 
materials  used,  details  such  is species,  breed  or strain  of animals,  categories  of 
animals, where they were .obtained, their identification and number,  the conditions 
under which they were housed and fed (stating inter. alia whether they were free from 
any specified pathogens and/or specified antibodies, the nature and quantity of  any 
additives contained in the feed), dose, route, schedule and dates of  adm.inistnition, a 
description of  the statistical methods used; 
4.  in the case of  control animals, whether they received a placebo or no treatment; 
I 
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92/18/EEC Art 1) 
(adapted)  . 'S.  ·all geueral_llld  individual  obietvations  and~  ~bt&med (wbh aw:nges  and·  11/852/EEC 
·  staDdard . deviations),  whether  favOurable · or  unfavourable.· ·no  dat&  ·sball· be  Annex· 
desc:ribecl  in ·  -Sumcient  detail  to·  allow  the  resUlts  to  be  critically  evaluated  (as amended by 
· indepeDd&mtly of  their~  by the author. The raw data Sball be·piesentecf in · 92/18/EEC An. 1) 
1abuJir:form. By way of  expJanation and illustration, the rest,llts ~Y  be accompai,iied  (adapted)  · 
by reproductions ofrecordinp, photomicrographs, etc.; 
6. ·  the nature, fieqUCDcY and duration of  ob~  sido-effects; 
7.  the number of  animals ~WD  prematurely ftom the studies and reasons for sUch 
withdrawal; 
8.  a statistical auilYsis of  the resu1U, where such is called for bY the test programme, 
and variance 'WitbiD the data;  .  .  . 
9.  occummce and course of  any iDtercuri'ent disease; 
10. all details concerning medicinal products (other than the product under study), the 
administration of  which was n~  during the course of  the study; 
11. an objective discussion of  the results obtained, leactmg to conclusions on the safety 
· and efficacy of  the product. 
C.  FIELD STUD~ 
Paniculars concerning field studies shall be sufficiently detailed to enable an objective 
judgement to be made. They sball include the followiDg: 
1.  a summary; 
2.  name, address, function and qualifications of  the investigator in charge; 
3.  place and date of  administration, name and address of  the owner of  the animal(s);. 
4.  details  of the  trial protocol,  giving  a description  of the  methods,  apparatus  and 
materials  used,  details  such  as  the  route  of administration,  the  schedule  of 
administr&tion, the dose, the categories of animals, the duration of observation, the 
serological  response  and  other  investigations  carried  out  on  the  animals  after 
administration;  ·  · 
... 
S.  in the case of  control animals, whether they received a placebo or no treatment; 
6.  identification  of the  treated  and  conttol  anjmals  (collective  or  individual,  as 
· appro~).  such as species, breeds or strains, age, weight, sex, physiological status;  .  . 
116' 7.  a. brief descripionof the. ·m~od of rearing _and  feeding,  ~the  natuie  and 
quantity of  any additives coDtaiDed in the feed;  ·  · 
a.  ~  the.  particulars  On  observations,  performaileeS. and  results-(with aver.s and 
.  .. stindard deviation); individual dam shall be mdicated When tests and measurements 
.  on in~  have been camed out; 
9.  all obserVations and results of  the studies, whether filvouRble or unfavourable~ With 
a fUll statement of  the  observati~ and the results of  the objective tests of  activity 
required  to evaluate  the product;  the  teclmiques -used  must  be  specified and  the 
significance of  any variations in the results explained; 
10.  effect on the animals' performances· (e.g. egg laying, milk production, reproductive 
. performance);  . 
11.  the number of  animals withdraWn prematurely from the studies and reasons for ~ 
withdrawal; 
12.  the nature, frequency and duration of  observed adverse reactions; 
13.  oCcurrence and course of  any intercurrent disease; 
14.  all details concerning medicinal products (other than the product under study) which 
have been administered either prior to or concurrently with the test product or during 
the observation period; details of  any interactions observed; 
15.  an objective discussion of  the results obtained, leading to conclusions on the safety 
and efficacy of  tht; product. 
D.  GENERAL CONCLUSIONS 
General conclusions on all results of  tests and trials carried out in compliance with Parts 
7 and  a  shall  be  given.  They shall contain an  objective  discussion  of all the results 
obtained  and  lead  to  a· conclusion  on  the  safety  and  efficacy  of the  immunological 
veterinary medicinal product. 
E.  BIBLIOGRAPIDCAL REFERENCES 
The bibliographical references cited in the summary mentioned under Section A shall be 
listed in detail.  . 
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Council Directive 90/676/EBC (OJ L 373,31.12.1990, p.l5) 
.  Council Directive 90/677/EEC (OJ L 373,31.12.1990, p. 26) 
Council Directive 92174/EEC (OJL 297, 13.10.1992, p. 12) 
Council Directive 93/40/EEC (OJ L 214,24.8.1993, p. 31) 
Council Directive 81/852/EEC (OJ L 317, 6.11.1981, p. 16) 
Council Directive 87/2Q/EEC (OJ L 15, 17.1.1987, p. 34) 
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· Directive 81/852/EEC. 
· Directive 87/20/EEC 
Directive 90/676/EEC 
Directive 90/677/EEC 
Directive 92/18/EEC 
Directive 92174/EEC 
D~ve  93/4QIEEC 
J-artB. 
.  .  . 
Deadli-..es for transposition into national law 
·  ·  '..  (referred to by Article 94) 
Directive  Deadline for 
9 Oetober 1983 
9 Oetober 1983 
1 July 1987 
1 January 1992 ' 
1 Januaiy 1992 
1 April1993 
31 December 1993 
1 January 1995 
1 January 1998 (An. 1.7) 
119 
itiOn This Directive  Dir. 65/65/EEC 
Art. 1 (I)  and (2)  Art. 1 ( 1) and (2)  · 
Art. 113)  I 
Art. II  4)  Art. 1. point 3 
Art. 1  ~ 5)and(6) 
Art.1(7) 
Art. 1 (8) 
Art. 1 (9) 
Art. 1 (10)to(l3) 
Art. 1 (14) 
Art 1 (IS) 
Art. 1 (16} 
Art.2  ' 
Art. 3 (1), 1st 
subJICU ..  .,. ..  .,h 
Art. 3 (I), 2nd 
sub.,... .. .,. ..  .,h 
Art. 
Art. 3 (2) 
ANNEX III 
CORRELATION TABLE 
Dir. 81/851/EEC  Dir. 81/852/EEC 
Art. I (1) 
Art. 1-(2). 2nd indent 
Art. 1 (I)  . 
Art. 1 (2). 3rd and 4th indents 
Art. S, 3rd subparamPh. POint 8 
Art.42b 
Art SOa (I)~ 2nd suboaraeraoh 
Art.16 (I) .. 
Art 18 ( n. footnote 
Art.2 (I) 
Art 2 (2), lst indent 
Art.2 (3) 
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